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Abstract
The advent of combination antiretroviral therapy (ART) in 1996 revolutionized the treatment of HIV/AIDS
and significantly decreased the incidence of HIV-associated neurocognitive disorders (HAND), a spectrum of
HIV-related CNS dysfunctions ranging from mild cognitive deficits to severe dementia. Although the long-
term prognosis for ART-treated, HIV-positive individuals continues to improve, the life-expectancy for this
population remains 10-30 years less than that of uninfected individuals. Additionally, the clinical and
pathologic presentation of HAND has evolved from a subacute, subcortical encephalitic condition, to a
prolonged, cortical, neurodegenerative disease with pathological features that resemble those found in
Alzheimer Disease (AD). The specific mechanisms driving these pathological changes remain unknown,
although emerging evidence suggests that antiretroviral neurotoxicity may be a significant contributing factor.
Here, we examined mechanisms by which antiretroviral drugs induce stress in neurons leading to changes in
amyloid precursor protein (APP) processing. Utilizing in vitro models of acute ART exposure, we observed
that HIV protease inhibitor (PI)-class ART drugs robustly active the unfolded protein response in primary
neurons leading to translational de-repression of beta-site cleaving enzyme 1 (BACE1) by phosphorylated
eIF2alpha; and augmented amyloidogenic cleave of APP. These results were corroborated in ART-treated,
SIV-infected macaques were we saw increased hippocampal expression of BACE1 AND IN HAND patients
where we also found similar increases in BACE1 expression in CA1 and CA3 hippocampal regions
accompanied by accumulation of intraneuronal oligomeric Abeta;. Finally, we demonstrate that inhibition of
neuronal BACE1 activity in vitro protects cells from hydrogen peroxide and antiretroviral drug-mediated
toxicity. From this body of work, we conclude that PI-class antiretroviral drugs play a prominent role in stress
activation of CNS neurons leading to aberrant changes in APP processing and potentially contributing to
neuronal damage and death in HAND. Lastly, we have identified BACE1 as an important adjunctive
therapeutic target in the treatment of chronic cognitive decline in ART-medicated, HIV-positive individuals.
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ABSTRACT 
ASSESSING THE CONTRIBUTION OF ANTIRETROVIRAL THERAPY TO NEURONAL 
DAMAGE AND DEATH AS A MEDIATOR OF COGNITIVE DECLINE IN HIV-ASSOCIATED 
NEUROCOGNITIVE DISORDERS 
 
Patrick Joseph Gannon 
Kelly L. Jordan-Sciutto 
 
The advent of combination antiretroviral therapy (ART) in 1996 revolutionized the treatment of 
HIV/AIDS and significantly decreased the incidence of HIV-associated neurocognitive disorders 
(HAND), a spectrum of HIV-related CNS dysfunctions ranging from mild cognitive deficits to 
severe dementia.  Although the long-term prognosis for ART-treated, HIV-positive individuals 
continues to improve, the life-expectancy for this population remains 10-30 years less than that of 
uninfected individuals.  Additionally, the clinical and pathologic presentation of HAND has evolved 
from a subacute, subcortical encephalitic condition, to a prolonged, cortical, neurodegenerative 
disease with pathological features that resemble those found in Alzheimer Disease (AD).  The 
specific mechanisms driving these pathological changes remain unknown, although emerging 
evidence suggests that antiretroviral neurotoxicity may be a significant contributing factor.  Here, 
we examined mechanisms by which antiretroviral drugs induce stress in neurons leading to 
changes in amyloid precursor protein (APP) processing.  Utilizing in vitro models of acute ART 
exposure, we observed that HIV protease inhibitor (PI)-class ART drugs robustly active the 
unfolded protein response in primary neurons leading to translational de-repression of beta-site 
cleaving enzyme 1 (BACE1) by phosphorylated eIF2α and augmented amyloidogenic cleave of 
APP.  These results were corroborated in ART-treated, SIV-infected macaques were we saw 
increased hippocampal expression of BACE1 AND IN HAND patients where we also found 
similar increases in BACE1 expression in CA1 and CA3 hippocampal regions accompanied by 
accumulation of intraneuronal oligomeric Aβ.  Finally, we demonstrate that inhibition of neuronal 
BACE1 activity in vitro protects cells from hydrogen peroxide and antiretroviral drug-mediated 
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toxicity.  From this body of work, we conclude that PI-class antiretroviral drugs play a prominent 
role in stress activation of CNS neurons leading to aberrant changes in APP processing and 
potentially contributing to neuronal damage and death in HAND.  Lastly, we have identified 
BACE1 as an important adjunctive therapeutic target in the treatment of chronic cognitive decline 
in ART-medicated, HIV-positive individuals.    
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CHAPTER 1 
INTRODUCTION 
1.1: HIV AND THE NEUROPATHOGENESIS OF HAND 
Since its first clinical diagnosis in 1981, acquired immunodeficiency syndrome (AIDS) has 
become a global pandemic responsible for over 22 million deaths worldwide with an estimated 
sixteen thousand new human immunodeficiency virus (HIV) infections occurring daily (1).  HIV, 
discovered in 1983 to be the causative agent of AIDS, is a retrovirus that primarily targets CD4
+
 T 
cells and cells of the monocyte/macrophage lineage that express the CD4 receptor and one of 
the two required co-receptors, CXCR4 or CCR5.  If untreated, HIV infection ends in the selective 
loss of the CD4
+
 T cell population, leading to severe immunodeficiency and eventually death (2).  
In addition to destruction of the immune system, HIV infection can also lead to a spectrum of 
central nervous system (CNS) complications, known collectively as HIV-associated 
neurocognitive disorders (HAND), in approximately 50% of infected individuals.  According to the 
diagnostic criteria established for the assessment of neurocognitive impairment in HIV-infected 
individuals, the neurological deficits in HAND are divided into three diagnostic groups.  This 
classification is based on the neuropsychological evaluation of multiple cognitive domains, 
including simple motor skills or sensory perceptual ability, complex perceptual motor skills, 
attention and working memory, learning and memory recall, verbal and language skills, 
abstraction and executive function.  First, asymptomatic neurocognitive impairment (ANI) is 
defined as acquired impairment in at least two cognitive domains without a decline in activities of 
daily living (ADL), while mild to moderate neurocognitive impairment that affects ADL is termed 
minor neurocognitive disorder (MND).  Finally, moderate to severe impairment in two or more 
domains with marked impact on ADL is defined as HIV-associated dementia (HAD). 
Additionally, behavioral and emotional problems such as depression, psychosis, and 
anxiety are commonly observed in HAND patients.  Since the multi-drug regimens that form the 
basis of antiretroviral therapy (ART) have become the mainstay for HIV treatment, the clinical 
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presentation and the course of HAND have become more unpredictable.  The severity of deficits 
appears to fluctuate over time during the course of infection: some patients may experience 
continuing decline in cognitive abilities, while others show improvement of more severe 
neurocognitive impairments and exhibit only minor deficits for the remainder of the disease.  
While clinical studies clearly establish that suppression of viral replication below the level of 
detection is paramount to a more favorable outcome, the clinical course of HAND, once 
diagnosed, cannot be predicted successfully in most patients.  Furthermore, while the prevalence 
of severe HAD has decreased in the post-ART era, the prevalence of ANI and MND, and HAND 
in general, has increased significantly due in part to the longer lifespan of HIV-infected individuals 
(3).  Pathological studies have revealed that brains of ART-naïve HAND patients exhibit classic 
hallmarks of neuroinflammation including microglial nodules, multinucleated giant cells 
astrogliosis, and myelin pallor (1).  However, in the post-ART era, these hallmarks are not 
frequently found in post-mortem HAND brain tissue, although syanptodendritic damage still 
persists (4-9).  Similarly, while extensive neuronal death in the CNS of HAND patients has been 
mitigated in the post-ART era, there remains evidence for ongoing neuronal damage in the form 
of dendritic pruning, decreased synaptic density and loss of interneurons (10).   
In the healthy brain, the blood brain barrier (BBB) and the blood-cerebrospinal fluid 
barriers are the first lines of defense against invading pathogens; however, HIV can circumvent 
these barriers and enter the CNS within 1-2 weeks after systemic infection.  The mechanism(s) of 
HIV neuroinvasion remain a matter of speculation, however there is evidence that HIV can enter 
via transcytosis across endothelial cells or within infected monocytes (11, 12).  The latter model 
was first proposed by Haase and colleagues who used visna virus to model HIV infection and 
proposed that HIV, and other lentiviruses, enter the CNS as passengers in infected monocytes 
(13-15).  According to this “Trojan Horse” model, supported by a multitude of in vitro and in vivo 
studies, the infected monocytes traverse the BBB and differentiate into macrophages, thus 
constituting the viral reservoirs in the CNS (15-18).  Direct contact of the infected cells with 
neighboring, resident immune cells of the CNS, including perivascular macrophages, astrocytes, 
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and microglia, leads to their subsequent infection and activation.  This population of infected 
immune cells then releases a variety of neurotoxic molecules, including proinflammatory 
cytokines, chemokines, reactive oxygen species (ROS), quinolinic and arachidonic acid, 
glutamate, and nitric oxide, leading to activation of uninfected immune cells and eventual 
neuronal damage and dysfunction observed in HAND.     
Importantly, neurons themselves are not a source of productive infection in the CNS, as 
they lack the CD4 receptor, rather HIV replication occurs primarily in monocyte-derived 
perivascular macrophages and microglia (18).  However, given the extensive evidence of 
neuronal damage in HAND, other mechanisms have been implicated in HIV-mediated 
neurodegeneration.  The first hypothesis, known as the indirect or bystander effect hypothesis, 
maintains that neuronal damage is mediated largely by the immune response mounted by 
infected and uninfected non-neuronal cells against HIV infection, as described previously.   
Chronic neuroinflammation then leads to an excitotoxic environment within the CNS, chronic 
activation of neuronal N-methyl-D-aspartate (NMDA) receptors and a toxic accumulation of 
intraneuronal Ca
2+
 leading to free radical production, oxidative stress, and activation of Ca
2+
-
dependent death proteases, such as calpains and caspases.  Alternatively, the direct injury 
hypothesis holds that HIV viral proteins, such as gp120, Tat, and Vpr, released from infected 
monocytes and microglia, interact directly with neurons through a variety of mechanisms, 
including interaction with chemokine receptors, leading to neuronal damage and apoptosis.  
Despite several lines of in vitro data supporting this hypothesis, in vivo studies suggest that 
markers of neuroinflammation continue to persist in post-ART HAND despite suppression of HIV 
replication in the CSF to levels below the limit of detection.  These findings suggest that indirect 
mechanisms of neuronal toxicity may be the major contributors to the underlying neuropathology 
of HAND in the post-ART era.         
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1.2: ANTIRETROVIRAL THERAPY: MECHANISMS OF ACTION 
Initial quantitative studies of in vivo HIV-1 dynamics and virion clearance rates using novel 
antiretroviral drugs yielded several critical findings: 1) viremia is sustained by continuous rounds 
of replication, infection, and rapid cell turnover, 2) mutations in the HIV-1 genome likely occur at 
every position multiple times per day accounting for the failure of previously-used monotherapy, 
3) when new cycles of infection are halted by antiretroviral drugs, plasma virus levels fall by as 
much as 99% within weeks after treatment, and 4) effective treatment of HIV must employ the 
use of multiple, potent antiretroviral drugs to force the viral genome to mutate at several distinct 
positions simultaneously (19, 20). From these landmark studies came the advent of combinatorial 
highly active antiretroviral therapy (HAART), now simply termed ART, which is the mainstay 
treatment for HIV, leading to suppression of viral replication to below the limits of detection, 
reconstitution of the immune system, and increased long-term survival rates in HIV-positive 
individuals (21).   
The United States Panel on Antiretroviral Guidelines for Adults and Adolescents currently 
recommends the initiation of ART when CD4 cell counts are below 350 /mm
3
 peripheral blood or 
in those with AIDS-defining illnesses irrespective of CD4 levels (22, 23).  Initial ART regimens 
typically include the use of two nucleoside reverse transcriptase inhibitors (NRTI) combined with 
either a non-nucleoside reverse transcriptase inhibitor (nNRTI), HIV protease inhibitor (PI), or 
integrase inhibitor.  The 24 FDA-approved antiretroviral drugs currently available fall into six 
broad categories based on which step of the HIV viral replication cycle they inhibit: entry, reverse 
transcription, integration, transcription, virus assembly and production, and protease processing 
(24).  The first step in HIV replication involves viral entry into helper T lymphocytes and 
monocytes via engagement of the viral envelope glycoprotein, gp120, with the CD4 receptor 
followed by binding to either the CXCR4 or CCR5 co-receptors (25).  These interactions induce a 
conformational change in the HIV envelope, leading to gp41-mediated fusion with the host cell 
membrane (26).  This process, which lasts approximately 1 hour, is targeted by entry inhibitors, 
divided further into attachment inhibitors, chemokine receptor antagonists, and fusion inhibitors.  
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Currently, two entry inhibitors, maraviroc and enfuvirtide, are approved for use in humans, 
however, antibody-based drugs directed at gp120 and CD4 are in development and show 
promising clinical results (24, 27).   
 Viral entry and fusion is followed by uncoating of the viral core and intracellular injection 
of the single-stranded RNA genome along with various viral enzymes, including reverse 
transcriptase (RT), which generates double-stranded, complimentary proviral DNA from viral RNA 
over a period of 10 hours (24, 28).  RT was the first HIV-1 enzyme targeted for antiviral treatment 
with the advent of zidovudine (AZT) in 1987, which comprised HIV monotherapy until combination 
ART in 1996 (29-31).  HIV-1 RT has since become a major area of drug development, which 
includes nucleoside and non-nucleoside reverse transcriptase inhibitors that encompass 12 FDA-
approved drugs, accounting for half of all approved antiretroviral drugs.  NRTIs are administered 
as prodrugs that must be phosphorylated in three steps by cellular thymidine kinases to become 
actively antiviral in vivo (32-35).  Following activation, NRTIs serve as structural analogs of native 
deoxynucleotides needed for reverse transcription, but lack the 3’-hydroxyl group on the 
deoxyribosyl moiety which prevents formation of a 5’-3’ phosphodiester bond between 
incorporated NRTIs and incoming native nucleosides (23, 36).  The net result is early chain 
termination of the growing viral DNA chain.  nNRTIs also prevent production of proviral DNA from 
viral RNA but do so by binding to an allosteric, hydrophobic site proximal to the active site, 
thereby changing its conformation and inhibiting its catalytic activity (37-39).  Unlike NRTIs, 
nNRTIs do not require phosphorylation to become active in vivo and they do not inhibit the RT 
activity of other lentiviruses.  One advantage of nNRTIs compared to NRTIs is their ability to 
evade pyrophosphorolysis as a viral resistance mechanism, which selectively removes NRTIs 
from the 3’ end of the nascent chain (24, 38).  However, viral resistance to nNRTIs has emerged 
in the form of amino acid substitutions in the allosteric binding site that prevents nNRTIs from 
binding (38, 40, 41).   
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 Reverse transcription and generation of proviral DNA leads to assembly of the pre-
integration complex which is transported into the nucleus of the host cell and integrated in the 
host genome, a process that is catalyzed by the integrase enzyme and occurs within roughly 20 
hours of initial cellular infection (42).  Integration occurs in three sequential steps: assembly of the 
viral DNA, removal of 2-3 nucleotides from one or both 3’ ends of the viral DNA, and finally strand 
transfer in which viral DNA is ligated to the host genome (43).  Integrase inhibitors represent the 
newest class of antiretrovirals, with two FDA-approved drugs, raltegravir and dolutegravir, that 
specifically inhibit strand transfer by preventing binding of the pre-integration complex to the host 
DNA (44).  These drugs have proven to be very efficacious in preventing viral replication in 
randomized clinical trials, and in some cases outperformed more widely-used drugs, such as 
efavirenz (45).      
 Integration is a necessary precursor to transcription of viral genes leading to the 
production and assembly of mature infectious HIV-1 particles.  HIV transcription is unique in that 
it requires binding of a regulatory protein, Tat, to the HIV RNA element (TAR) for transcript 
elongation, making it a promising therapeutic target (24, 46).  However, efforts to design small 
molecule inhibitors against this process have proved to be inefficacious in clinical trials.  Similarly, 
while HIV assembly and maturation has become an area of increasing interest for drug discovery, 
inhibitors, such as betulinic acid, have not shown evidence of sufficient in vivo antiviral activity to 
be considered viable for use in humans (47).   
 The final step in the 24 hour intracellular HIV-1 replication cycle is proteolytic cleavage of 
the viral gag and gag-pol polyprotein precursors by the HIV-1 aspartyl protease enzyme at the 
inner surface of the host cell plasma membrane leading to generation of mature virions (37, 48).  
Targeting the last essential enzyme in the viral replication cycle, HIV protease inhibitors (PIs) 
constitute some of the most potent antiretroviral agents developed to date.  The 10 approved PIs 
all share similar peptidomimetic structural features and bind to the active site of the HIV protease 
inhibiting its ability to cleave viral polyprotein precursors (49).  Given the large size and 
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lipophilicity of PIs, co-administration of a boosting agent, ritonavir, is typically recommended to 
enhance bioavailability via reduction of CYP450-mediated inactivation in the liver during first-pass 
metabolism (50, 51).   
Despite the remarkable achievement of ART in transforming HIV-1 disease into a 
manageable, chronic disorder, numerous issues remain including treatment failure, poor 
adherence to life-long therapy due to drug toxicity and pill burden, and sub-optimal 
pharmacokinetics of ART in many patients (52).  Fixed-dose combination antiretrovirals, such as 
Kaletra (lopinavir/ritonavir) have been developed to improve regimen adherence and reduce pill 
burden for patients, while efforts to enhance the pharmacokinetic profile of ART drugs include the 
use of nanoformulated ART (NanoART).  Recently, Gendelman and colleagues developed a 
long-acting, folic-acid coated, NanoART formulation that improved targeting of ART to HIV-
infected macrophages while increasing plasma and tissue drug concentrations by five-fold up to 
two weeks after a single dose in mice (53, 54).  More importantly, these NanoART formulations 
were also shown to improve biodistribution of ART to viral reservoirs in the CNS, leading to 
speculation that nano-targeting of ART could alleviate the growing problem of HAND persistence 
in the post-ART era (55-57).  However, the toxic side effects of many ART drugs has led to 
questions regarding the role of antiretrovirals in the persistence of HAND among the aging HIV-
positive population in the developing world.   
1.3: HIV AND AGING IN THE POST-ART ERA 
The widespread use of ART has drastically decreased the incidence of AIDS-related 
complications and improved the long-term prognosis of HIV-positive individuals.  As of 2011, 30% 
of the HIV-positive population in the United States was over the age of 50, and by 2015 it is 
estimated that more than 50% will be over the age of 50 (58, 59).  Despite this remarkable 
development, the life expectancy for ART-treated, HIV-positive individuals remains 10-30 years 
less than that of uninfected individuals (60).  Given the rapid global expansion of this population, 
8 
 
it has become increasingly important to understand the risk factors that lie at the intersection of 
HIV, ART, and aging.   
 Older HIV-positive patients, including those treated with ART, are at increased risk for 
systemic diseases including atherosclerosis, liver and kidney failure, cancer, and osteoporosis 
(60, 61).  The aging brain may also be more vulnerable to the effects of HIV as older adults 
display an increased susceptibility to HAND, and emerging evidence suggests an increased 
prevalence of neurodegenerative diseases, including Alzheimer and Parkinson, in this patient 
population (62, 63).  It remains unclear if the increased prevalence of HAND is a result of HIV and 
related comorbidities, including hypertension, insulin resistance, and lipodystrophy, or other 
confounding factors such as immunosenescence and ART toxicities, all of which are likely to 
impact CNS disease progression in older HIV-positive individuals (64, 65).   
 Antiretroviral therapy effectively limits HIV disease progression, maintains patients in a 
state of partial immune competence, and arrests subjects in a pre-symptomatic state (66).  
However, despite the ability of ART to reduce plasma HIV RNA to undetectable levels, HIV-
positive individuals remain at higher risk for opportunistic infections and premature death (3, 67).  
Thus, ART may reduce, but does not appear to eliminate, premature and/or accelerated aging in 
HIV-infected individuals.  This may be attributed to many factors including drug toxicity and 
slower immune recovery following ART initiation in older patients, compared to younger adults 
(68).  Furthermore, advanced age has been linked to decreased production of T cells, B cells, 
and cytokines, as well as to chronic immune activation, the latter of which may be linked to the 
breakdown of gut-associated lymphoid tissue (GALT) and to the elevated levels of systemic 
lipopolysaccharide (LPS) (69, 70). 
 Older patients also display a dampened recovery of CD4 cells following treatment with 
ART, which may increase their risk for systemic diseases ranging from heart disease to cancer 
(70).  Thus, it is not surprising that advanced age at seroconversion and/or onset of ART 
treatment is considered a major risk factor for severe HIV disease (71, 72).  Gotez et. al. 
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performed a retrospective study on HIV-positive patients receiving ART treatment at the 
Veteran’s Administration Greater Los Angeles Medical Center between 1996 and 1999, and 
found that for every 10 years of additional age at the onset of ART treatment, the rate of CD4 cell 
replenishment decreased by 35 cells per microliter of blood (73).  Despite the obvious benefits of 
beginning ART treatment in asymptomatic HIV-positive individuals, there remain significant 
concerns for initiating drug therapy sooner than necessary and how this may negatively impact 
drug toxicity, long-term patient outcome, and the evolution drug resistant strains of HIV (72, 74).  
Based on the updated recommendations for treatment initiation, all HIV-infected individuals will 
be put on an ART regimen upon diagnosis, and the impact of this approach on older patients will 
be revealing. 
 Lower CD4 count, in addition to advanced age, also places older patients at a nearly 
four-fold higher risk for liver-related mortality compared to younger patients (75).  This risk is 
exacerbated by other factors  commonly afflicting ART-treated, HIV-positive individuals including 
diabetes, alcohol abuse, as well as antiretroviral and cholesterol drug toxicity (75).  Among all 
non-AIDS-related complications, liver disease is the primary cause of death in HIV-positive 
patients (75).  In addition, older HIV-positive individuals are at increased risk for frailty, bone loss, 
and non-AIDS related cancers (76, 77).  It remains unclear if HIV itself places older individuals at 
higher risk for heart disease compared to older, HIV-negative individuals, though specific classes 
of antiretrovirals, especially protease inhibitors, have been linked to atherosclerosis  (69, 78, 79).   
 The CNS is particularly susceptible to the synergistic neurodegenerative effects of HIV 
and aging.  Several studies have demonstrated that, compared to younger (age 20 to 39 years) 
cohorts, older HIV-positive individuals (age >50 years) display decreased neurocognitive 
functioning in several areas including memory, psychomotor speed, and executive functions (59, 
80, 81).  The persistence of HAND in individuals with an undetectable viral load and CD4 cell 
counts greater than 200/µL is not well understood and may be a result of aging-associated 
processes rendering the cells of the CNS more vulnerable.   
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 Several recent neuroimaging studies have begun to address the structural, physiological, 
and functional changes in the CNS in the context of HIV and aging.  Six MRI investigations that 
assessed the structural changes in the brains of older HIV-positive individuals between 1998 and 
2012 found evidence of premature or accelerated aging characterized by significant brain atrophy 
in the basal ganglia, cerebellum, and frontal and temporal brain regions, when compared to 
seronegative controls (64).  However, several diffusion tensor imaging (DTI) studies found only 
normal, age-dependent changes in mean diffusion and fractional anisotropy, which reflects the 
directionality of water diffusion in the brain, and is greater along organized white matter tracts, but 
decreased in pathologically damages, disorganized tracts (64, 82-84).   
 Other studies have employed proton magnetic resonance spectroscopy (MRS) to assess 
changes in brain metabolite levels that are indicative of neuronal damage and death or glial 
activation.  Ernst and Chang demonstrated a five-fold acceleration of aging effects in a relatively 
young (mean age 36 years) ART-naïve, HIV-positive cohort, as compared to HIV-negative 
controls, as reflected by increased levels of glial activation markers, myoinositol (MI), and choline 
compounds (CHO) and a decrease in the neuronal marker, N-acetylaspartate (NAA) (85).  A 
recent multicenter MRS study of slightly older (ages 30-70), ART-treated HIV-positive individuals 
demonstrated elevated MI and CHO in all brain regions of patients with asymptomatic or mild 
neurocognitive impairment, but decreased levels of MI in those with dementia, which the authors 
interpreted as premature microglial senescence (64, 86).  In addition, this study found an age-
dependent decrease in NAA in frontal white matter, but only in patients with HAD (87).  Thus, 
while ART-naïve, HIV-positive patients show evidence of increased, age-dependent glial 
activation and neuronal damage leading to accelerated aging, ART-treated individuals show only 
signs of premature aging.   
 As discussed previously, the clinical and pathological hallmarks of post-ART HAND differ 
from those in the pre-ART era.  While HAND presented as a subcortical dementia afflicting the 
basal ganglia and white matter, many post-ART studies suggest the focus of the inflammation 
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has shifted primarily to the hippocampus, even in effectively treated patients (88-90).  
Furthermore, there is emerging evidence that pathologic similarities exist between HAND and 
some common neurodegenerative disorders such as Alzheimer disease, which is characterized 
by the presence of extracellular beta amyloid (Aβ) plaque deposits and intracellular neurofibrillary 
tangles composed of hyperphosphorylated Tau (61, 66, 91, 92).  In vitro work involving the viral 
protein Tat has demonstrated the ability of this viral protein to inhibit the activity of the Aβ-
degrading enzyme, Neprilysin, and bind to the receptor for advanced glycation end products 
(RAGE), all of which may promote Aβ accumulation in the CNS.  Indeed, some individuals with 
HAND display CSF levels of Aβ42 comparable to those observed in AD patients (61, 93, 94).  
Among the studies underlining the similarities between HAND and AD, Esiri et. al. were the first to 
report a predisposition to plaque formation in the brains of pre-ART, HIV-positive individuals (95).  
Such pathological changes have since been observed in HIV-positive patients despite successful 
virologic control with ART, suggesting that antiretrovirals either cannot achieve therapeutic 
concentrations within the brain parenchyma, allowing for ongoing viral replication and 
neuroinflammation, or may have toxic effects that could facilitate neurodegeneration (96, 97).  To 
address the latter concern, several reports investigated differences in either phospho-Tau or Aβ 
in ART-naïve vs. ART-treated individuals.  Two groups independently reported elevated Aβ 
deposition/accumulation in the hippocampus of ART-treated individuals compared to pre-ART 
patients, while Bell and colleagues reported only increased hyperphosphorylated Tau, but no Aβ 
deposition in the hippocampus and entorhinal cortex of HIV-positive individuals (61, 90, 92, 98).  
To date, no group has reported concomitant phospho-Tau accumulation and Aβ plaque 
deposition in the same brain samples from HIV-positive cohorts.  Although differences in patient 
age and the antibodies used to detect Aβ may account for the varied outcomes of these reports, 
studies utilizing the amyloid-binding, carbon 11-labeled Pittsburgh compound B (
11
C-PiB) and 
PET imaging found that irrespective of neurocognitive impairment, HIV-positive individuals 
showed no increase in 
11
C-PiB levels, highlighting a potential key difference between Aβ 
metabolism in HAND vs. AD despite some overlapping pathological features (91, 99).   
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 Importantly, the aforementioned studies highlight the potentially underappreciated 
concern of antiretroviral-associated neurotoxicity and its effect on neuropsychological outcomes 
in long-term ART-treated patients.  ART drugs have been linked to wide-ranging, peripheral 
metabolic and neural disturbances that could themselves influence the progression of HAND and 
foretell potential mechanisms of toxicity in the CNS (78, 100-111).  Specifically, PIs have been 
associated with ER stress and the development of premature atherosclerosis as well as 
metabolic syndrome, characterized by lipohypertrophy, hypercholesterolemia, and insulin 
resistance (78, 112-114).  Yet, the most serious limitation of ART drugs, specifically NRTIs, is 
mitochondrial dysfunction and oxidative stress, manifested clinically as peripheral neuropathy and 
myopathy (100, 115). NRTI toxicity is specific to myocytes and peripheral neurons due to the 
presence of thymidine kinase isoforms in these cell types capable of phosphorylating the 
prodrugs to their active form. Following phosphorylation, NRTIs are sequestered by DNA 
polymerase γ and are either incorporated into mitochondrial DNA (mtDNA), causing permanent 
damage, or terminate the growing DNA chain, depleting mtDNA-encoded enzymes necessary for 
the electron transport chain (ETC).  Decreased mtDNA results in the loss of mitochondrial 
membrane potential, decreased oxidative phosphorylation, increased reliance on glycolysis for 
ATP production, and lactic acidosis.  While direct CNS effects of ART are poorly understood, 
Schweinsburg et. al. demonstrated an association between NRTIs and decreased levels of frontal 
white matter NAA, which they attributed to NRTI-mediated mitochondrial dysfunction and 
depletion of cellular respiration (102).  Recently, a cross-sectional analysis of 540 HIV-infected 
individuals in Amsterdam found that cumulative use of high dose ritonavir (> 400 mg/ 24 hours) 
was associated with an increased risk factor for age-associated non-communicable comorbidities, 
potentially due to the known effects of ritonavir on endothelial dysfunction and induction of 
premature cellular senescence (116).   
Confounding the issue of direct CNS toxicity of antiretroviral medications is the variability 
in BBB permeability amongst different drug classes as determined by various physicochemical 
properties such as plasma protein binding, lipophilicity, molecular size, and interaction with drug 
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transporters in the BBB, such as P-glycoprotein (P-gp) and multidrug resistance associated 
proteins.  Based on these properties, a scoring system, called the CNS penetrance effectiveness 
(CPE) score, was developed to estimate the efficacy with which various ART drugs would reach 
therapeutic concentrations in the brain (117).  ART drugs with poorer CNS-penetrating properties, 
such as nelfinavir and saquinavir, are given a score of 0, while those with intermediate 
penetrance are given a score of 0.5, and others with high penetrance, such as AZT, receive a 
score of 1.  However, the accuracy of this scoring system has recently been called into question 
based on a number of experimental and clinical studies that refute these assumptions.   For 
example, based on the CPE scoring system many PIs, which are targets of P-gp transporters, 
have high molecular weights ( >500 Daltons) and are highly protein bound (up to 99%) in blood, 
are estimated to achieve sub-therapeutic concentrations in the brain based on CSF levels 
measured in humans (118, 119).  Yet, a recent pharmacokinetic analysis of ART administration in 
guinea pigs showed significantly higher uptake of [
3
H] ritonavir into brain parenchyma compared 
to CSF, suggesting that clinical estimates of CNS penetrance for some antiretrovirals may be 
lower than actual drug concentrations in the brain (50, 120, 121).   
 Although it is widely held that ART regimens with higher CNS penetrance generally 
confer improved neuropsychological outcomes in HIV-positive individuals, numerous clinical 
studies have suggested these regimens may negatively impact cognition.  In a prospective study, 
Marra et. al. found a significant association between highly CNS-penetrant ART regimens and 
worse neurocognitive and motor performance 24 and 52 weeks after beginning or changing 
therapy, despite decreased CSF HIV RNA in a small HIV-positive cohort (122).  In addition, 
Robertson et. al. reported an improvement in neuropsychological outcomes in a cohort of patients 
with interrupted drug treatment (123).  Studies using SCID mice, which display neuropathological 
hallmarks similar to those associated with HIV, showed reduced viral load and astrogliosis 
following administration of ART, but no improvement in cognitive dysfunction (124).  Altogether, 
these studies reinforce an emerging hypothesis that chronic use of antiretroviral drugs may be 
contributing to the rising prevalence of HAND in the aging HIV-positive population.   
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 In contrast, numerous clinical studies have demonstrated beneficial effects on 
neurocognitive functioning by ART regimens with high CPE scores (125, 126).  A cross-sectional 
study of 2636 adults from the AIDS Clinical Trials Group Longitudinal Linked Randomized Trials 
(ALLRT) cohort on effective ART for at least 6 weeks showed better neurocognitive performance 
in individuals receiving ART medications with higher CPE scores, although in some cases, 
participants required more than 3 antiretrovirals to treat HIV in the CNS. (127).  Letendre et. al. 
demonstrated improvements in cognition over a 15-week period in patients beginning ART with 
higher CPE scores versus those beginning ART with lower CPE scores (128).  Another recent 
investigation utilized MRS imaging to investigate the effect of multiple ART regimens with various 
CPE scores on changes in brain NAA metabolite levels.  Over 48 weeks, HIV-positive, ART-naïve 
individuals receiving regimens with the highest CPE scores displayed the greatest increases in 
NAA levels and showed the most improvement in a battery of neuropsychological tests (129).  
These studies suggest that ART medications with higher CNS penetrance may have a 
neuroprotective effect, at least initially, in successfully treated HIV-positive adults.  Importantly, 
these studies assess the effects of ART only after initiation of therapy, but given the well-
characterized toxicities of ART medications in the periphery and the potential impact of related 
co-morbidities on brain pathology, the long-term synergistic effects of aging and ART warrant a 
careful longitudinal examination of the safety profile of these drugs in the CNS.       
1.4: THE UNFOLDED PROTEIN RESPONSE AND TRANSLATIONAL PROTEIN CONTROL 
The unanticipated persistence and evolution of HAND in the post-ART era has led to a concerted 
effort to understand the underlying molecular pathways affected in chronic HIV-1 disease in the 
CNS.  As discussed previously, there is extensive evidence for chronic neuroinflammation, 
oxidative stress, and accumulation of neurodegenerative proteins in brains of ART-medicated, 
HIV-positive individuals.  Common among these various conditions is their ability to induce ER 
stress and activate the unfolded protein response (UPR), a ubiquitous cellular response 
mechanism conserved from yeast to humans (130).  While the UPR has long been implicated in 
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many neurodegenerative diseases, such as Parkinson and Alzheimer disease, Lindl et. al. were 
the first to show evidence of ER stress activation in HAND, as evidenced by increased CNS 
expression of the ER-resident molecular chaperone, BiP, ATF-6β, and phosphorylated eIF2α (p-
eIF2α) (131-138).  These findings suggest that chronic UPR activation, which has been linked to 
long-term memory loss and neurodegeneration, may play an important role in the pathogenesis of 
HAND (139, 140). 
 In eukaryotes the UPR is comprised of three major pathways, each under the control of 
an upstream effector protein, PKR-like endoplasmic reticulum kinase (PERK), activating 
transcription factor 6 (ATF6), and inositol-requiring enzyme 1α (IRE1α), located in the ER 
membrane (141, 142).  In the absence of ER stress, each of the effector proteins is kept inactive 
via interaction at its luminal domain with the molecular chaperone, BiP/GRP78 (Immunoglobulin 
heavy-chain binding protein/glucose-regulated protein 78), which serves as the main regulator of 
the UPR (143).  Accumulation of misfolded proteins and exposed hydrophobic residues in the ER 
disrupts the interaction between BiP and PERK, ATF6, and IRE1α, permitting their subsequent 
activation (144).  The most evolutionarily conserved pathway of the UPR, IRE1α is a 100 kDa 
type I transmembrane protein that homo-oligomerizes after dissociation from BiP and activates 
both its kinase and endoribonuclease activity via autophosphorylation of its C-terminal kinase 
domain (145).  IRE1α regulates the expression of numerous molecular chaperones and protein 
degradation genes via use of its endoribonuclease activity, which is utilized to non-conventionally 
splice a 26-nucleotide intron from XBP1-mRNA (146-148).  The resulting 376 amino acid spliced 
XBP1 acts as a potent transcription factor that enhances expression of many genes including 
P58
IPK
, which inhibits PERK activity (149).  If transient UPR activation is unable to restore cellular 
homeostasis, sustained IRE1α activation leads to autophagy and later apoptosis through its 
regulation of B-cell lymphoma 2 (Bcl2) expression and activity (142, 150).  
 ATF6 activation is unique among the three branches of the UPR in that it does not 
involve dimerization and autophosphorylation, but rather translocation to the Golgi and sequential 
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regulated intramembrane proteolysis in two steps by serine protease site-1 protease (S1P), which 
cleaves at the luminal domain, followed by N-terminal cleavage by metalloprotease site-2 
protease (S2P) (141, 147).  The resulting 50 kDa cleaved ATF6 product constitutes the 
transcriptional domain, which translocates to the nucleus and activates transcription of a cohort of 
genes with ATF/cAMP and ER stress response elements (ERSE) in their promoters (151).  These 
genes include molecular chaperones, such as BiP, transcription factors, and ER-associated 
degradation (ERAD) machinery (142).  The ATF6 transcriptional profile is ultimately a 
cytoprotective, pro-survival program designed to aid cells in adapting to sub-toxic accumulation of 
misfolded proteins.     
Under mild stress conditions, PERK, a serine-threonine kinase, is the first initiator protein 
to be activated in the UPR, although following sustained ER stress PERK can initiate pro-death 
signaling, similar to IRE1α.  Following dissociation from BiP, PERK dimerizes and activates its 
kinase domain via autophosphorylation.  This phosphorylation event results in a subsequent, 
PERK-mediated phosphorylation of the eukaryotic translation initiation factor 2 (eIF2) at Ser51 of 
the α subunit and global repression of cap-dependent protein translation (152, 153).  eIF2 is 
composed of three subunits, α, β, and γ, and when bound to GTP and Met-tRNA, comprises the 
ternary complex that binds to the 40S ribosomal subunit to form part of the 43S pre-initiation 
complex (154, 155).  After binding to the eIF4F cap recognition complex at the 5’ end of mRNA, 
the pre-initiation complex scans the 5’ leader sequence for an AUG start codon.  Once an AUG is 
recognized within a favorable sequence for translation initiation, GTP is hydrolyzed releasing eIF2 
from the pre-initiation complex allowing the 60S ribosomal subunit to bind the mRNA and begin 
the elongation phase of translation (156).  Phosphorylation of eIF2α inhibits this process by 
blocking the dissociation of eIF2 from eIF2B, a guanine nucleotide exchange factor that is needed 
for the exchange of GDP for GTP on the γ subunit of eIF2 (157).  This converts eIF2 from a 
substrate into a competitive inhibitor of eIF2B, slowing the exchange rate of GDP for GTP and 
limiting the availability of competent ternary complex to form the pre-initiation complex (158).  
Repression of global protein synthesis ultimately reduces influx of new mRNAs into the ER, 
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allowing folding enzymes and molecular chaperones to reduce the burden of misfolded proteins 
and prevent cellular toxicity. 
Importantly, eIF2α is phosphorylated by numerous kinases that respond to a wide variety 
of stress factors, highlighting its importance in cellular adaptation and protein translational control 
(Figure 1).  The first eIF2α kinase identified was heme-regulated inhibitor of translation (HRI) 
kinase, which serves the critical function of balancing the amount of globin production with the 
amount of heme available by inhibiting protein translation in reticulocytes in response to low 
heme levels (159-162).  HRI binds heme at its N-terminus which triggers the formation of stable 
HRI dimers (162).  When heme levels are low, HRI dimers undergo autophosphorylation, similar 
to PERK, activating its kinase domain and leading to eIF2α phosphorylation and inhibition of 
global protein synthesis (160).  HRI knockout mice display hyper-sensitivity to heme deficiency 
but no other physiological abnormalities (163-165).  HRI is not thought to play a significant role in 
neuronal p-eIF2α levels given that it is primarily expressed in erythroid cells and has no known 
roles in other cell types.   
Double-stranded RNA-dependent protein kinase (PKR) is a cytosolic, constitutively-
expressed, mammalian kinase that was discovered after the initial observation that extracts from 
vaccina virus-infected cells treated with interferon showed enhanced sensitivity to translational 
inhibition after addition to a cell-free system of exogenous mRNAs or synthetic double-stranded 
RNA (dsRNA) (166-168).  Follow-up studies revealed that activation of PKR kinase is stimulated 
through binding of dsRNA at its N-terminal double-stranded RNA-binding domains (DSRBs),  
leading to dimerization and autophosphorylation of its kinase domain  (167).  Downstream 
phosphorylation of eIF2α limits translation of viral mRNAs while enhancing the expression of 
antiviral proteins (159, 169, 170).  PKR can also be activated by a variety of dsRNA-independent 
stress conditions including type 1 interferons, oxidative stress, and ER stress via interaction with 
the PKR Activator (PACT) (171).  PACT is phosphorylated under various stress conditions and 
utilizes one of its three DSRBs to interact with and activate PKR (172).  Overexpression of PACT 
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sensitizes cells to viral infection and other stresses while knockdown of PACT mitigates stress-
induced PKR activation and promotes clonal cell growth.  Following activation by PACT, PKR 
phosphorylates eIF2α and a variety of other targets, including signal transducers and activators of 
transcription (STAT), interferon regulatory factor 1 (IRF-1), Jun-N terminal protein kinase (JNK) 
and p53, which may mediate some of the observed tumor suppressor activity of PKR (167, 173, 
174).  Overexpression of PKR leads to potent activation of apoptosis, likely as a protective 
response against the spread of viral infection.  However, despite the ability of PKR to regulate cell 
survival and death, PKR knockout mice develop normally and display no phenotypic 
abnormalities (175).  Several studies have suggested that PKR may play a key role in AD 
pathogenesis based on observations that phospho-PKR is upregulated in the AD brain and 
correlates with increased levels of the beta-site APP cleaving enzyme 1 (BACE1) (176-178).   
  General control non-derepressible 2 (GCN2) was originally identified in yeast as a gene 
that senses and responds to amino acid deprivation, although in mammals it appears to be 
sensitive to other stressors including viral infection and UV irradiation (179, 180).  GCN2 is 
activated when uncharged tRNAs bind to its histidyl-tRNA synthetase (HisRS)-related domain 
inducing dimerization and autophosphorylation to activate its kinase domain (172).  GCN2-
mediated phosphorylation of eIF2α results in translational upregulation of activating transcription 
factor 4 (ATF4), which stimulates the transcription of numerous genes involved in the amino acid 
biosynthetic pathway (181, 182).  GCN2 can sense infection by RNA viruses, such as Sindbis 
virus and Semliki Forest virus, by binding to viral RNA at its HisRS-related domain and inhibiting 
translation via eIF2α phosphorylation (159, 183).  One recent study also demonstrated that GCN2 
inhibits replication of HIV in vitro and in vivo and is directly cleaved by the HIV-1 protease (184).  
Given its prominent expression in the brain and interaction with HIV, GCN2 may provide a 
mechanistic link between HIV infection in the CNS and UPR activation observed in HAND.   
PERK was the final eIF2α kinase to be identified although it is the most physiologically 
important for control of protein translation in mammals.  In addition to alleviating ER stress, PERK 
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plays a critical role in limiting oxidative stress via activation of nuclear factor (erythroid-derived 2)-
like 2 (Nrf2), a transcription factor that regulates the expression of a battery of genes involved in 
the antioxidant response, including detoxifying enzymes such as glutathione S-transferase A2 
(GSTA2) and NADPH quinone oxidoreductase (NQO1) (185).  Normally, Nrf2 is kept inactive in 
the cytoplasm via interaction with and constitutive targeting for degradation by Kelch-like ECH-
associated protein 1 (KEAP1) (186).  Following phosphorylation by PERK, Nrf2 dissociates from 
KEAP1, migrates to the nucleus and activates transcription of genes with an antioxidant response 
element (ARE) in the promoter (187).  The importance of this link between ER stress and Nrf2 
activation is highlighted by the fact that cells lacking Nrf2 are hyper-sensitive to compounds that 
activate ER and oxidative stress (188).  PERK also plays an important physiological role in 
secretory cell types, such as pancreatic β-cells, which are frequently under a large biosynthetic 
load in response to varying demands for insulin production.  Missense mutations in the PERK 
gene have been linked to Wolcott-Rallison syndrome in humans, which is characterized by 
permanent neonatal diabetes, growth retardation, pancreatic and skeletal system deficits, and in 
some cases mental retardation (189, 190).  Similar phenotypic abnormalities have also been 
observed in PERK -/- mice.  Forebrain-specific ablation of PERK in mice results in impairments in 
cognitive and information processing, suggesting that PERK plays a key role in cognition in the 
adult brain. However, aberrant PERK signaling is also implicated in neurodegenerative disorders, 
such as AD, where it is known to be upregulated early in disease and may contribute to increased 
amyloidogenic processing of APP via upregulation of BACE1 (133, 191-201).  Similarly, genetic 
and pharmacologic disruption of PERK activity in the CNS has been shown to have protective 
effects in mice inoculated with prions and in an AD mouse model (197, 202).  Altogether, these 
studies suggest that eIF2α phosphorylation by HRI, PKR, GCN2, and PERK is a critical cellular 
and physiological mechanism of protein translational control that protects cells against a wide 
variety of stressors, but can lead to pathogenic conditions when activated in a chronic, 
uncontrolled fashion, as in AD and other neurodegenerative diseases. 
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Importantly, eIF2-mediated repression of protein translation is not universal; a subset of 
genes involved in redox homeostasis, protein refolding and cell survival, such as ATF4, are 
translationally upregulated in response to ER stress.  These mRNAs escape translational 
repression through a variety of mechanisms including the presence of internal ribosome entry 
sites (IRESs) within the 5’ untranslated region (UTR).  Originally discovered in piconavirus RNAs, 
IRESs are cis-acting elements found in the 5’ UTR of many viruses and up to 3-5% of eukaryotic 
mRNAs (203).  IRESs directly recruit the small ribosomal subunit in a cap-independent manner to 
internal codons with the help of trans-acting cellular proteins known as IRES trans-acting factors 
(ITAFs) which can confer tissue-specific regulation of protein translation (204, 205).  Although the 
regulation and function of cellular IRESs remains unclear, it appears that many genes with IRESs 
encode for proteins involved in cell differentiation, growth, and apoptosis (206).  Although IRES-
dependent translation also requires active ternary complex for initiation, some evidence suggests 
that eIF2 phosphorylation augments IRES-mediated translation of some genes, including 
vascular endothelial growth factor (VEGF), but not others (BiP) (206).  Currently, the specific role 
of p-eIF2α in cap-independent translation remains unknown.   
A second method of evading translational repression, known as leaky ribosome scanning 
(LRS), occurs when one or more upstream open reading frames (uORFs) in the 5’ UTR of an 
mRNA are bypassed by the 40S ribosomal subunit allowing for translation to begin at a distal 
AUG sequence.  Typically, LRS occurs when a particular upstream AUG is located in a 
suboptimal nucleotide context to initiate translation.  AUG initiators that differ drastically from the 
optimal context 5’-CCRCCAUGG-3’ for initiation are likely to allow for stronger LRS, compared to 
those that differ only slightly (207).  The use of alternative codons due to weak LRS is emerging 
as a common mechanism by which cells can derive several protein isoforms from a single mature 
transcript, as has been characterized for histone H4 and C/EBP mRNA (207-209).   
 The most well characterized mechanism of cap-dependent escape from translational 
repression, and the most relevant for ER stress-regulated genes, such as ATF4, is the utilization 
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of small (~30 codons) uORFs in the 5’ UTR of gene transcripts (172, 181).  When eIF2α 
phosphorylation is low and eIF2-GTP levels are high, scanning ribosomes will translate the first 
uORF it encounters assuming the AUG is in an optimal context for initiation.  If a transcript 
contains uORFs upstream of the authentic start codon, as with ATF4, most of the ribosomes will 
initiate translation at the proximal uORFs, which decreases the likelihood that scanning 
ribosomes will re-initiate in time to begin translation at the authentic AUG start codon, resulting in 
suppressed protein translation.  However, when p-eIF2α levels are high and eIF2-GTP is limiting, 
scanning ribosomes will still initiate translation at the first uORF, but are more likely to scan 
through subsequent uORFs and re-initiate at the authentic start codon due to decreased 
availability of the pre-initiation complex.  Thus, decreased availability of the ternary complex/pre-
initiation complex simultaneously reduces the translation rate of most cellular mRNAs that contain 
one start codon, while increasing the efficiency of translation in mRNAs with multiple uORFs.  
This mechanism was first characterized in the yeast homologue of ATF4, GCN4, which contains 
four uORFs and has subsequently been established for a variety of genes involved in stress 
response, survival, and apoptosis (152, 172, 206, 210-212).  It is estimated that 35-49% of 
human gene transcripts contain uORFs, indicating that protein translational control via p-eIF2α is 
likely a widespread mechanism of regulation involved in many cellular functions and may be a 
rich area of investigation for therapeutic intervention in the pathophysiology of human disease 
(213). 
 Many genes encoding for growth factors, transcription factors, and proto-oncogenes also 
utilize long, GC-rich 5’ UTRs to regulate protein translation levels through formation of extensive 
secondary structures, which inhibit the helicase activity of eIF4A and promote dissociation of 
ribosomes from the mRNA prior to initiating translation at the first start codon (214).  Secondary 
structures in GC-rich 5’ UTRs, typically hairpins, are the result of complementary base-pairing 
and strong hydrogen bond formation between guanosines and cytosines.  The position and 
stability of the secondary structures determines how effectively they inhibit translation of a 
transcript.  For example, a hairpin with a free energy of -30 kcal/mol located near the 5’ cap is 
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sufficient to prevent binding of the pre-initiation complex, while hairpins located further down the 
5’ UTR require free energies of at least -50 kcal/mol to inhibit translation (214-216).  The 
endogenous mechanism(s) by which cells overcome translational block by secondary structure is 
unclear, however, overexpression of eIF4A and eIF4B can partially overcome the free energy 
requirements needed for unwinding (214, 217).  Notably, many transcripts utilize secondary 
structure in conjunction with uORFs, IRESs, or trans-acting factors, such as RNA binding proteins 
to further suppress protein translation.  One of the most well characterized examples of this is 
found in the mRNA of transforming growth factor-beta 1 (TGF-β1), which controls cell growth and 
proliferation and is stimulated by growth factors and cytokine signaling (218).  The 5’ UTR OF 
TGF-β1, which is 867 nucleotides in length, forms stable stem loops which utilize the RNA-
binding protein, Y-box protein-1 (YB-1), to cooperatively facilitate formation of duplex structures 
that significantly downregulate translation of TGF-β1 under normal conditions in renal proximal 
tubular cells (214, 218-220).  In the presence of platelet-derived growth factor, YB-1 dissociates 
from the 5’ UTR and the translational block is overcome (218).  In summary, eukaryotic cells have 
evolved eloquent mechanisms to regulate protein translation of critical gene transcripts allowing 
for rapid cellular adaption to ever-changing inter- and intracellular conditions.    
1.5: REGULATION AND FUNCTION OF BACE1 IN NEURONS 
Alzheimer disease (AD) is a debilitating neurodegenerative condition characterized by 
progressive memory loss and impaired cognition over a period of 15-20 years.  AD remains the 
leading cause of dementia in the elderly, affecting over 5.4 million people in the United States and 
an estimated 26.6 million people worldwide (221).  Although patients with AD often follow a 
stereotypic pattern of short-term memory loss followed by impairment in other cognitive domains, 
such as language and reasoning, a definitive diagnosis of AD can be made only after post-
mortem analysis of brain tissue in patients suffering from dementia.  The pathological hallmarks 
of AD include intraneuronal neurofibrillary tangles (NFTs), composed of hyperphosphorylated 
Tau, and extracellular senile plaques composed primarily of 38 to 42 amino acid-length Aβ 
peptides.  Although most AD is sporadic, approximately 5% of cases result from genetic 
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mutations that invariably affect production of Aβ, supporting the idea that Aβ accumulation and 
deposition is a critical early event in AD pathogenesis.  This theory, known as the amyloid 
cascade hypothesis, posits that Aβ dysregulation precedes and contributes to NFT formation and 
the ensuing loss of synapses and neurons that underlie dementia (222).  Despite overwhelming 
genetic and pathophysiological evidence that Aβ accumulation is critical in AD development, the 
number of NTFs, and not senile plaques, correlates with the degree of dementia in patients.  
These observations suggest that senile plaques themselves are not toxic, but rather an attempt to 
sequester and segregate toxic Aβ oligomers and aggregates that induce neuronal death.  Under 
pathological conditions, Aβ monomers can undergo rapid aggregation to form oligomeric species 
that slowly transition into the large, insoluble fibrils that comprise senile plaques (223, 224).  A 
growing body of work suggests that Aβ oligomers are the toxic intermediates responsible for 
neuronal death in AD, while the fibrils found in plaques are relatively inert (225).   
 Aβ is produced constitutively from the sequential endoproteolysis of the amyloid 
precursor protein (APP), a ubiquitously expressed type I transmembrane protein of unknown 
function found at highest levels in the CNS.  During amyloidogenic processing, APP localized in 
endosomes or the trans-golgi network (TGN) is first cleaved at the N-terminus by β-secretase 
yielding a large, secreted fragment, sAPPβ, and a small, membrane-bound C-terminal fragment, 
C99, that contains the Aβ domain.  C99 is then cleaved by a second protease complex, γ-
secretase, which is comprised of four transmembrane proteins: presenilin 1/2 (active site), Aph-1, 
PEN-2, and nicastrin.  The γ-secretase cleavage, which also occurs in the TGN or endosome 
compartments, releases the APP intracellular domain (AICD) fragment and Aβ peptides of either 
40 or 42 amino acids in length, which are exocytosed out of the cell.  While Aβ42 peptides 
constitute only a small fraction of the total Aβ produced, they are known to be more highly 
amyloidogenic and are more likely to contribute to fibril formation in the CNS.  Alternatively, APP 
can be cleaved by α-secretase (primarily by ADAM10, a matrix metalloprotease) at the plasma 
membrane yielding sAPPα and C83 fragments and, after sequential cleavage by γ-secretase, a 
non-toxic p3 peptide plus AICD. Importantly, α-secretase cleavage of APP occurs within the Aβ 
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domain, preventing the production of any Aβ peptides and thus constituting the non-
amyloidogenic pathway of APP metabolism.  Although Aβ is produced during normal cellular 
conditions, its physiological function remains elusive.  Additionally, it is unclear when normal 
production of Aβ becomes pathogenic, although familial AD (FAD) mutations that lead to early-
onset AD typically result in enhanced processing of APP through the amyloidogenic pathway, 
indicating that cleavage of APP is normally skewed heavily towards α-secretase and disruption of 
this homeostatic balance can lead to pathology.  Other FAD mutations linked to γ-secretase shift 
the ratio of Aβ40:Aβ42 production towards increased Aβ42, triggering enhanced fibrillogenesis 
and plaque deposition (226).  Importantly, overexpression of APP, even in the absence of FAD 
mutations that alter APP processing, is sufficient to cause amyloid pathology, which is best 
exemplified in trisomy 21, wherein patients harbor three copies of the APP gene and develop 
early onset memory loss accompanied by senile plaque and NFT formation in the CNS (227, 
228).    
Following the characterization of APP processing in the early 1990s, intensive efforts 
were directed towards identifying the enzyme responsible for β-secretase activity in neurons.  
Extensive biochemical analysis revealed that β-secretase was insensitive to pepstatin, closely 
associated with membranes, highly expressed in neurons, and most enzymatically active in acidic 
compartments of the secretory pathway (221, 229).  Initially, cathepsin D, a major endosomal/ 
lysosomal aspartyl protease upregulated in AD and located in senile plaques, was thought to be 
responsible for β- or γ-site cleavage of APP (230-232).  However, follow up studies in cathepsin 
D knockout mice indicated this protease had no role in amyloidogenic or non-amyloidogenic APP 
processing and was responsible only for lysosomal degradation of Aβ (233, 234).  In 1999, a 
novel, 501 amino acid transmembrane aspartyl protease, BACE1, was identified by five 
independent groups as the major β-secretase enzyme (235-239).  BACE1 was found to be 
expressed in most cell types and tissues throughout the body with the highest levels in the brain 
and pancreas.  Within the CNS, BACE1 protein and mRNA are expressed at high levels in 
neurons and at much lower levels in astrocytes.  Importantly, BACE1 protein and activity are 
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elevated in transgenic mouse models of AD and in brains of familial and sporadic AD patients 
compared to age-matched controls (240-242).  Furthermore, immunohistochemical analysis by 
Vassar and colleagues showed BACE1 elevation occurs in swollen dystrophic neurites near 
amyloid plaques and co-localizes with APP, implicating BACE1 as a causal agent in AD 
pathogenesis (243).    
Further characterization of BACE1 revealed that it is synthesized in the ER as a 60 kDa 
zymogen that undergoes rapid maturation to the active 70 kDa form following N-terminal 
cleavage by furin and N-linked glycosylation at four asparagine residues in the ER and Golgi.  
Mature BACE1 cycles between compartments of the secretory pathway, similar to APP, and 
displays peak enzymatic activity in endosomes at pH 4.5, from where it can be ubiquitinated and 
sent to the proteasome or transported to the lysosome for degradation.  In addition to APP, 
BACE1 has been shown to cleave a variety of other targets, including neuregulin 1 (NRG1) type 
III, which plays an important role in myelination of the peripheral nervous system (PNS). Although 
BACE1 knockout mice were initially thought to be physiologically normal, it is now evident that 
these animals display hypomyelination in the PNS, similar to that observed in NRG1 type III 
knockouts, indicating that a key physiological role of BACE1 may be regulation and/or 
maintenance of myelination via cleavage of NRG1.  Within the CNS, BACE1 is concentrated 
within pre-synaptic terminals and is believed to play a role in maintenance of synaptic function.  
Consistent with this idea, BACE1 -/- mice display a variety of complex neurological and 
behavioral abnormalities including memory deficits, axon guidance defects, hyperactivity, reduced 
serotonin and dopamine levels in the hippocampus, and spontaneous seizures.  These 
phenotypes are not recapitulated in APP or APP-like protein null mice, suggesting they are 
related to other established BACE1 substrates, such as NRG1 and Nav1 β2, or novel functions of 
BACE1 within the CNS.   
 BACE1 expression peaks in early postnatal brain indicating it may also play a role in 
growth and differentiation (244).  Given the multitude of processes mediated by BACE1, it is thus 
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unsurprising that BACE1 expression is tightly controlled at the transcriptional and translational 
levels.  The human BACE1 gene spans 30 kb and contains a complex promoter with binding sites 
for a host of transcription factors including Sp1, HIF-1α, and nuclear factor-κB (NF-κB), which 
suppresses BACE1 under normal cellular conditions but increases the transcription of BACE1 in 
the presence of stressors, such as Aβ peptides, indicating BACE1 may play a role in stress 
response or homeostasis signaling (245, 246).  The BACE1 promoter is also differentially 
regulated by oxidative stress and inflammatory mediators, such as interferon gamma (INFγ) 
which activates Janus Kinase 2 (JAK2) and extracellular signal related MAP kinase 1/2 (ERK 1/2) 
leading to STAT1 phosphorylation and subsequent upregulation of BACE1 expression (247).  
Yet, despite the presence of inflammation and oxidative stress in AD, upregulation of BACE1 
appears to be mediated primarily at the post-transcriptional level given that protein levels are 
consistently elevated in the CNS without corresponding changes in mRNA (241, 248-252).  
BACE1 translation is known to be strictly regulated on multiple levels, consistent with the 
presence of a long, highly conserved leader sequence (246).  In particular, the BACE1 5’ UTR is 
446 nucleotides long, with 3 uORFs, two of which contain uAUGs that reside in optimal contexts 
for translational initiation, and has a GC content of 77%, which contributes to the formation of 
stable secondary structures (253).  Translation of BACE1 occurs through a cap-dependent 
mechanism with no detectable IRES activity, indicating that uORFs and secondary structure are 
the primary mechanisms of BACE1 translational regulation (253, 254).  Although there is 
disagreement in the literature, several mutagenesis analyses revealed that uAUG #2 has the 
strongest inhibitory effect on translation initiation while the other two uAUGs are largely bypassed 
via leaky ribosome scanning or ribosome shunting and do not contribute significantly to 
translational block (253-256).  In contrast, a report by Lammich et. al. concluded that the uORFs 
in BACE1 contribute minimally to translational repression and that tightly folded secondary 
structures in the UTR with a predicted free energy of -215.3 kcal/mol were sufficient to inhibit 
translation (253).  Additionally, there is evidence that the BACE1 5’ leader sequence undergoes 
alternative splicing that can reduce the number of uAUGs and improve translational efficiency 
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(257).  In short, BACE1 is subject to complex translational controls that result in very low protein 
expression under normal conditions.  However, recent evidence indicates that translational block 
of BACE1 is overcome during various stress conditions that activate mediators of the unfolded 
protein response.  A report by O’Connor et. al. in 2008 was the first to describe that energy 
deprivation in neurons results in chronic activation of PERK, phosphorylation of eIF2α, and 
translational de-repression of BACE1 leading to enhanced amyloidogenesis in vivo (191).  Others 
have shown that oxidative stress leads to translational upregulation of BACE1 through PKR-
mediated phosphorylation of eIF2α (176, 178).  Altogether, these observations strongly reinforce 
an emerging hypothesis that BACE1 may act as a stress response protein in the CNS.  Potential 
mechanisms by which BACE1 activity could be protective to neurons remains an area of active 
investigation.  A recent report demonstrated that BACE1 is upregulated in zebrafish in response 
to low oxygen levels via transcriptional upregulation by HIF-1, similar to what is seen in 
mammals, suggesting that activation of BACE1 is an evolutionarily conserved mechanism (258).  
Furthermore, BACE1 processing of APP to generate Aβ appears to be an activity dependent 
process in hippocampal neurons whereby Aβ protects cells from hyperactivity and excitotoxicity 
(259).  Therefore, it is reasonable to assume that BACE1 upregulation serves a neuroprotective 
function during acute stress conditions in the brain.  However, chronic inflammation, hypoxia, 
oxidative stress, and ER stress, which are hallmarks of many neurodegenerative disorders, might 
lead to unchecked, maladaptive BACE1 activation and over-production of Aβ.  This would 
explain, in part, why amyloid pathology is often found in neurodegenerative disorders other than 
AD.  Thus, BACE1 has emerged as a key therapeutic target that lies at the crossroads between 
cellular stress, stress response signaling, and Aβ production in AD and a growing list of other 
chronic, neurodegenerative diseases. 
1.6: RATIONALE AND HYPOTHESIS  
 HAND has evolved into a complex, neurodegenerative condition that has persisted 
despite the use of successful antiretroviral therapy.  Initial studies of the underlying mechanisms 
contributing to dementia in patients with HIV suggest that inflammation and excitotoxicity are key 
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mediators of neuronal damage and death.  However, adjunctive therapies with anti-inflammatory 
and anti-excitotoxic properties have proved to be unsuccessful in the treatment of HAND.  
Additionally, the use of ART regimens with high CNS penetrance has yielded mixed 
neuropsychological results in patients with HIV, suggesting that ART is either unable to mitigate 
neuronal damage in HAND or contributes to the neurodegenerative process.  We hypothesized 
that the persistence and evolution of HAND is a direct result of antiretroviral neurotoxicity in the 
CNS, leading to chronic ER stress, translational upregulation of BACE1, and aberrant 
amyloidogenic processing of APP.   First, we provide an extensive review the contributing factors 
to HAND pathogenesis, including inflammation, aging, drugs of abuse, and antiretroviral 
neurotoxicity (Chapter 2).  Next, we used in vitro models to demonstrate for the first time that ART 
drugs, and PIs in particular, potently activate the neuronal unfolded protein response leading to 
PERK-dependent phosphorylation of eIF2α and translational upregulation of BACE1 (Chapter 3).  
Importantly, enhanced BACE1 expression was accompanied by increased Aβ42 production in 
ART-treated cells, which was dose-dependently blocked with a cell-permeable beta-secretase 
inhibitor.  These findings were corroborated by our in vivo findings that SIV-infected, ART-treated 
macaques and ART-treated, HIV-positive patients display increased expression of UPR markers, 
BACE1, and Aβ oligomers compared to age-matched controls (humans only) (Chapter 3).   
 We also sought to determine the role of BACE1 in neuronal survival under conditions of 
oxidative and ER stress (Chapter 4).  In contradiction to the idea that BACE1 plays a protective in 
acute cellular adaptation to stress, we found that inhibition of BACE1 protected neurons against 
damage and death in the presence of hydrogen peroxide or ritonavir in vitro.  Furthermore, using 
a pharmacological approach, we found that PKR may be critical for ART-mediated 
phosphorylation of eIF2α and BACE1 upregulation. 
 Altogether, this body of work implicates HIV protease inhibitor class ART drugs in the 
persistence and evolution of HAND pathology via chronic induction of ER stress in neurons.  We 
have characterized a specific mechanism by which PIs induce translational upregulation of 
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BACE1 leading to enhanced amyloidogenic cleavage of APP and corroborated these findings 
with post-mortem analysis in human patients.  We have also identified BACE1 as a key 
therapeutic target in HAND, that appears to be mediate some of the neurotoxic effect of 
antiretroviral drugs and, more broadly, oxidative stressors, such as hydrogen peroxide.  
Ultimately, this work contributes to our understanding of HAND pathogenesis and the basic 
biological functions of BACE1 in neurons, which will enhance our ability to treat and prevent 
neurodegenerative disease.  
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Figure 1.  Phosphorylation of eIF2α by four kinases integrates cellular stress responses.  A 
wide variety of stress conditions result in phosphorylation of the eukaryotic translation initiation 
factor 2α (eIF2α) which is mediated by four distinct kinases, PERK, PKR, GCN2, and HRI that 
display cell- and tissue-specific expression levels.  Phosphorylated eIF2α results in decreased 
translation of most mRNAs, which reduces the influx of new proteins into the ER to alleviate ER 
stress.  Paradoxically, a subset of mRNAs that contain upstream open reading frames (uORFs) in 
the 5’ UTR, which are normally repressed, are translationally upregulated leading to increased 
expression of transcription factors, such as ATF4, that active gene transcription of molecular 
chaperones involved in protein re-folding .  Alternatively, chronic induction of phospho-eIF2α can 
lead to expression of CHOP which activates apoptotic cell death.  
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2.1: ABSTRACT 
Purpose:  This review discusses current concepts of HIV-associated neurocognitive disorders 
(HAND) in the era of anti-retroviral therapy (ART).  As the HIV epidemic enters its fourth decade 
(the second decade of ART), research must address evolving factors in HAND pathogenesis.  
These include persistent systemic and central nervous system (CNS) inflammation, aging in the 
HIV infected brain, HIV subtype (clade) distribution, concomitant use of drugs of abuse, and 
potential neurotoxicity of ART drugs.     
Recent findings:  Although the severest form of HAND, HIV-associated dementia (HAD) is now 
rare due to ART, the persistence of milder, functionally important HAND forms persist in up to half 
of HIV-infected individuals.  HAND prevalence may be higher in areas of Africa where different 
HIV subtypes predominate, and ART regimens that are more effective in suppressing CNS HIV 
replication can improve neurological outcomes.  HAND is correlated with persistent systemic and 
CNS inflammation, and enhanced neuronal injury due to stimulant abuse (cocaine and 
methamphetamine), aging, and possibly ART drugs themselves.  
Summary:  Prevention and treatment of HAND requires strategies aimed at suppressing CNS HIV 
replication and effects of systemic and CNS inflammation in aging and substance-abusing HIV 
populations.  Use of improved CNS-penetrating ART must be accompanied by evaluation of 
potential ART neurotoxicity. 
Key words:  HIV, cognitive dysfunction, inflammation, antiretroviral therapy, HIV- associated 
neurocognitive disorders 
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2.2: INTRODUCTION 
The term HIV-associated Neurocognitive Disorders, or HAND, represents a group of syndromes 
of varying degrees of impairment of cognition and associated functioning in HIV infected 
individuals [1,2].  Its clinical severity ranges from asymptomatic neuropsychological impairment 
(ANI) through Minor Cognitive Motor Disorder (MCMD) and HIV-associated dementia (HAD), 
grouped collectively as HAND.  The neuropathogenesis of HAND is generally considered to be 
initiated and driven by HIV invasion and replication within the brain parenchyma, largely through 
productive infection of brain perivascular macrophages and endogenous microglia, and perhaps 
to some degree by restricted infection of astrocytes [3,4].  Associated with this infection is 
neuroinflammation and immune activation of resident glia (macrophages, microglia, astrocytes), 
which is associated with neuronal injury (both reversible and irreversible).  Although the 
widespread utilization of anti-retroviral therapy (ART) has dramatically decreased the prevalence 
of the severest form of HAND, HAD, the overall prevalence of HAND and associated morbidity 
remain high (~50%) [5-8**].  The persistence of this high risk for HAND in individuals 
experiencing effective control of systemic HIV viral load is incompletely explained, and suggested 
factors include effects of aging on brain vulnerability, persistence of HIV replication in brain 
macrophages, evolution of highly neurovirulent CNS HIV strains, and even long-term CNS toxicity 
of ART [8**,9**].  This review will discuss several of these key factors implicated in modulating 
HAND pathogenesis:  inflammation, HIV-1 subtype (clade), drugs of abuse, aging, and 
antiretroviral drug effects.  Other important factors, including co-morbidity effects of Hepatitis C, 
host genetic susceptibility, viral gene adaptations, and others are discussed elsewhere 
[4,10*,11*].            
 
2.3: ROLE FOR INFLAMMATION IN NEUROPATHOGENESIS OF HIV-ASSOCIATED 
NEUROCOGNITIVE DISORDERS 
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Inflammation is associated with HIV replication, both in the periphery and within the CNS where 
macrophage activation has been correlated with HAND [12,13].  In the last few years the 
inflammatory response in the systemic circulation has been recognized as a key driver of HIV 
pathogenesis, both in the periphery and in the CNS [14**-26].  In the CNS there is considerable 
evidence that this inflammatory response drives the development of HAND or worsens it, possibly 
independently of viral replication [4,27*-29].     
 
Evidence for persistent inflammation in the CNS in the ART-experienced patients. The era of ART 
is associated with changes in the neuropathology of HIV infection, which reflects the partial 
efficacy of ART drugs in suppressing, albeit incompletely, CNS virus replication and associated 
inflammation [30-32].  Before the introduction of ART, robust neuroinflammation was frequently 
observed in brain autopsies from HIV-infected patients and the severity of inflammation generally 
increased throughout clinical disease progression from the early asymptomatic stage to AIDS to 
severe HAND [33-36].  Although inflammation is less severe since ART inception, it nonetheless 
persists within the macrophage/microglial populations, which represent the primary reservoir for 
HIV in the brain [37-38].  Perivascular monocyte-derived macrophages (MDM) and microglia are 
the primary CD4+cells in the CNS and the major sources of productive HIV infection in the brain 
[39-42] and clinical disease severity correlates more strongly with the amount of monocyte 
infiltration and MDM/microglia activation than with the quantity of infected cells or viral load 
[12,13].  This suggests that MDM/microglia play a predominant role in the neuroinflammation and 
neurodegeneration seen in HAND.  Immune activation of MDM/microglia is demonstrated by 
expression of CD14 (LPS receptor), CD16, CD68, and MHC class II in vivo [34,43-45].     
Furthermore, cerebrospinal fluid markers of immune activation and inflammation are commonly 
detected in individuals with HAND.  These markers include CCL2 [46,47]  [48-
51], quinolinic acid [52-55], arachidonic acid metabolites [56,57], oxidative stress markers [58,59], 
and platelet activating factor [60].  
Although ART has limited the severity of pathological changes characteristic of HAND, it has not 
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eliminated them.  These persistent pathological findings in ART-experienced individuals include 
neuronal loss with apoptosis, astrocytosis, myelin pallor, and at least some activated microglia 
and perivascular macrophages, although the neuropathological hallmarks of HIVE, multinucleated 
giant cells and microglial nodules, are typically absent [37].  Persistent CNS immune activation 
has also been documented in pediatric AIDS patients, as evidenced by detection of sCD14 and 
an elevated CSF IgG index despite prolonged (>4 years) ART use and undetectable serum viral 
loads [61].  Thus, despite some ART effectiveness in limiting the infiltration of infected cells 
(monocytes/macrophages) into the CNS, neuroinflammation still persists. Nonetheless, the 
primary sites of neuroinflammation are different; the characteristic involvement of the basal 
ganglia in pre-ART specimens is less commonly seen in post-ART specimens, which display 
inflammation in the hippocampus and in adjacent parts of the entorhinal and temporal cortices 
[32,38,62].  Overall these studies confirm the notion that neuroinflammation continues to be 
associated with HIV CNS infection in ART-experienced individuals [63]. 
Chronic systemic inflammation and microbial translocation in the gut as a driving force for CNS 
inflammation and HAND. Chronic systemic inflammation has been tightly linked to morbidity and 
mortality in HIV infected patients receiving ART, which suggests that adjunctive anti-inflammatory 
drug therapy is needed to improve outcomes [14**-26]. Studies have correlated systemic 
inflammation (elevated plasma sCD14, LPS), CNS inflammation and HAND [64] and persistence 
of CSF immune activation (sCD14, elevated IgG index) despite ART use and undetectable serum 
viral loads [61].  A strong association between the early and persistent damage caused to gut-
associated lymphoid tissue (GALT) by HIV infection (SIV infection in macaques), increased 
microbial translocation resulting in systemic immune/monocyte activation, and disease 
progression has been established [21,22*,24-26,65].    An association between this systemic 
immune activation and HAND has also been established, and a causal relationship between 
increased systemic monocyte activation, increased transendothelial migration of activated 
monocytes into the brain, and neurocognitive decline secondary to neurodegeneration has been 
proposed [64].  Furthermore, the persistence of HAND (~50% prevalence) despite prolonged 
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ART use is associated with not only neuropathologic but also neuroradiologic evidence of 
persistent CNS inflammation [7,61,66*-68].  Persistent systemic and CNS inflammation in ART-
treated individuals are thus clear targets for adjunctive therapies against disease progression. 
 
2.4: ASSOCIATION OF HIV-1 CLADES/SUBTYPES AND RISK OF HIV-ASSOCIATED 
NEUROCOGNITIVE DISORDERS 
Until recently, HAND has been studied nearly exclusively in developed countries (United States 
and Europe), where a single HIV clade, or genotypically-defined subtype predominates (HIV 
clade B).  The distribution of HIV-1 clades varies worldwide, and differences in phenotypic 
characteristics including induction of immune responses, viral fitness, drug resistance, co-
receptor utilization, antibody neutralization sensitivity, and neuruovirulence among HIV clades 
have been described [69-76].  Several recent publications have suggested that HAND prevalence 
varies among populations based upon clade predominance, thus representing an independent 
risk factor for HAND [77,78].  The majority of clinical studies have been performed in cohorts 
infected with clade B, and the neuropathogenesis of HAND has, until recently, been exclusively 
described in these populations. Furthermore, HIV clades can be further modified through genetic 
recombination events, which could alter their pathogenic potential.  Early studies in Uganda 
(where clades A and D predominate), have shown that prevalence of some HAND features is 
comparable to that observed in the United States during the pre-ART era, and that advanced age 
and low CD4+ T cell count are major risk factors [81*]. Other investigators observed a greater 
prevalence of HAND in anti-retroviral-naïve HIV+
 
individuals in Uganda who are infected with 
clade D strains in comparison with individuals infected with clade A strains (89% vs. 24%) [79*].  
Notably, the use of ART can significantly improve neurocognitive function in these individuals 
within a few months [80]. 
 
More studies have focused on clade C, as it is the most common HIV clade and it accounts for 
approximately 50% of HIV infections worldwide, Clade C is linked to growing epidemics in sub-
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Saharan Africa and parts of Asia, including China and India [81*]. Some studies have associated 
infection with clade C with a low risk for HAND (in Ethiopia) while others (performed by Australia-
Pacific NeuroAIDS consortium in many countries in the Pacific Rim) associate it with a higher 
risk.  Studies in India, where clade C accounts for 95% of HIV infections, have produced 
conflicting results.  In southern India, approximately 60.5% of ART-naïve HIV+
 
individuals in one 
study (n=119) were found to have neuropsychological test impairments without clinically 
identifiable neurological symptoms (consistent with asymptomatic HAND, ANI), while another 
study indicated a higher than expected prevalence of clinically symptomatic HAND.  A study of 
HIV+ (clade C) individuals in China, showed that the prevalence, pattern and severity of some 
HAND deficits were comparable to those reported for (clade B) in western countries.  Finally, a 
recent study of clade C-infected ART-experienced (average 2 years on ART) individuals in 
Botswana, demonstrated a prevalence of neurocognitive impairment detected by 
neuropsychological testing and a modified International HIV Dementia Scale (IHDS) of greater 
than 33%, which exceeds the expected prevalence of HAD, even in the pre-ART era [82*].  Thus, 
several studies in distinct clade C cohorts worldwide suggest a potentially high risk for moderate 
to severe HAND complications with clade C infection.  Notably, despite possible different risks for 
HAND among these different HIV clades, beneficial effects of ART have been demonstrated 
worldwide (reviewed in [83*]). 
 
2.5: ASSOCIATION OF DRUGS OF ABUSSE AND RISK FOR HIV-ASSOCIATED 
NEUROCOGNITIVE DISODERS 
Although the strict definition of HAND requires the exclusion of other co-morbid conditions 
(besides HIV infection) as the cause of neurocognitive dysfunction, the contribution of drugs of 
abuse as a major co-morbidity risk for neurocognitive dysfunction in HIV+ individuals is a major 
concern worldwide [84-87*].  Among the major drugs of abuse contributing to HIV pathogenesis 
are opiates (morphine), and stimulants (cocaine, methamphetamine/METH).  In developed 
countries, approximately 30% of HIV+ individuals are intravenous drug abusers, and the risk for 
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HAND is clearly greater among these individuals [87*]. The neuroinflammation associated with 
HAND appears to be exacerbated by drugs of abuse, as demonstrated by brain autopsy studies 
revealing a higher prevalence of HIV encephalitis (microglia activation, presence of 
multinucleated giant cells, and blood brain barrier disruption) in drug-abusing HIV+ individuals in 
comparison with non-abusing HIV+ controls [88-90]. These findings suggest that drug abuse, 
exerts an additive (if not synergistic) effect with HIV within the CNS. However, the inherently 
heterogeneous nature of drug abusing patient populations confounds the specific effects of drugs 
of abuse on neuronal function and survival in vivo.  
 
Both in vitro and in vivo studies, however, clearly implicate drugs of abuse in exacerbating 
neuronal injury induced by HIV (or the primate homolog, SIV/simian immunodeficiency virus), 
although conflicting evidence for certain drugs of abuse has been presented [91-97].  Enhanced 
HIV replication in MDM and T lymphocytes through opioid exposure has been demonstrated [98-
100] as has enhancement of MDM-associated inflammation and oxidative stress [101].  Opiates 
(methadone) also activate HIV replication in latently infected macrophages in vitro [102].  In 
nonhuman primate models of simian immunodeficiency (SIV) infection (the primate homologue of 
HIV infection), carefully controlled studies show that chronic morphine administration markedly 
increases viral loads in the plasma and cerebrospinal fluid (CSF) [103]. Interestingly, activation of 
mu opioid receptors, which are expressed in neurons, MDM, and T lymphocytes, can increase 
the expression of some of the chemokine receptors (CCR3, CCR5, and CXCR4) that serve as 
HIV co-receptors for HIV in susceptible cells (MDM, T lymphocytes) [104,105].  Furthermore, 
activation of Kappa opioid receptors (MDM, T lymphocytes) can decrease CCR5 expression, and 
thus decrease cell susceptibility to HIV infection [106,107].  Nonetheless, a role for opiates in 
exacerbating neurodegeneration in HAND remains controversial [85*,108].   
 
A role for stimulants such as cocaine and methamphetamine in exacerbating the risk for HAND is 
more strongly established by in vivo and in vitro studies [109].  Enhancement of HIV replication in 
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MDM by stimulants (cocaine, methamphetamine) has been consistently demonstrated in vitro, 
and the expected consequence of enhanced HIV replication in MDM is enhanced 
neurodegeneration through enhanced production of neurotoxic factors from infected and 
activated macrophages within the CNS [3,84].   Cocaine can also increase HIV replication in 
monocytes, and even astrocytes in vitro [110,111]. The later observation could be significant, as 
restricted infection of astrocytes in vivo has been demonstrated in several studies, suggested that 
this could be a second HIV reservoir (in addition to the primary HIV reservoir, 
macrophages/microglia) [112-114].  In addition, cocaine can facilitate HIV infection by 
upregulating DC-SIGN, another HIV co-receptor, in dendritic cells, through dysregulation of 
mitogen-activated protein kinases [115]. Methamphetamine can increase macrophage HIV 
infection in association with increased expression of CXCR4 and CCR5, and perhaps by 
downregulation of extracellular-regulated kinase (ERK) and the upregulation of p38 mitogen-
activated protein kinase [116].  Methamphetamine can also enhance HIV replication in monocyte-
derived dendritic cells [116].   
 
Alterations in blood-brain-barrier (BBB) integrity by cocaine and methamphetamine are another 
proposed mechanism for enhancing neurodegeneration through enhanced monocyte entry and 
disruption of cellular homeostasis.  In vitro, cocaine can enhance monocyte transendothelial 
migration, induce the expression of adhesion molecules on endothelial cells, and disrupt 
intercellular junctions [117-119]. Methamphetamine and the HIV envelope protein, gp120, can 
modulate tight junction expression in brain endothelial cells, leading to decreased 
transendothelial resistance across the blood–brain barrier and enhanced transendothelial 
migration of monocytes [120].  Morphine alone, on the other hand, does not appear to alter the 
integrity of the blood–brain barrier, although in combination with the HIV transactivator protein, 
Tat, it can alter tight junction expression in brain endothelial cells in vitro.  Interestingly, although 
morphine by itself is not toxic to striatal neurons in culture, it can significantly potentiate Tat 
toxicity in striatal neurons [121].  Thus, these studies of effects HIV-derived proteins and cocaine 
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and methamphetamine that demonstrate alterations in endothelial cell function and/or disruption 
the blood–brain barrier suggest potential additive effects of HIV infection, cocaine and 
methamphetamine in vivo.    
 
Evidence for in vivo neuropathologic effects of cocaine and methamphetamine in HIV+ individuals 
is also accumulating [85*].  Disruption of the blood–brain barrier in such individuals has been 
demonstrated in neuropathologic studies, and this disruption correlates with early inflammatory 
changes in the CSF, particularly with increased monocyte chemoattractant protein-1 (MCP-
1/CCL2) levels [122]. However, whether BBB integrity is even further compromised in individuals 
abusing cocaine or methamphetamine is unknown.   Autopsy studies of adult methamphetamine 
abusers have demonstrated neuronal loss within the substantia nigra and structural and 
metabolic changes within the brain have been detected in children after prenatal exposure 
[123,124].  Injury to dopaminergic pathways and the basal ganglia also occurs in HIV+ individuals 
in the presence and absence of abuse of cocaine, which can result in profound clinical symptoms 
of basal ganglia dysfunction [125].  Thus, drugs of abuse, particularly cocaine and 
methamphetamine are strongly associated with enhanced brain injury in HIV+ individuals, which 
is expressed as enhanced risk for HAND and other neurologic complications.   
 
2.6: AGING AND HIV-ASSOCIATED NEUROCOGNITIVE DISODERS  
The long-term prognosis for ART-treated HIV+ individuals continues to improve as the incidence 
of many AIDS-related complications declines, and by 2015 more than 50% of the HIV+ population 
in the United States will be over 50 years of age [14**].  Nonetheless, life expectancy for treated 
HIV+ individuals remains 10 to 30 years less than uninfected individuals [14**].  ART-treated 
patients are at increased risk for systemic and CNS diseases associated with aging:  renal failure, 
osteoporosis, cancer, cardiovascular disease, and cognitive decline, which can be associated 
with Alzheimer’s disease (AD) and Parkinson’s disease (PD)-like pathology [14*,126*].  This 
suggests that the aging brain might be more vulnerable to neuronal injury associated with HIV 
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infection, although co-morbidity factors in aging patients complicate establishing a causal 
relationship between age and HAND risk. 
 
Several published neuroimaging and neurobehavioral studies have suggested an increased risk 
for cognitive impairment with increased age in HIV+ individuals [66*,127,128], although an 
additional study has suggested that the effects of HIV infection and aging in the brain might act 
independently [129].   Ernst and Chang [127] used brain proton magnetic resonance 
spectroscopy (MRS) to demonstrate that the combined effects of HIV+ serostatus resulted in a 
greater than five-fold acceleration of aging effects (rather than additive effects) in the basal 
ganglia, in a cohort of 46 HIV+ subjects in comparison with HIV negative controls.  Cherner et al 
[128] showed that an HIV+ subject cohort with an age greater than 50 years and detectable CSF 
viral loads had a two-fold higher prevalence of neuropsychological impairment in comparison with 
a younger cohort (less than 35 years of age) showing undetectable viral loads.  Notably, this 
relationship was not found in those individuals younger than 50 years of age.  These studies 
suggest that older adults are at higher risk for neurocognitive dysfunction because of age-related 
brain vulnerability;  however, whether this dysfunction reflects accelerated neuropathological 
processes associated more specifically with HAND or processes more specifically associated 
with other familiar neurodegenerative diseases, or neither, remains to be determined.   
 
Some recent studies have begun to address the underlying neuropathology of age-related 
neurocognitive dysfunction in HIV+ subjects.  AD and PD-like pathological changes observed in 
ART-treated patients [130*,131] include elevated levels of hyperphosphorylated Tau (p-Tau) in 
the hippocampus and beta-amyloid (Aβ) deposition, both intra and extracellular, in the frontal 
cortex and hippocampus [132-135]. Recent evidence has also shown increased levels of alpha-
synuclein in the substantia nigra and increased risk for PD in aging HIV+ patients on ART [131].  
Although accumulation of neurodegenerative-related proteins might be accounted for by the 
increased lifespan associated with ART, possible toxic effects of ART in the CNS are now being 
59 
 
considered as a contributing factor in HAND [11*,136*]. One study demonstrated that pre-ART 
subjects who lived up 15 years with HIV infection did not express excessive levels of 
hyperphosphorylated Tau or beta-amyloid, nor were they associated with HAND [38]. Other 
studies have demonstrated increased levels of amyloid precursor protein in damaged axons in 
brain specimens from ART-naive patients without evidence for elevated p-Tau expression or 
neuritic plaque formation [137,138].  Thus, studies utilizing neuropsychological performance 
testing, neuroimaging, and neuropathological analyses strongly support a strong correlation 
between accelerated neurocognitive decline driven by HIV infection in aging individuals, even 
those with what is considered ‘effective’ suppression of systemic HIV replication.  These studies 
further emphasize the need for developing new strategies, involving current ART and possibly 
adjunctive therapies, for protecting the brain against injury in the aging HIV+ population.   
 
2.7: POSSIBLE ROLE FOR ANTIRETROVIRAL THERAPY DRUGS IN HIV-ASSOCIATED 
NEUROCOGNITIVE DISORDERS 
The persistent high prevalence of less severe forms of HAND, including ANI and MCMD, after 
widespread implementation of ART was not anticipated, and several causes have been 
suggested, including effects of aging and associated co-morbidity factors on the brain [9*,39,66*].  
Antiretroviral drugs, particularly nucleoside reverse transcriptase inhibitors (NRTIs) are highly 
neurotoxic, and ART drug-induced neuropathy is a major complication of HIV treatment [10*].  In 
addition, some clinical studies have also suggested a role for direct and/or indirect neurotoxic 
effects of ART drugs in the CNS [139-141].  In addition to direct neurotoxicity, ART has been 
linked to multiple risk factors for neurodegenerative disease, such as insulin resistance, 
lipodystrophy, atherosclerosis, coronary artery disease, and immune reconstitution syndrome 
[142-149].  These studies suggest possible direct and indirect effects of ART drugs in the CNS 
that could be linked to impaired neurocognitive performance.  
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However, other studies have demonstrated beneficial effects on neurocognitive functioning by 
ART regimens ranked according to their predicted effectiveness (termed CNS penetration-
effectiveness ranking, CPE) in suppressing HIV replication within the CNS [8*, 150*-152].  Better 
neurocognitive performance was observed over a 15 week period in adult individuals beginning 
ART with regimens of higher CPE [151] and improved survival rates over 6+ years of follow up of 
pediatric HIV encephalopathy patients receiving higher CNS-penetrating regimens were also 
observed [153**,154**].   A cross sectional study of 2636 adults (ALLRT cohort) on effective ART 
(less than 50 HIV RNA copies/ml) also demonstrated better neurocognitive performance in those 
receiving higher CPE ART [150*].  Another recent study utilized MRS brain imaging and 
neurocognitive testing to demonstrate partial reversal of neuronal injury in patients and greater 
improvements in neurocognitive functioning in other patients receiving different ART regimens 
over a 48 week period, which might relate to CNS drug penetrance [155*].  These studies 
suggest a neuroprotective effect of ART based upon use of higher CPE regimens, and ongoing 
prospective clinical studies are further addressing this critical issue [8**,9**,154**].   
 
2.8: CONCLUSION 
HAND pathogenesis is driven by HIV replication and the factors associated with amplifying the 
inflammatory milieu within the CNS.  Systemic immune activation, migration of activated 
monocytes, drugs of abuse, and secondary effects of aging all contribute to neuronal injury 
associated with HAND, which persists despite effective systemic control of HIV replication by 
current ART. Accordingly, drugs that suppress systemic immune activation and associated 
inflammation, both systemically and within the CNS compartment, could represent effective 
adjunctive neuroprotectants [4, 27*-29]. Investigating drugs in current clinical use that target 
these cellular pathways could rapidly facilitate testing and implementation of feasible adjunctive 
neuroprotective strategies against HAND.  
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3.1: ABSTRACT 
The clinical and pathologic presentation of HIV-associated neurocognitive disorders (HAND) has 
changed in the post-antiretroviral (ARV) era, evolving from a subacute, subcortical dementia to a 
cortical, neurodegenerative disease.  Mounting evidence implicates ARVs as potential 
contributing factors to the persistence and evolution of HAND.  Based on their ability to induce ER 
stress in a wide variety of cell types, we hypothesized that ARVs also cause ER stress in the 
CNS, resulting in chronic dysregulation of the unfolded protein response (UPR) and altered 
amyloid precursor protein (APP) processing.  Here, we utilized in vitro and in vivo models to show 
that HIV protease inhibitor (PIs) class ARVs induce neuronal ER stress leading to PKR-like ER 
kinase (PERK)-dependent phosphorylation of the eukaryotic translation initiation factor 2α 
(eIF2α), and enhanced translation of β-site APP cleaving enzyme-1 (BACE1).  Additionally, we 
demonstrate PI-mediated Aβ production, indicative of amyloidogenic APP processing, in primary 
rodent neuroglial cultures and Chinese Hamster Ovary (CHO) cells expressing human APP.  
These effects were abrogated by genetic excision of PERK or overexpression of a kinase-dead 
PERK mutant.  Finally, ARVs administered to SIV-infected macaques resulted in elevated levels 
of APP in the CNS. Altogether, these findings implicate PIs as potential mediators of 
neurodegeneration in HAND.   
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3.2: INTRODUCTION 
The advent of antiretroviral (ARV) therapy as the mainstay for HIV treatment has significantly 
reduced the prevalence of HIV-associated dementia (HAD), a severe motor/cognitive disorder 
afflicting AIDS patients (1-3), from ~20-30% to 1-2% (1).  However, the prevalence of HIV-
associated neurocognitive disorders (HAND), a spectrum of HIV-related CNS dysfunctions 
ranging from mild cognitive deficits to HAD, has remained high despite this dramatic reduction in 
HAD prevalence (1, 4-7).  In addition, HIV-associated neuropathology has evolved from a 
subcortical encephalitis to a prolonged, cortical, neurodegenerative disease (8).  Recently, 
several groups have reported beta-amyloid (Aβ) immunoreactivity, both intra and extracellular in 
the frontal cortex and hippocampus of ARV-medicated subjects, while others have observed only 
accumulation of hyperphosphorylated Tau (8-14).  While increased longevity of HIV-infected 
populations is suggested to contribute to these changes in HAND neuropathology, other risk 
factors, such as peripheral toxicities of ARVs and potential central effects linked to enhanced 
amyloidogenesis and aging, remain largely underexplored.   
Among the six classes of ARVs currently prescribed, nucleoside reserve transcriptase 
inhibitors (NRTIs) and HIV protease inhibitors (PIs) are the oldest and continue to provide the 
backbone for treatment regimens.  NRTIs inhibit the viral reverse transcriptase enzyme, 
preventing the generation of proviral DNA from viral RNA (15).  In addition, PIs are 
peptidomimetics that bind to the active site of the HIV aspartyl protease and prevent cleavage of 
gag-pol precursor polyproteins, blocking viral maturation (16).  As a result of combination ARV 
therapy, HIV-infected individuals have experienced a 50% reduction in death rates and incidence 
of HAD (16).  Despite their numerous benefits, ARVs have been linked to wide-ranging, 
peripheral metabolic and neural disturbances that could themselves influence the progression of 
HAND.  Specifically, NRTIs have been linked to mitochondrial dysfunction, manifested clinically 
as peripheral neuropathy and myopathy. (17-19).  On the other hand, PIs have been associated 
with dyslipidemia, hypercholesterolemia, and metabolic syndrome, characterized by 
lipodystrophy, atherosclerosis, and insulin resistance (20-27). 
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We have shown that ARVs administered to healthy adult rats and SIV-infected macaques 
lead to extensive synaptodendritic damage in the CNS.  Furthermore, treatment of rat cortical 
neurons with ARVs led to accumulation of ROS and eventual synaptic damage and neuronal 
death (28).  These data support a growing body of evidence that ARVs have significant 
neurotoxic effects in the CNS, as they do in the peripheral nervous system (PNS), and may 
influence the long-term neurocognitive outcome of patients.  Importantly, NRTIs and PIs have 
each been shown to induce numerous cellular stressors, including ER and oxidative stress, both 
of which are commonly found in HAND and other neurodegenerative diseases, such as 
Alzheimer disease (AD) (29, 30).  Recently, it has become clear that diverse cellular stressors 
converge on a ubiquitous intracellular response mechanism termed the unfolded protein 
response (UPR) or ER stress response (31, 32).  In eukaryotes, the UPR entails three sensor 
proteins, pancreatic ER kinase (PERK), activating transcription factor 6 (ATF6), and inositol-
requiring enzyme 1α (IRE1), located in the ER membrane, which are kept inactive through 
complex formation with the ER-resident chaperone, Binding Protein (BiP)/GRP78 (33-35).  
Accumulation of misfolded proteins in the ER disrupts interaction between BiP and the lumenal 
domain of one or more of the three UPR sensors, permitting their consequent activation (33).  
Downstream effects of UPR induction include global protein synthesis attenuation via eIF2α 
phosphorylation, upregulation of genes containing the ER Stress Response Element (ERSE), and 
ER-mediated protein degradation (35).   
While transient UPR activation serves a protective function, the chronic nature of cellular 
stress and stress response activation in the CNS during HIV infection may ultimately overwhelm 
the capacity of the ER resulting in aberrant UPR activation and eventual cell death (30, 36).  We 
and others have demonstrated a potential role for ER stress and the UPR in the pathogenesis of 
HAND as well as other neurodegenerative diseases (30, 37-40).  The examination of post-
mortem brain tissue from ARV-treated, HIV-positive patients and AD patients shows increased 
expression of BiP, p-eIF2α, ATF6, and other markers of the UPR primarily in neuronal cells (30, 
35, 41).  Interestingly, in vivo studies utilizing glucose deprivation or tunicamycin to induce UPR 
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activation in CNS neurons have demonstrated consequent increases in APP and A deposition 
(42-44).  Vassar and colleagues subsequently showed that impaired brain energy metabolism, 
induced by glycolysis inhibition, leads to chronic activation of the PERK arm of the UPR, allowing 
for sustained phosphorylation of eIF2α and upregulation of -secretase (BACE1) (44).  Extensive 
studies have shown that phosphorylation of eIF2α globally inhibits protein translation while 
upregulating the translation of a subset of mRNA species that contain multiple upstream open 
reading frames (uORF) in the 5’-UTR, one of which is BACE1 (44).  BACE1 is an aspartyl 
protease critical for generation of Aβ from APP and is upregulated in brains of patients suffering 
from AD (45, 46).  Increased BACE1 expression and activity in the brain have been correlated 
with plaque number and cognition status, and has been implicated as a biomarker of mild 
cognitive impairment (MCI) and AD (46).  Altogether, these studies suggest that UPR-mediated 
upregulation of BACE1 may function as an early event in AD pathogenesis.     
In the present study, we sought to determine the mechanisms by which ARVs induce 
damage and death in primary CNS neurons and whether BACE1 expression and function could 
contribute.  Here, we report that PIs induce ER stress in primary neurons leading to PERK-
dependent translational upregulation of the APP-cleaving enzyme, BACE1.  Additionally, we 
found that PIs enhance production of Aβ in neurons and CHO cells stably expressing human 
APP.  Moreover, these findings were corroborated with in vivo findings that chronic ARV drug 
treatment results in CNS damage and increased expression of APP.  These findings suggest that 
PIs may be altering APP processing, and thus contributing to the changing neuropathology and 
the persistence of cognitive decline among ARV-treated, HIV-infected individuals. 
 
3.3: EXPERIMENTAL METHODS 
Chemicals and Reagents.  The following antibodies used in this study were purchased from the 
indicated vendors:  BACE1 (5606S); phospho-eIF2α (9721S); Total eIF2α (9722); Lamin A/C 
(2032S); Presinilin-1 (5643) [Cell Signaling Technology], BiP/Grp78 (610978) [BD Transduction 
Laboratories], APP (6E10) [Covance], Synaptophysin (ab8049); ADAM10 (ab1997); MAP2 (5392) 
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[Abcam], GAPDH (sc-32233) [Santa Cruz], Actin (A2066) [Sigma].  The mouse monoclonal 
antibody against BACE1 (3d5) was a generous gift from Dr. Robert Vassar (Feinberg School of 
Medicine, Northwestern University, Chicago, IL).  The antibody against Aβ-oligomers (Nab61) 
was kindly provided by Dr. Virginia Lee (The Perelman School of Medicine, University of 
Pennsylvania, Philadelphia, PA).  The antibody against ATF4 was generously provided by Dr. 
Ron Wek (School of Medicine, Indiana University, Indianapolis, IN).  The rabbit monoclonal 
antibody against PERK was a generous gift from Dr. Alan Diehl (The Abramson Family Cancer 
Research Institute, University of Pennsylvania, Philadelphia, PA).  The following chemical 
reagents used in the study were purchased from the indicated vendors: 4’,6-diamidino-2-
phenylindole (DAPI); Citifluor, Ltd. (London, UK): citifluor AF1; Dulbecco’s Modified Eagle’s 
Medium (DMEM); Neurobasal media and B27 supplement [Invitrogen], Protein assay dye (500-
0005), Polyvinylidene fluoride (PVDF) membrane; Prestained broad range molecular weight 
ladder [BioRad], Neuromag Transfection Reagent (NAN14000) [Nanotherics], Fast Green FCF; 
Protease inhibitor cocktail, 4-hydroxytamoxifen (H7904); Anisomycin (A9789); Actinomycin D 
(A1410) [Sigma].  Antiretroviral reagents (AIDS Research and Reference Reagent Program, 
Division of AIDS, NIAID, NIH).  Poly-L-Lysine (Peptide International).  Tyramide Amplification 
System (New England Biolabs).  Normal Antibody Diluent (Scytek Labs).  All horse radish 
peroxidase (HRP)-conjugated secondary antibodies were obtained from Thermo Scientific and all 
dye-conjugated secondary antibodies were obtained from Jackson ImmunoResearch Labs. 
Immunofluorescence.  Paraffin-embedded tissue sections from the hippocampus of control and 
HIV(+) human autopsy cases obtained from the NNTC and paraffin-embedded tissue sections 
from hippocampus of pigtailed macaques (Macaca nemestrina) were prepared for 
immunofluorescent staining with minor modifications of previously described protocols (30, 47).  
The age, neurocognitive status, sex, and postmortem interval of each human specimen was 
provided by the NNTC (Table 1).  Glass slides containing paraffin-embedded tissue sections (10 
μM) were heated overnight to 55
o
C, deparaffinized in histoclear and rehydrated in 100%, 95%, 
90%, and 70% ethanol washes.  Tissue was then incubated in 3% H202 in methanol to inactive 
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endogenous peroxidase activity. Antigen unmasking was performed with target retrieval solution 
at 95
o
C for 1 h.  Sections were then blocked with 10% normal goat serum and incubated with 
various primary antibodies overnight at 4
o
C.  Tyramide amplification was used to detect BACE1 
and DNA was visualized with DAPI staining.  Slides were washed with PBS plus 0.1% Tween-20 
(PBS-T) and mounted in Citifluor AF1 and analyzed by laser confocal microscopy at 600x on a 
BioRad Radiance 2100 equipped with Argon, Green He/Ne, Red Diode, and Blue Diode lasers 
(BioRad, Hercules, CA).  Post-acquisition analysis was performed using Metamorph 6.0 
(Universal Imaging, Downingtown, PA).  Total intensity for MAP2 and APP were determined by 
the measurement of integrated pixel intensity per z-stack image, where integrated pixel intensity 
is defined as total pixel intensity per image times the area of pixels with positive MAP2 or APP 
signal.  Averages are expressed as mean ± SEM.  All data was analyzed by Prism 5.0 software 
(Graphpad Software, San Diego, CA). 
SIV/pigtail macaque model of HIV CNS disease.  Pigtailed macaques (Macaca nemestrina) were 
inoculated with SIV/DeltaB670 and SIV/17E-Fr, as described previously (48).  12 days after 
infection, animals were divided into placebo and ARV-treated groups until necropsy (range, day 
161-175).  ARV treatment was composed of the NRTI tenofovir (Gilead) at 30 mg/kg 
subcutaneously given once daily, saquinavir (Roche) and atazanavir (Bristol-Myers Squibb) at 
205 and 270 mg/kg, respectively, given twice daily via oral administration, and an integrase 
inhibitor, L-870812 (Merck) (49) at 10 mg/kg orally twice daily (50).  Tenofovir dosing was based 
on previous studies (51) while saquinavir and atazanavir dosing was based on pharmacokinetic 
analysis carried out in pigtail macaques to reflect similar area under the curve parameters as 
those detected in human treated with atazanavir and saquinavir (50).  L-870812 integrase 
inhibitor dosing was based on previous work conducted in rhesus macaques (49).         
Preparation of Primary Cortical Neuroglial Cultures.  Primary rat or mouse cortical neuroglial 
cultures were isolated from brains of embryonic day 16 Sprague Dawley rat pups or embryonic 
day 16.5-17.5 floxed PERK mice, with modifications of previously described protocols (52).  
Briefly, to generate neuroglial cultures, cortical cell suspensions were isolated from rat or mouse 
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pups and plated in poly-L-lysine coated tissue culture dishes and maintained in neurobasal media 
supplemented with B27 at 37
o
C with 5% CO2, as described previously (53, 54).  Unless otherwise 
indicated, all experiments were performed at 21 days in vitro (DIV) on cultures containing 
approximately 90% neurons and 10% astrocytes/glia.  Pure neuronal cultures were prepared by 
treating neuroglial cultures with 10μM Ara-C 48 hours after plating and were maintained in 
neurobasal media with B27 at 37
o
C with 5% CO2.   
Human primary cortical neurons were obtained from the Comprehensive NeuroAIDS Center 
(CNAC), Temple University, Philadelphia, PA.  Cultures were prepared from fetal brain tissue 
(gestational age, 16-18 weeks) performed in full compliance with National Institutes of Health and 
Temple University ethical guidelines as described previously (55).  Neurobasal medium 
supplemented with B27 was half-changed every 4 days and cultures were maintained at 37
o
C 
with 5% CO2 for 21 DIV.   
Previously characterized Floxed PERK (Perk
loxP/loxP
) mice (56) were crossed with tamoxifen-
inducible cre (Cre-ERT2) heterozygous mice and the resulting PERK
loxP/loxP
; Cre-ERT2 mice were 
kindly provided by Dr. Alan Diehl.  PERK deletion was achieved by treating 10 DIV mouse 
neuroglial cultures with various concentrations of 4-hydroxytamoxifen (4-OHT).  Antiretroviral 
drug treatments were performed 4 days following 4-OHT treatment to allow for maximal PERK 
excision.  16 h following antiretroviral drug treatment, PERK
-/-
 neuroglial cultures were harvested 
for Immunoblotting or genotyping using routine methods.   
Drug Treatments.  21 DIV rat cortical neurons or human fetal neurons were treated with various 
log-fold concentrations of either AZT, prepared in sterile water at 25 mM stock, saquinavir, or 
ritonavir, both prepared in DMSO at 25 mM stock concentrations.  All antiretroviral drugs were 
added to neuroglial cultures 16 h prior to harvest.  Anisomycin and Actinomycin D were prepared 
in DMSO at 50 mM and 5 mM stock concentrations, respectively.  21 DIV rat cortical neurons 
were pre-treated with either 10 μM or 50 μM Anisomycin or 5 μM Actinomycin D for 12 hours then 
treated with 10 μM ritonavir 16 h prior to harvest.          
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Immunoblotting.  Flash-frozen whole-brain tissue samples from HIV (-) control (n=4), HIV (+) 
neurocognitively normal (n=8), and HIV (+) HAND (n=6) human autopsy cases were obtained 
from the tissue banks of the National NeuroAIDS Tissue Consortium (NNTC).  Tissue was 
prepared for western blotting as described previously (30).  30 μg protein for each sample was 
loaded into each lane of 10% Bis-Tris gels and transferred to PVDF membranes followed by 
blocking with TBS-T with 5% bovine serum albumin (BSA) for 30 min at room temperature.  
Membranes were probed with various primary antibodies overnight at 4
o
C. 
Whole-cell extracts of mouse brain tissue samples were prepared by homogenization in ice-cold 
tissue extraction buffer (50 mM Tris pH 7.5, 0.5M NaCl, 1% NP-40, 1% SDS, 2 mM EDTA, 2 mM 
EGTA, 5 mM NaF, 0.4 mM Na3VO4, 1 mM dithiothreitol (DTT) and 1:100 protease inhibitor 
cocktail).  Extracts were then centrifuged at 12,000 g at 4
o
C for 20 min.    
Whole cell extracts of primary rat cortical cultures were prepared with ice-cold whole-cell lysis 
buffer containing 50 mM Tris pH 7.5, 120 mM NaCl, 0.5% NP-40, 0.4 mM Na3VO4, 100 mM, and 
1:100 protease inhibitor cocktail.  Lysates were centrifuged at 14,000 g at 4
o
C for 10 min.  Protein 
concentrations were determined using the Bradford method and equal amounts of protein (15-20 
μg) were loaded into each well of 4-12% Bis-Tris Gradient gels or 3-8% Tris-Acetate gradient gels 
(for confirmation of PERK overexpression) followed by transfer at 25 V at room temperature for 1 
h to PVDF membranes.  Membranes were subsequently blocked in TBS-T and 5% BSA for at 
least 30 min at room temperature.  Membranes were then incubated in primary antibodies 
overnight at 4
o
C, washed with TBS-T, and incubated with appropriate HRP-conjugated secondary 
antibodies for 30 min. at room temperature.  Membranes were developed using SuperSignal 
West Dura extended duration substrate and densitometric analysis was performed using the NIH 
ImageJ software program (Image J v1.44, NIH).  Equal loading and transfer was confirmed by 
fast green staining of membranes.  Band densities of interest were normalized to indicated 
loading controls or fast green stains of membranes.  Immunoblots shown are representative of at 
least three independent biological replicates.  
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RNA Isolation and Quantitative RT-PCR.  Total RNA was isolated from primary rat neuroglial 
cultures using the RNeasy Mini Kit (Qiagen, Valencia, CA).  To assess the expression of spliced 
XBP-1 and BACE1 genes, 1 μg total RNA from each sample was subjected to the SuperScript II 
First-Strand Synthesis system (Invitrogen).  Approximately 100 ng cDNA was amplified via 
quantitative RT-PCR using Custom TaqMan® Gene Expression Assays purchased from Applied 
Biosystems.  Relative expression of mRNA levels from each sample were quantified using the 
comparative CT method and data was normalized to unspliced XBP-1 and TBP for spliced XBP-1 
and BACE1 genes, respectively.  All samples were run in triplicate and experiments were 
repeated in at least three biological replicates.       
Human/Rat Aβ ELISAs.  Cell media from 21 DIV primary rat neuroglial cultures and CHO cells 
stably expressing Human wild-type APP were diluted 25-fold and subjected to a human/rat Aβ42- 
or Aβ40-specific sandwich ELISA (Wako Chemicals, Richmond, VA) according to manufacturer’s 
protocols.  For CHO cell experiments, cultures were pre-treated with 10 nM, 100 nM, or 1 μM 
Beta-Secretase IV (Calbiochem, Billerica, MA) for 12 h followed by treatment with 10 μM ritonavir 
or DMSO vehicle for 16 h at which time media was collected.  For rat neuroglial cultures, cells 
were treated with combinations of antiretroviral drugs followed by media collection at 4 and 16 h.  
Human sAPP ELISAs.  Cell culture media from CHO cells stably expressing human wild-type or 
APP were pre-treated with 10 nM, 100 nM, or 1 μM Beta-Secretase IV (Calbiochem, Billerica, 
MA) for 12 h followed by treatment with 10 μM ritonavir or DMSO vehicle for 16 h at which time 
media was collected.  Conditioned media was then diluted 25-fold and subjected to a human 
sAPPα or sAPPβ ELISA (IBL International, Toronto, ON) according to manufacturer’s 
recommendations.    
Pulse-Chase and Immunoprecipitation.  Primary rat neuroglial cultures were grown in 60 mM 
plates for 21 DIV in neurobasal media supplemented with B27.  Cultures were pulse-labeled with 
2 mL methionine/cysteine-free DMEM containing 0.4 mCi 
35
S-labeled methionine and cysteine for 
30 minutes.  Cultures were washed twice with sterile DPBS and chased with neurobasal media 
supplemented plus B27 with or without 10 μM ritonavir.  At 0, 6, 12, 18, and 24 hr after labeling, 
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cultures were harvested with ice-cold lysis buffer (50 mM Tris pH 7.5, 120 mM NaCl, 0.5% NP-40, 
0.4 mM Na3VO4, 100 mM, and 1:100 protease inhibitor cocktail).  Lysates were 
immunoprecipitated with Dynabeads Protein A [Novex] and 2 μg anti-BACE1 [Cell Signaling].  
Immunoprecipitates were run on a 4-12% Bis-Tris gradient gel for separation and transferred onto 
PVDF membranes for approximately 7 hr.  Membranes were dried and exposed via 
autoradiography. 
Subcellular Fractionation.  To evaluate ATF4 nuclear translocation in the context of antiretroviral 
drug toxicity, 21 DIV rat neuroglial cultures were treated with 10 μM ritonavir, or DMSO vehicle, 
for 16 h and fractionated.  To prepare nuclear extracts, cultures were washed twice in ice-cold 
PBS and lysed for 10 min in 10 mM HEPES (pH 7.9), 10 mM KCL, 10 mM EDTA, 1 mM DTT, 
AND 0.4% Nonidet P-40 supplemented with protease inhibitor cocktail.  Extracts were centrifuged 
at 4
o
C for 3 min at 15,000 x g and the supernatant (cytoplasmic fraction) stored at -80
o
C.  The 
resulting nuclear pellet was resuspended in 20 mM HEPES (pH 7.9), 400 mM NaCl, 1mM EDTA, 
10% glycerol, and 1 mM DTT with protease inhibitor cocktail then incubated at 4
o
C, with shaking, 
for 2 h.  The nuclear fraction (supernatant) was then generated by centrifuging the extracts at 
15,000 x g for 5 min at 4
o
C.  Protein concentrations were then determined using the Bradford 
method and lysates run on 4-12% Bis-Tris gradient gels.  Membranes containing nuclear fractions 
were probed with rabbit anti-ATF4 (generous gift from Dr. Ron Wek, Indiana University). 
Nanomagnetic Transfection.  For transfection of primary rat neurons, pure neuronal cultures were 
generated by treating DIV 3 neuroglial cultures with 10 μM AraC.  DIV 10 pure neuronal cultures 
were transfected with plasmid DNA via magnetotransfection using the Magnefect-Nano II system 
(Nanotherics Ltd., Stoke-On-Trent, UK).  Briefly, 0.5 μg, 1 μg, or 2 μg of plasmid DNA: 
pcDNA3.1Zeo(+) + BACE1 5’ UTR and -5’ BACE1 UTR (a generous gift from Robert Vassar), 
pLenti CMV/TO Puro destination vector (backbone), wild-type mouse PERK, or kinase-dead, 
K618A PERK was complexed with 2.4 μl of Neuromag transfection reagent (Nanotherics Ltd.) for 
15-20 min in serum-free neurobasal media.  Complexes were added drop-wise to 24-well plates 
of pure neuronal cultures containing 500,000 cells per well.  Plates were incubated for 30 min at 
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37
o
C with 5% CO2 over a magnet array oscillating at 3 Hz with 0.2 mm amplitude of 
displacement.  Following transfection, plates were immediately removed from the magnet array 
and placed on a shelf in the incubator at the same temperature and CO2 conditions.  Plates were 
harvested after 48-72 h for Immunoblotting or cell staining following routine methods.           
  
  
Statistical Analysis.  All data were analyzed by Prism 5.0 software (GraphPad Software, San 
Diego, CA).  All quantifications are expressed as mean ± SEM.  Paired results were analyzed by 
Mann-Whitney U test or unpaired student t test while data with multiple categories were analyzed 
by one-way analysis of variance (ANOVA) plus Newman-Keuls or Dunnett post hoc test, as 
indicated.  Values of p < 0.05 were considered significant. 
Study Approval.  All animal studies were performed in accordance with protocols approved by the 
Institutional Animal Care and Use Committees of the University of Pennsylvania and Johns 
Hopkins University. 
 
3.4: RESULTS 
BACE1 and Aβ oligomer immunostaining are elevated in brains of HIV(+) individuals.  Previous 
studies have shown accumulation of neurodegenerative proteins in the brains of HAND patients.  
To investigate the mechanisms underlying age-related pathologies that are increasingly observed 
in HAND, we  first assessed levels of Aβ oligomers (Aβ-oligo), the Aβ species suggested to be 
responsible for CNS neurotoxicity in AD, in the hippocampus of HIV(+) HAND patients (see Table 
1 for a summary of cases).  We observed elevated levels of intraneuronal Aβ oligomers in HAND 
patients compared to HIV(+) neurocognitively normal and uninfected, healthy controls (Figure 1A, 
Table 1).  Importantly, we found no evidence of senile or diffuse Aβ plaque deposition in the 
hippocampus using the BC05 antibody, an Aβ42-specific antibody generated by Dr. Virginia Lee 
(not shown).  As oligomeric Aβ is derived from cleavage of APP by the β secretase enzyme 1, we 
determined whether BACE1 expression was altered in the same cohort of samples.  When we 
stained for BACE1 in the CA1, CA3, and dentate gyrus regions of the hippocampus, we observed 
significantly elevated BACE1 immunoreactivity in HAND patients compared to healthy controls, 
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consistent with our finding of elevated Aβ oligomers, despite decreased microtubule-associated 
protein 2 (MAP2) expression (Figure 1B).  Interestingly, no significant changes in BACE1 were 
observed in the dentate gyrus.  To confirm our immunostaining findings, we assessed protein 
levels of BACE1 and APP in whole brain lysates from the mid-frontal cortex of uninfected (HIV(-)), 
HIV(+) neurocognitively normal (HIV(+) Normal) and HIV(+) HAND patients by immunoblotting.  
As shown in Figure 1D, and quantified in Figure 1E, BACE1 was elevated both in HIV(+) Normal 
and HAND patients compared to uninfected controls; however, no differences were observed 
between HIV(+) Normal and HAND samples.  As increased Aβ production may also result from 
changes in total APP expression, we also immunoblotted these lysates for full-length APP.  As 
seen in Figure 1F, we found no significant differences in APP protein levels when groups were 
compared according to infection or cognitive status.  Of note, levels of full-length APP showed 
more variation among different samples from the HIV(+) HAND group.  The significance of this 
variation remains unclear.  Importantly, we found that BiP levels were elevated in HIV(+) Normal 
brain samples, but not in HAND (Figure 1D), in agreement with our previous findings.  However, 
p-eIF2α was unchanged with HIV infection and regardless of neurocognitive status, compared to 
healthy controls (Figure 1G).   
Antiretroviral therapy induces axonal damage and ER stress in vivo.  Several clinical studies have 
reported an inverse relationship between ARV regimens with high CNS penetration-effectiveness 
(CPE) scores and neurocognitive outcome (57-59).  However, it has been difficult to separate out 
CNS toxicity induced by HIV versus that of ARV drugs themselves.  Previously, we have shown 
that ARV drugs administered to SIV-infected pigtail macaques lead to decreased markers of 
synaptodendritic integrity, including synaptophysin in the hippocampus and calmodulin kinase II 
in the frontal cortex, compared to SIV-infected, placebo-treated or uninfected controls (28).  In 
this model of lentiviral-induced neurodegeneration, adult pigtail macaques are inoculated with two 
strains of SIV, SIV/DeltaB670 and SIV/17E-Fr, as described previously (48).  12 days post-
inoculation animals receive either a placebo or ARV therapy (ART) that includes tenofovir (NRTI), 
atazanavir (PI), saquinavir (PI), and L-870812a (integrase inhibitor).  90% of placebo-treated 
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animals develop neurologic disease within 12 weeks post-inoculation (p.i.), as described 
previously (48).  However, animals that receive ART do not develop SIV encephalitis, nor do they 
demonstrate neurological dysfunction (50).  Further, ART-treated animals display a rapid 
reduction in plasma and CSF viral load and suppression of viral replication with conservation of 
CD4+ T cell counts until elective euthanasia at day 160 p.i.  To expand upon our previous 
findings, we utilized immunofluorescence and immunoblotting to retrospectively assess formalin-
fixed, paraffin-embedded hippocampal tissue from SIV-infected animals for APP expression, 
which serves as a sensitive marker of neuronal damage and impaired axonal transport in the 
SIV/macaque model of HIV CNS disease (60).  Consistent with our previous report, we found 
significantly elevated APP expression in the SIV(+)/ART group compared to both SIV(+)/placebo 
and uninfected controls (Figure 2A and 2B).  Interestingly, placebo-treated animals showed a 
reduction in hippocampal APP expression compared to uninfected controls.  These changes were 
corroborated by immunoblotting of total APP (Figure 2C).  To validate our SIV/pigtail macaque 
model of HIV CNS disease we also immunoblotted for BiP, BACE1,and p-eIF2α (Figure 2C).  
Similar to our observations in human tissue, we observed increased BiP expression with infection 
(SIV(+)/placebo animals) compared to uninfected controls but no significant change in the 
SIV(+)/ART group (Figure 2D).  Importantly, SIV(+) macaques treated with ART displayed a 
significant increase in BACE1 compared to both SIV(+)/placebo and uninfected controls (Figure 
2E).  However, no significant changes in p-eIF2α were observed (Figure 2G).        
Antiretroviral drugs activate the unfolded protein response and upregulate BACE1 expression.  
We and others have shown that ARVs are toxic to primary neurons (28, 61, 62).  Although it is 
suggested that such toxicity is mediated by mitochondrial DNA damage and/or pro-oxidant 
properties of these drugs, additional mechanisms may also contribute to ARV-mediated neuronal 
damage and death.  Given our previous observations of elevated UPR markers in the post-
mortem mid-frontal cortex of patients with HAND and the established role of PIs inducing ER 
stress in a variety of cell types, we hypothesized that antiretroviral drugs may be activating the 
UPR in neurons.  Therefore, we examined canonical UPR markers in primary rat neuroglial 
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cultures in response to increasing concentrations of zidovudine (AZT), saquinavir (Saq), or 
ritonavir (Rit) (Figure 3A).  Drug dose ranges used in our in vitro studies were based on reported 
plasma and CSF levels of ARVs (63, 64).  At 16 h post-treatment with ritonavir or saquinavir, 
neurons displayed a five-fold increase in BiP expression and more than four-fold increase in 
phospho-eIF2α (p-eIF2α) (Figure 3B and 3C).  25 μM AZT treatment resulted in a three-fold 
increase in BiP expression, but had no significant effect on p-eIF2α.  As an added parameter to 
ensure the presence of ARV-mediated UPR activation, we treated primary neurons with 10 μM 
Rit, 1 μM Saq, 25 μM AZT, or 1 μM thapsigargin (positive control) for 16 h and assessed levels of 
spliced XBP-1 (sXBP1) by TaqMan quantitative real-time PCR relative to unspliced XBP-1 
(uXBP1) (Figure 3H).  We observed nearly a two-fold increase in sXBP1 mRNA in Rit and Saq-
treated cultures, but no change in AZT-treated neurons, compared to vehicle controls.  To rule 
out the possibility of species-specific effects, we also treated 21 days in vitro (DIV) human fetal 
neurons with increasing doses of AZT, Saq, and Rit for 16 h and found similar trends in both BiP 
and p-eIF2α expression in Saq and Rit-treated cultures compared to rat cortical neuroglial 
cultures (Figure 3I).   
 Recent studies have shown that induction of ER stress in neurons can increase protein 
expression of the APP-cleaving enzyme, BACE1 (44, 65).  Therefore, we sought to determine 
whether ARV-treated neuroglial cultures, which show robust activation of ER stress, display 
changes in BACE1 expression.  Immunoblotting analysis revealed that 16 h drug treatment with 
AZT, Saq, or Rit resulted in 4 to 5-fold increases in BACE1 expression (Figure 3E).  Similar 
results were observed in human fetal neurons treated with ARVs (Figure 3I).   
In addition to BACE1, APP may be cleaved by two additional secretases, γ-secretase 
and α-secretase, the latter of which comprises the non-amyloidogenic cascade.  To examine 
whether ARV-mediated BACE1 upregulation is specific to BACE1, or a shared mechanism 
among all APP secretases, we also immunoblotted for presenilin-1 (PS-1) (γ-secretase) and 
ADAM metalloproteinase domain 10 (ADAM10) (α-secretase) (Figure 3A).  We found no 
significant changes in the expression of either of these enzymes regardless of drug treatment or 
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dosage (Figure 3F and 3G).  Notably, SIV(+)/ART macaques displayed increased hippocampal 
expression of PS-1 and ADAM10 compared to uninfected controls (Figure 2H and 2I).  Previous 
work has shown that ER stressors are capable of altering APP expression as well (38); therefore 
we also immunoblotted for APP and observed a small, but significant increase in APP levels in 25 
μM AZT and Rit-treated neuroglial cultures (Figure 3D).  Taken together, these data indicate that 
antiretroviral drugs, and PIs in particular, induce ER stress in neurons leading to enhanced APP 
and BACE1 expression.  
Ritonavir increases amyloidogenic APP processing in primary neurons.  Based on our 
observation that ARVs induce BACE1 expression in neurons, we sought to determine whether 
this translated into functional changes in enzymatic APP processing.  To that end, we treated 
Chinese Hamster Ovary (CHO) cells stably expressing human APP with 10 μM Rit, as a 
representative PI, for 16 h and measured the relative amount of Aβ species in the culture media 
using a commercially available human/rat Aβ40- or Aβ42-specific sandwich ELISA.  While ritonavir 
had no effect on secreted Aβ40 levels, Aβ42 peptide was increased by nearly two-fold (Figure 4A).  
Addition of a cell-permeable BACE1 inhibitor (BSI) blocked ritonavir-mediated elevations in Aβ42 
in a dose-dependent manner.  These findings contradict previous reports that changes in BACE1 
activity affect the generation of all Aβ isoforms equally (66).  To further understand how ritonavir 
affects human APP processing, CHO cell conditioned media was subjected to sAPPβ and sAPPα 
ELISAs (Figures 4B and 4C).  In contrast to the observed elevations in Aβ42 peptide, no 
significant changes in sAPPβ or sAPPα were detected in the culture media from ritonavir-treated 
CHO cells.  We also utilized the human/rat Aβ40- or Aβ42-specific sandwich ELISA to assess Aβ40 
and Aβ42 release into the media of rat cortical neuroglial cultures treated with combinations of 
ARV drugs (Figures 4D and 4E).  At 4 h post-treatment, no changes were observed in secreted 
Aβ40 or Aβ42 peptides.   However, at 16 h post-treatment, all combinations of ARV drugs resulted 
in 1.5 and 3 fold increases in Aβ40 and Aβ42 levels, respectively.  In conjunction with our in vivo 
findings of elevated Aβ oligomers in HAND patients and increased APP in SIV-infected, ARV-
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treated macaques, these findings suggest that ARVs promote amyloidogenic APP processing in 
CNS neurons.    
Ritonavir upregulates BACE1 expression in a translation-dependent manner.  Vassar and 
colleagues first reported that chronic activation of ER stress results in translational upregulation of 
BACE1.  To determine if antiretroviral drugs increase BACE1 expression by altering mRNA 
levels, we first treated 21 DIV rat neuroglial cultures with Rit, Saq, Azt, or thapsigargin for 16 h 
and harvested mRNA for quantitative real-time PCR (qRT-PCR).  We observed no changes in 
BACE1 mRNA in any of the ARV-treated cultures compared to controls; however, there was a 
significant decrease in BACE1 mRNA in thapsigargin-treated neurons (Figure 5A).  To confirm 
that BACE1 regulation is occurring via a post-transcription mechanism, we pre-treated neurons 
with a translation inhibitor, anisomycin, or a transcription inhibitor, actinomycin D for 12 hours 
followed by 16 h treatment with ritonavir and harvested protein lysates for analysis by 
immunoblotting for BACE1.  Inhibition of transcription with 5 μM actinomycin D did not affect 
upregulation of BACE1 protein levels by ritonavir; however translation inhibition by 10 or 50 μM 
anisomycin abrogated Rit-mediated BACE1 protein upregulation (Figures 5B and 5C) indicating 
that PIs are exerting their effects on neuronal BACE1 expression through a translational or post-
translational mechanism.  
Activating transcription factor 4 (ATF4) is a canonical target of translational control by 
phospho-eIF2α.  Similar to BACE1, ATF4 mRNA contains multiple uORFs in the 5’ UTR, which 
act to suppress translation under basal conditions, but undergo scan-through following 
phosphorylation of eIF2α, leading to selective translational upregulation during conditions of ER 
stress (44, 65, 67, 68).  ATF4 subsequently translocates to the nucleus to upregulate expression 
of genes involved in the ER stress response.  Thus, we determined whether ATF4 was increased 
in the nucleus of ritonavir-treated neurons following 16 h treatment.  We observed nearly a five-
fold increase in nuclear ATF4 in Rit- and thapsigargin-treated neuroglial cultures while 
cytoplasmic levels remained unchanged (Figures 5D and 5E).  Similarly, BACE1 expression was 
increased greater than two-fold in the cytoplasm of Rit-treated cultures (Figures 5D and 5E).   
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To confirm that translational control of BACE1 is occurring through its 5’ UTR, we 
transfected rat cortical neurons with vectors containing full-length human BACE1 with (+5’ UTR) 
or without (-5’ UTR) the 5’ UTR then treated cultures with DMSO or ritonavir for 16 h.  Similar to 
our wild-type rat cortical cultures, the neurons transfected with BACE1 +5’ UTR displayed nearly 
a three-fold increase in BACE1 expression following treatment with ritonavir compared to vehicle 
controls (Figure 5F).  Deletion of the 5’ UTR resulted in a significant increase in overall BACE1 
expression in transfected cells as described previously (44, 69), however overexpression of the -
5’ UTR BACE1 construct prevented ritonavir-mediated upregulation of BACE1 in neurons (Figure 
5F and 5G).  
To rule out the involvement of a post-translational mechanism in BACE1 upregulation by 
ritonavir, we performed a pulse-chase experiment using 
35
S-metabolic radiolabeling to determine 
the half-life of BACE1 in Rit-treated neurons compared to vehicle controls.  After confirming 
immunoprecipitation of BACE1 from neurons (Figure 6A), we pulse-labeled 21 DIV neuroglial 
cultures for 30 min and then chased with neurobasal media with or without 10 μM Rit for up to 24 
h (Figure 6B).  Compared to controls, we observed no apparent difference in BACE1 half-life in 
Rit-treated neuroglial cultures over the course of 24 h (Figure 6C).  In both treatment conditions, 
we observed that BACE1 half-life was approximately 12 h, similar to what has been reported 
previously (44, 70).  Collectively, these data strongly suggest that ritonavir-mediated upregulation 
of BACE1 in neurons occurs through a 5’ UTR-dependent translational mechanism. 
PERK is necessary for ARV-mediated BACE1 upregulation in neurons.  Several reports have 
proposed a role for p-eIF2α in post-transcriptional regulation of BACE1 under conditions of 
oxidative and ER stress (44, 65, 71).  However, eIF2α can be phosphorylated by one of four 
kinases (PERK, PKR, HRI, and GCN2) depending on the type of stress impinging on cells.  Given 
that PERK is the central kinase responsible for eIF2α phosphorylation under conditions of ER 
stress, we assessed whether PERK was involved in the stress response signaling in neurons 
treated with antiretroviral drugs.  First, we determined the effect of blocking PERK signaling in 
neurons through overexpression of a kinase-dead mutant of PERK (dnPERK).  We 
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overexpressed wild-type (PERK) or kinase-dead (dnPERK) PERK in 14 DIV pure neuronal 
cultures using magnetofection.  72 h after transfection, lysates were harvested for immunoblotting 
and probed for markers of ER stress and BACE1 (Figure 7A).  In addition to successful 
overexpression of both wild-type and kinase-dead PERK, we observed a significant decrease in 
both p-eIF2α and BACE1 in neurons overexpressing dnPERK compared to cultures 
overexpressing wild-type PERK (Figures 7B-7D).  Consistent with our hypothesis, BACE1 and p-
eIF2α levels in dnPERK-expressing cultures were not significantly different from neurons 
transfected with the empty vector control (pLENTI).     
 Next, we sought to determine whether PERK signaling was necessary for ARV-mediated 
BACE1 upregulation.  To that end, we isolated PERK-excised neuroglial cultures from brains of 
tamoxifen-inducible cre recombinase conditional PERK knockout embryonic mice.  At DIV 10, 
neuroglial cultures were treated with 100 nM or 1 μM 4-hydroxtamoxifen (4-OHT) to excise the 
PERK gene (56).  The estimated efficiency of PERK excision in neurons was approximately 50 to 
60% after 96 h 4-OHT treatment (Figure 8A).  Wild-type and PERK-excised neurons were treated 
with 10 μM ritonavir (Rit) or 1 μM saquinavir (Saq) for 16 h.  As shown in Figures 8B and 8C, 
PERK-excised neuroglial cultures treated with Rit or Saq displayed reduced p-eIF2α, BACE1, 
and APP compared to wild-type cultures treated with the same drugs.  These findings indicate 
that ARV-mediated BACE1 upregulation in neurons is dependent on ER stress response 
signaling. 
 
3.5: DISCUSSION 
The unanticipated persistence of neurocognitive deficits in HIV-positive individuals has become a 
growing public health concern as the average age of HIV-infected patients in the U.S. is expected 
to be over the age of 50 by the year 2015 (72).  Increasing clinical and experimental evidence 
suggests that ARV drugs are toxic to CNS neurons, yet the potential mechanisms by which ARVs 
may be contributing to HAND neuropathology remain elusive.  Previously, we have reported that 
ARVs induce ROS production in primary neurons leading to activation of the endogenous 
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antioxidant response (28).  Additionally, there is extensive evidence that ARVs induce ER stress 
in a wide variety of peripheral cell types.  Our findings provide a mechanistic link between ARV-
mediated ER stress in cortical neurons and our observations of increased BACE1 and Aβ 
oligomers in post-mortem brain tissue of ARV-treated, HIV-positive individuals. 
In the present study, we demonstrate for the first time the ability of ARV drugs, and PIs in 
particular, to robustly activate the UPR in primary rat neuroglial cultures and human fetal neurons 
as demonstrated by increased expression of BiP, p-eIF2α, and spliced XBP1.  Additionally, we 
observed increased levels of nuclear ATF4, indicating that ARV-mediated eIF2α phosphorylation 
leads to functional changes in the translational profile of neurons.  The specific mechanism by 
which PIs and NRTIs activate ER stress in neurons remains unclear, but is likely to be 
multifactorial.  In other cell types, PIs have been shown to induce ER stress via proteasome 
inhibition and depletion of ER calcium stores (21, 22, 73-75).  Interestingly, Zhang, et. al., 
reported that pharmacological inhibition of proteasome activity can activate PERK, the primary 
kinase responsible for phosphorylating eIF2α under ER stress conditions (76).  Further studies 
will be necessary to determine if: 1) PIs can inhibit proteasome function in primary neuroglial 
cultures, 2) proteasome inhibition precedes phosphorylation of eIF2α, and 3) rescue of 
proteasome function abrogates phosphorylation of eIF2α and all purported downstream effects, 
including translational upregulation of ATF4 and BACE1.  
 In agreement with our in vitro studies, BiP was elevated in HIV(+) Normal cases, 
however, no significant difference was observed between HIV(+) HAND cases and uninfected 
controls, indicating that severity of CNS impairment may be less important than early events 
associated with HIV pathogenesis.  Unexpectedly, phospho-eIF2α was unchanged with HIV 
infection in our cohort of patient samples, where it was previously reported to be elevated in HIV-
positive cases (77).  One potential reason for the conflicting results may be the variability of tissue 
used to generate the whole-cell protein extracts from patient samples, and the relative 
percentage of specific cell types, such as astrocytes and microglia, in the specimen used (77).  
As the inflammation in ARV-medicated, HIV-infected brains is typically focused in the 
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hippocampus and entorhinal cortex, there may be region-specific elevations in ER stress markers 
correlating with these focal points of inflammation.  Many clinical factors are also likely contribute 
to the level of neuronal ER stress in HAND patients, including duration of HIV infection, co-
morbidities, latency between infection and onset of ARV medication, adherence to ARV 
regimens, and the specific treatment regimen(s) prescribed during the course of infection.  
Despite these complications, our data are consistent with UPR activation, BACE1 upregulation, 
and Aβ oligomer generation as underlying contributors to pathology in HAND.   
Our work also confirms a report by Vassar and colleagues that chronic activation of ER 
stress in neurons is linked to translational BACE1 upregulation.  AZT, saquinavir, and ritonavir all 
increased expression levels of BACE1 in neuroglial cultures and human fetal neurons at 16 h 
post-treatment, parallel to an increase in nuclear ATF4.  This increase appears to be at least 
partially mediated by PERK, although we cannot rule out the potential contribution of other eIF2α 
kinases.  Interestingly, PERK excision decreased expression of p-eIF2α and BACE1, but had no 
effect on BiP or APP, indicating that the mechanism by which these markers are increased in 
ARV-treated cultures is likely distinct from that of BACE1.  While extensive evidence has shown 
that BiP is increased transcriptionally following ER stress, the mechanism of APP upregulation 
remains unclear, and may be unrelated to ER stress induction.  Additionally, we report elevated 
BACE1 expression in CA1 and CA3 hippocampal regions of HAND patients by IFA and confirmed 
by immunoblotting of whole brain lysates.  Notably, BACE1 was elevated in HIV-positive cases, 
regardless of neurocognitive status, suggesting that BACE1 elevation may be an early event in 
the pathogenesis of HAND; similar to what has been reported in AD (46).  Importantly, neither γ-
secretase nor α-secretase, both of which cleave APP, showed any changes in expression 
following ARV treatment.  This distinction is likely a result of the different mRNA structure of these 
enzymes.  Unlike, γ-secretase and α-secretase, BACE1 mRNA contains three uORFs in its long, 
GC-rich 5’-UTR, which act to suppress translation under normal cellular conditions (44, 68).  
However, phosphorylation of eIF2α induces bypass, or scan-through, of the inhibitory uORFs 
leading to more efficient translation of BACE1 mRNA.  Indeed, placement of multiple uORFs in 
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the 5’-leader sequence of mRNAs is an evolutionarily conserved mechanism among many 
species to control translation of stress-related genes (67).  However, it remains unclear what 
protective role BACE1 might have, if any, in neurons undergoing ER stress.   
One potentially detrimental consequence of elevated BACE1 expression is increased 
amyloidogenic processing of APP to generate Aβ peptides.  Giunta, et. al., first demonstrated the 
ability of ARVs to increase Aβ production in N2a cells transfected with Swedish mutant APP (78).  
Similarly, our ELISA results demonstrate that ritonavir, as a representative PI, induces increased 
production of Aβ42 in rat neurons and CHO cells expressing human APP.  Unexpectedly, no 
changes in Aβ40 production were observed in CHO cells treated with ritonavir, although Aβ40 was 
increased in media of rat neuroglial cultures treated with all combinations of ARVs.  This 
inconsistency may be a result of potential differences in APP processing in CHO cells versus 
neurons, or an artifact resulting from overexpression of human APP, which itself may be 
activating ER stress and the UPR.  Ultimately, these data suggest that ARVs alter APP 
processing in CNS neurons, likely through upregulation of BACE1.   
Contrary to these findings is a previous report by Ikezu and colleagues that PIs, including 
ritonavir and saquinavir, modestly inhibit Aβ degradation in human monocyte-derived 
macrophages, but decrease Aβ40 production and BACE1 activity in human cortical neurons (79).  
Furthermore, they showed that oral administration of nelfinavir or lopinavir/ritonavir had no effect 
on Aβ accumulation in an APP SCID mouse model.  While these results are striking, several 
caveats must be considered: 1) previous work indicates CRND8 transgenic animals begin to 
show plaque deposition at approximately 9 weeks of age, yet the APP SCID mice generated by 
Ikezu (BALB/cBy-Prkdc
scid
 mice crossed with CRND8 mice) displayed no overt amyloid pathology 
at 12 weeks of age.  Therefore, the inclusion of age-matched, CRND8 transgenic controls is 
necessary to ensure pathology in the APP SCID mice occurs in a similar, time-dependent 
manner, 2) concentrations of PIs tested in human fetal neurons were 2.5 – 5 fold greater than the 
highest concentrations of PIs tested in our experiments, 3) ARV concentrations tested on purified 
BACE1 protein in vitro were up to 30-fold greater than concentrations employed in our studies, 
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and 4) the effect of PIs on Aβ42 was not tested by Ikezu and colleagues, while we found that PIs 
had the greatest effect on Aβ42 production.  Notably, we found that concentrations of ARVs similar 
to those employed by Ikezu were highly toxic to primary neurons even at time points less than 16 
h.  Thus, it is difficult to directly compare the results of our studies with those of Ikezu and 
colleagues due to variations in drug concentrations and in vitro/in vivo model systems.   Clearly, 
further investigation is needed in this area. 
Previous studies investigating amyloid pathology in HIV-positive, ARV-medicated brain 
tissue have yielded conflicting results.  Green et al., were the first to show increased APP 
accumulation, primarily intraneuronal, and amyloid-associated pathology in ARV-treated, HIV-
positive individuals compared to ARV-naïve controls (9).  These findings were confirmed by Xu 
and Ikezu who observed intraneuronal Aβ immunoreactivity and Aβ plaques in ARV-treated, 
HIVE brains but only intraneuronal Aβ in ARV-untreated, HAD brains, with no evidence of 
extracellular deposition (8).  In contrast, Anthony et. al., found no evidence of increased Aβ 
deposition or plaque accumulation in HIV-infected cases, but did observe increased hippocampal 
hyperphosphorylated Tau, especially in ARV-medicated patients, compared to unmedicated 
controls (10, 80, 81).  To reconcile these differences and shed light on the clinical significance of 
our in vitro findings, we stained aged-matched HIV-negative and HIV-positive post-mortem brain 
tissue with Aβ42 C-terminal-specific (not shown) and Aβ oligomer-specific antibodies.  We found 
no evidence for Aβ plaque deposition in HIV-positive cases, but strikingly, we did observe 
intraneuronal Aβ immunoreactivity, consistent with previous reports.  More importantly, we show 
for the first time, evidence for abundant intraneuronal Aβ oligomer formation in hippocampus of 
ARV-treated patients.  As Aβ oligomers are believed to be highly cytotoxic, and thus responsible 
for neuronal damage and death in AD, this may be a contributing factor to early aging in HIV-
positive individuals as well.  However, future studies investigating ARV therapy as a specific 
contributor to HIV pathogenesis are warranted.   
 One major caveat associated with human studies in HAND is the inability to separate out 
pathological effects associated with HIV from those associated with confounding variables such 
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as co-morbidities, drug abuse and antiretroviral toxicity.  To address these concerns, we utilized 
two animal models of chronic ARV drug treatment.  We have previously shown that SIV-infected, 
pigtailed macaques treated with an ARV cocktail show increased hippocampal synaptodendritic 
damage compared to placebo-treated and uninfected controls.  Here, we expand upon those 
findings to report elevated neuronal APP in hippocampus of SIV(+)/ART macaques compared to 
controls.  Taken together, these observations strongly suggest that antiretrovirals in the presence 
of virus may contribute to the neurodegenerative process associated with HAND.  Although it 
remains unclear why placebo-treated animals displayed decreased APP compared to uninfected 
controls, several caveats must be considered when interpreting these results.  First, the time to 
euthanasia after the initial SIV infection is different between SIV(+)/placebo and SIV(+)/ART 
groups, as these samples were obtained from animals used to address a distinct question 
regarding use of ART.  Second, there was persistent viral DNA in the CNS of SIV(+)/ART 
macaques, though it is uncertain if this DNA is replication competent (50).  Lastly, there was no 
SIV(-)/ART control group to account for the effects of the drugs by themselves in the absence of 
virus.  Future studies that include the use of SIV(-)/ART controls will be invaluable for separating 
out the contribution of virus to CNS damage from that of ARVs.  Importantly, concentrations of 
ARV drugs used in the SIV/macaque studies have been demonstrated by Clements and 
colleagues to closely reflect dose ranges measured in human plasma and CSF.        
Although CNS effects of ARVs are still poorly understood, clinical studies have begun to 
address the effect of drug regimens with high CNS penetration on populations of HIV-positive 
individuals.  While many studies have shown that ARVs are beneficial for improving cognition in 
treated patients, others have found a significant association between ARV regimens with high 
CPE scores and poorer neurocognitive performance (5, 57-59, 82-90).  Confounding the issue of 
ARV toxicity in the CNS is variation in blood brain barrier (BBB) permeability among different drug 
classes, persistence of viral load in the brain, and the resulting difficulty to separate out neuronal 
toxicity induced by HIV from that of antiretroviral drugs.  While many ARV drugs are thought to 
suffer from various physicochemical properties that impair their ability to penetrate an intact BBB, 
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there is extensive evidence demonstrating increased entry of small molecules and serum proteins 
into the CNS following HIV-mediated disruption of BBB endothelial cells and tight junctions (91-
98).  Therefore, it is reasonable to consider that higher-than-anticipated concentrations of ARV 
drugs may penetrate the compromised BBB of HIV-infected individuals.  Notably, 
pharmacokinetic analysis of ARVs in guinea pigs revealed significantly higher uptake of 
[
3
H]ritonavir into brain parenchyma compared to CSF, suggesting that clinical estimates of CNS 
penetrance for PIs may be lower than actual drug concentrations in the brain (63).  In addition to 
uncertainties in ARV CNS penetration with currently prescribed regimens, current efforts to 
enhance delivery of ARV drugs to the CNS via nanotherapeutics necessitate a careful 
examination of the potential neurotoxic effects these drugs may exert in the brain.   
While concentrations of ARVs utilized in this study are significantly higher than peak CNS 
levels obtained in patients, the effects of ARV drugs on neurons we demonstrate here are likely to 
occur in vivo over long-term exposures.  In the present study, we sought to model these chronic, 
low-dose effects of ARVs in a more acute time frame with higher doses of drug.  Our results 
indicate that nanomolar concentrations of HIV protease inhibitors robustly activate the UPR in 
primary cortical neurons leading to PERK-dependent phosphorylation of eIF2α and translational 
upregulation of BACE1.  ARVs alone and in combination were also shown to increase production 
of Aβ peptides in multiple cells types, which could be dose-dependently blocked by addition of a 
cell-permeable BACE1 inhibitor.  Lending further support to these findings were our observations 
that ARV-medicated, HIV(+) patients display elevated levels of Aβ oligomers, BACE1, and BiP.  
Taken together with our previous reports of elevated p-eIF2α and ATF6 in HAND tissue, these 
data suggest a role for ER stress in CNS HIV pathogenesis.  These results bear striking 
similarities to observations made in AD, PD, ALS and prion disease conditions in which markers 
of ER stress, including phospho-PERK are elevated in multiple brain regions.  While transient 
eIF2α phosphorylation is protective to cells coping with ER stress, sustained suppression of 
global protein synthesis in the CNS may ultimately lead to impaired LTP and synaptic failure.  
However, promising therapeutics targeted at the UPR have already been reported.  Several 
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studies have indicated that genetic and pharmacological suppression of PERK activity can 
decrease brain p-eIF2α expression, improve synaptic plasticity and rescue memory deficits in an 
AD mouse model and alleviate prion-mediated pathology and cognitive deficits in mice inoculated 
with prion proteins (99, 100).  Additionally, BACE1 inhibitors, which have already been tested 
extensively in clinical trials, may have therapeutic benefits in patients suffering from HAND.  
Future investigations will be necessary to determine the role of BACE1 in the ER stress 
response.  Furthermore, we propose to investigate the potential effect of ARVs on BACE1 
redistribution to the trans-golgi network and early endosomal compartments as a mechanism of 
increased amyloidogenic APP processing, similar to what has been reported by Tan et. al (71).  
These studies will enhance our understanding of BACE1’s role in cellular maintenance under 
normal and stressed conditions in the CNS and provide insights into potential therapeutic targets 
for neurodegenerative disease.  
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Figure 1.  BACE1 and Aβ oligomer immunostaining are elevated in the brain of HIV(+) cases.  
Paraffin-embedded tissue sections from hippocampus of HIV(-) control, HIV(+) Normal and 
HIV(+) HAND cases were prepared for immunofluorescent analysis and visualized by laser 
confocal microscopy.  A)  Representative images are shown from hippocampal sections triple-
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labeled for Aβ oligomers (red), MAP2 (green), and nuclei (blue).  Red and green colocalization 
appears yellow.  Aβ oligomers (red) are increased in MAP2-positive neurons in hippocampus of 
HIV(+) cases compared to controls.  B)  CA1, CA3, and dentate gyrus hippocampal sections were 
double-labeled for BACE1 (green) and MAP2 (red).  Representative images are shown.  Despite 
a loss of MAP2 (red) in HIV(+) HAND cases compared to controls, BACE1 (green) 
immunostaining was increased in CA1 and CA3 regions in HAND cases.  C)  Whole brain lysates 
from the mid-frontal cortex of HIV(-) controls (n=4), HIV(+) neurocognitively normal (HIV(+) 
Normal) (n=7), and HIV(+) HAND (n=6) cases were prepared for immunoblot and probed for BiP, 
BACE1, APP, phospho- and total eIF2α.  D-G)  Densitometric analysis revealed no significant 
changes in expression levels of phospho-eIF2α or APP in HIV(+) cases, however, BiP was 
elevated in HIV(+) Normal cases and BACE1 was elevated in HIV(+) Normal and HIV(+) HAND 
cases compared to controls (*p<0.05, ns: not significant, one-way ANOVA plus Newman-Keuls 
post hoc testing).  
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Figure 2.  Antiretroviral drugs administered to SIV(+) macaques induce CNS damage and 
elevated BACE1.  Using double-label confocal microscopy, formalin-fixed, paraffin-embedded 
hippocampal brain sections from pigtailed macaques were labeled by immunofluorescence for: 
MAP2 (red) and APP (green).  Pigtail macaques were either uninfected (n=6), SIV-infected and 
treated with placebo (n=7), or SIV-infected and treated with combination antiretroviral therapy 
(ART) (tenofovir, atazanavir, saquinavir, and L-870812a) (n=4).  A)  Representative images of 
cases stained with APP and MAP2 are shown.  B) Quantification indicates a significant increase 
in intraneuronal APP in SIV(+) ART-treated macaques compared to uninfected and 
SIV(+)/placebo-treated controls (**p<0.01, ***p<0.001, one-way ANOVA plus Newman-Keuls post 
hoc testing). C)  Fresh-frozen tissue sections from the hippocampus of pigtailed macaques were 
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subjected to standard protein extraction and immunoblotting for expression of BiP, BACE1, APP, 
p-eIF2α, total eIF2α, PS-1 CTF, and ADAM10.  Fast green was used as a loading control.  D-I) 
Quantification of band densities from immunoblots shown in Figure 2C (*p<0.05, 
**p<0.01,***p<0.001, ns: not significant, one-way ANOVA plus Newman-Keuls post hoc testing). 
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Figure 3.  Antiretroviral drugs activate the unfolded protein response and upregulate BACE1 
expression in primary neurons.  A) 21 DIV rat neuroglial cultures were treated with indicated 
concentrations of AZT, saquinavir, or ritonavir for 16 h, lysed, and immunoblotted for markers of 
ER stress (BiP, phospho- and total eIF2α), APP, BACE1, ADAM10, and PS-1).  Actin was used 
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as a loading control for all targets except phospho-eIF2α which was normalized to total eIF2α.  
Representative blots shown.  B-G) Quantification of immunosignals were normalized to actin and 
expressed as fold change relative to vehicle controls.  BiP, p-eIF2α, APP, and BACE1 protein 
levels were significantly elevated compared to controls.  ADAM10, and PS-1 did not show any 
significant changes (n=5, vehicle: 0.04% DMSO, *p<0.05, **p<0.01, one-way ANOVA with 
Dunnett post hoc testing).  H)  Rat neurons were treated with 0.04% DMSO (Vehicle), 10 μM 
Ritonavir, 1 μM Saquinavir, 25 μM AZT, or 1 μM thapsigargin for 16 h.  Total mRNA was isolated 
and expression levels of spliced XBP1 mRNA measured via TaqMan using the comparative Ct 
method relative to unspliced XBP1 (uXBP1).  qRT-PCR assays were performed in triplicate.  
Ritonavir and saquinavir induced significant increases in spliced XBP1 (n=4, *p<0.05, ***p<0.001, 
one-way ANOVA with Dunnett post hoc testing).  I)  21 DIV human fetal neurons were treated as 
in (A) and lysates subjected to immunoblotting.  Representative blot shown.  Similar to (A), ARVs 
appeared to induce increased protein expression of BiP, phospho-eIF2α, and BACE1, relative to 
vehicle controls (n=3). 
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Figure 4.  ARV drugs increase amyloidogenic APP processing in primary neurons.  CHO cells 
stably expressing human APP were treated with 10 μM ritonavir for 16 h or pre-treated with 
various doses of a cell-permeable beta secretase inhibitor (BSI) for 12 h then treated with 
ritonavir for 16 h.  After 16 h, culture media was collected and subjected to a human/rat Aβ42- or 
Aβ40-specific sandwich ELISA (A) or a human sAPPα or sAPPβ ELISA (B, C).  A)  Ritonavir 
treatment resulted in a two-fold increase in Aβ42 production that was dose-dependently blocked 
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by addition of a beta secretase inhibitor, while Aβ40 levels were unaffected by addition of ritonavir 
(n=6, ***p<0.001, ns: not significant, one-way ANOVA plus Newman-Keuls post hoc testing).  B)  
No statistically significant changes in sAPPβ or sAPPα were observed in ritonavir-treated 
cultures, though sAPPβ was dose-dependently decreased by the presence of a beta secretase 
inhibitor.  D, E) Primary rat neuroglial cultures were treated with various combinations of ARV 
drugs (10 μM ritonavir, 1 μM saquinavir, and 25 μM AZT) for 4 or 16 h.  Culture media was then 
subjected to a human/rat Aβ42- or Aβ40-specific sandwich ELISA as in (A).  At 16 h, both Aβ42 and 
Aβ40 levels were increased in most treatment conditions.  AZT appeared to blunt PI-mediated 
enhancement of amyloidogenic APP processing in combination treatment (n=3, *p<0.05, 
**p<0.01, one-way ANOVA plus Dunnett post hoc testing). 
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Figure 5.  Ritonavir upregulates neuronal BACE1 expression via translation-dependent control.  
A)  Rat neurons were exposed to the indicated treatments for 16 h.  mRNA was isolated for RT-
PCR and cDNA subjected to real-time PCR.  Levels of BACE1 mRNA were determined using the 
ΔΔCt method relative to TBP.  qRT-PCR assays were performed in triplicate.  No significant 
changes in BACE1 mRNA were observed in ARV drug-treated cultures (n=4, **p<0.01, one-way 
ANOVA plus Dunnett post hoc).  B)  Rat neurons were treated with ritonavir alone or pre-treated 
with anisomycin or actinomycin D for 12 h then treated with ritonavir.  Fast green was used as a 
loading control.  C)  Compared to ritonavir-only treated neurons, anisomycin pre-treatment 
resulted in decreased BACE1 expression.  Actinomycin D had no significant effect (n=4, 
**p<0.01, ns: not significant, one-way ANOVA plus Newman-Keuls post hoc).  D)  Rat neurons 
were treated with the indicated drugs for 16 h, separated into cytoplasmic and nuclear fractions, 
and analyzed by immunoblotting.  E)  Densitometric analysis revealed a significant increase in 
ATF4 and BACE1 (n=4, **p<0.01, one-way ANOVA plus Dunnett post hoc).  F) 14 DIV rat cortical 
cultures were transfected via magnetotransfection with pcDNA3.1Zeo(+) vector containing the 
entire human BACE1 coding region including the BACE1 5’ UTR but missing the 3’ UTR (+5’ 
UTR) or pcDNA3.1Zeo(+) vector containing the human BACE1 coding region including the 3’ 
UTR but missing the 5’ UTR (-5’ UTR).  48 hours following transfection, cultures were treated with 
0.04% DMSO or 10 µM ritonavir for 16h, lysed, and immunoblotted for BACE1.  Representaive 
blots shown.  G) Quantification of BACE1 immunosignal was normalized to actin (n=3, *p<0.05, 
ns: not significant, one-way ANOVA plus Newman-Keuls post hoc testing).   
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Figure 6. Ritonavir does not affect BACE1 protein stability in primary neurons.  A)  Primary rat 
neurons were pulse-labeled for 30 min with 
35
S-methionine/cysteine-containing DMEM and 
chased with neurobasal media + B27.  Radiolabeled BACE1 was immunoprecipitated with 
Dynabeads Protein A and 2 μg anti-BACE1 12h post-labeling to confirm enrichment.  B)  Neurons 
were pulse-labeled as in (A) and chased with neurobasal media +/- 10 μM ritonavir for 24 h.  
BACE1 was immunoprecipitated as in (A), and visualized via autoradiography. Note that 
immature BACE1 runs at ~60 kDa while mature, fully glycosylated BACE1 runs at ~70 kDa.  
Representative blots shown (n=3).  C)  The levels of 
35
S-methionine/cysteine-labeled BACE1 
were quantified and the percentage changes, relative to 0h time point, are plotted.  No significant 
differences in BACE1 half-life were observed between control and ritonavir-treated neurons (n=3, 
linear regression analysis).    
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Figure 7. PERK regulates basal BACE1 expression in neurons.  A)  DIV 14 pure neuronal 
cultures were transfected via magnetotransfection with one of three plasmids: pLENTI CMV/TO 
Puro destination vector (backbone), wild-type mouse PERK, or kinase-dead, K618A mutant 
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PERK (dnPERK) and complexed with Neuromag transfection reagent.  72 h after transfection, 
cultures were harvested and lysates prepared for immunoblotting.  Representative blots shown.  
B) Densitometric analysis of PERK immunosignals indicate significant overexpression of wild-type 
and kinase-dead PERK in pure neuronal cultures compared to empty vector controls (n=3, 
*p<0.05, ***p<0.001, one-way ANOVA plus Newman-Keuls post hoc testing).  C, D)  
Quantification of p-eIF2α and BACE1 blots show a significant decrease in expression of these 
respective proteins in neuronal cultures overexpressing dnPERK compared to neurons 
overexpressing wild-type PERK when transfected with 2 μg of plasmid DNA (n=3, Student’s t 
test).   
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Figure 8.  HIV protease inhibitor-mediated BACE1 upregulation is PERK-dependent.  A-C)  
Floxed PERK mouse cortical neuroglial cultures were generated by isolating neurons from brains 
of tamoxifen-inducible cre recombinase conditional PERK knockout embryonic mice at E16.5-
17.5.  At DIV 10, neuroglial cultures were treated with 0.1 μM or 1 μM 4-hydroxtamoxifen (4-
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OHT), for 96 h to excise the PERK gene (note that estimated PERK half-life is 13 h).  Efficiency of 
PERK excision was estimated to be approximately 50 to 60% via densitometric analysis (A) (n=4, 
*p<0.05, **p<0.01, one-way ANOVA plus Newman-Keuls post hoc testing).  Wild-type and PERK-
excised neuroglial cultures were treated with 10 μM ritonavir (B) or 1 μM saquinavir (C) for 16 h 
and lysates prepared for immunoblotting.  Representative images shown (n=4).  Compared to 
wild-type cultures treated with ritonavir or saquinavir, PERK-excised neuroglial cultures treated 
with ARVs showed reduced expression of p-eIF2α and BACE1.     
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4.1: ABSTRACT 
Despite advances in antiretroviral therapy (ART), HIV remains the leading cause of dementia 
among young adults in the United States.   Approximately 50% of HIV+ individuals develop some 
form of cognitive/motor dysfunction, which can range from asymptomatic neurocognitive 
impairment (ANI) to frank dementia. Collectively, the spectrum of neurological dysfunctions 
caused by HIV infection is known as HIV-associated neurocognitive disorders (HAND).  A 
growing body of evidence suggests that HAND in the post-ART era has evolved from a subacute 
dementia to a more insidious, neurodegenerative disease with pathological hallmarks similar to 
Alzheimer disease (AD).  Common features among HAND and AD include the presence of 
chronic oxidative stress and inflammation, as well as misfolded proteins in the CNS.  Additionally, 
we recently demonstrated that beta-site APP cleaving enzyme 1 (BACE1), which is the rate-
limiting enzyme in the production of beta amyloid (Aβ) from the amyloid precursor protein (APP), 
is upregulated in brains of ART-medicated, HIV+ individuals and that ART drugs increase BACE1 
expression and Aβ peptide production in primary neurons via chronic activation of the unfolded 
protein response (UPR).  Therefore, we hypothesized that ART-mediated BACE1 upregulation in 
neurons may be contributing to neurological dysfunction in patients with HIV via aberrant 
production of Aβ peptides.  In this report, we demonstrate that pharmacological inhibition of 
BACE1 is neuroprotective against ART-mediated toxicity and that inhibition of the unfolded 
protein response can mitigate ART-mediated upregulation of BACE1 in neurons.    Together, 
these results suggest that inhibiting neuronal BACE1 function, either directly or upstream, may be 
a viable adjunctive neuroprotective therapy in the treatment of HAND.  
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4.2: INTRODUCTION 
Beta-site APP cleaving enzyme 1 (BACE1) is a transmembrane aspartyl protease that was 
initially identified as the primary beta-secretase enzyme responsible for cleaving the amyloid 
precursor protein (APP) to generate beta amyloid (Aβ), the primary component of senile plaques 
in AD (1, 2).  Post-mortem analyses have revealed that BACE1 expression and enzymatic activity 
are significantly upregulated in AD brains compared to age-matched controls and BACE1 co-
localizes with amyloid plaques (3-6).  BACE1 expression is controlled at the transcriptional and 
translational level by a host of stress factors including inflammation, ischemia, oxidative stress, 
and energy deprivation (7-9).  Oxidative stress, which is a common feature among many 
neurodegenerative diseases, is particularly important in the pathogenesis of AD as it has been 
shown to increase expression of β- and γ-secretase leading to overproduction of Aβ, which itself 
induces oxidative stress, yielding a positive feedback loop (10). 
Recent studies have shown that oxidative stress and BACE1 upregulation are salient 
features of many CNS inflammatory and neurodegenerative diseases.  In particular, HIV infection 
is associated with a spectrum of neurocognitive impairments, termed HIV-associated 
neurocognitive disorders (HAND), characterized by chronic neuroinflammation, oxidative stress, 
and neurodegeneration (11-13).  Despite the successes of antiretroviral therapy (ART) in 
suppressing HIV viral loads to undetectable levels and decreasing HIV-related morbidity and 
mortality, the prevalence of HAND continues to escalate.  Furthermore, increasing evidence 
suggests that HAND pathology has evolved in the post-ART era from a subcortical encephalitis to 
a more cortical and hippocampal, neurodegenerative condition with Alzheimer disease (AD)-like 
pathological hallmarks, including neurofibrillary tangles and intracellular Aβ accumulation (14-19).  
We recently showed that ART-medicated, HIV+ individuals also display increased expression of 
intraneuronal Aβ oligomers and beta-site APP cleaving enzyme (BACE1) compared to ART-naïve 
and uninfected controls, suggesting that antiretrovirals may be contributing to enhanced Aβ 
production in the CNS of HAND patients through a BACE1-dependent mechanism (20). 
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 Although it remains unclear what specific role ART has on the persistence and 
progression of HAND, many classes of ART drugs induce a wide range of systemic metabolic 
and neural disturbances that could themselves influence the neurocognitive status of HIV+ 
individuals.  Nucleoside reverse transcriptase inhibitors (NRTIs) have been linked to oxidative 
stress and mitochondrial dysfunction, manifested clinically as peripheral neuropathy and 
myopathy, while HIV protease inhibitors (PIs) are associated with atherosclerosis, lipodystrophy, 
and diabetes (21-31).  Recently, several groups have shown that PIs can also induce oxidative 
stress via production of reactive oxygen species (ROS) leading to neuronal damage and death in 
vitro (12, 32).  Through these and numerous other cellular mechanisms, including 26S 
proteasome inhibition, ART drugs, and PIs in particular, induce ER stress and activate the 
unfolded protein response (UPR) in a wide variety of cell types (25, 26, 28, 33-36).  In 
eukaryotes, the UPR is tightly regulated by the ER-resident chaperone, Binding Protein 
(BiP)/GRP78, which binds to and keeps inactive, three sensor proteins, pancreatic ER kinase 
(PERK), activating transcription factor 6 (ATF6), and inositol-requiring enzyme 1α (IRE1α), under 
basal cellular conditions (37-39).  Following induction of ER stress, BiP is recruited to aid in 
protein refolding allowing for the subsequent activation of PERK, ATF6, and IRE1α.  Transient 
activation of the UPR initially results in PERK-mediated phosphorylation of the translation 
initiation factor, eIF2α, and global suppression of protein translation. Paradoxically, this event is 
accompanied by selective translational upregulation of a subset of mRNAs, characterized by the 
presence of multiple uORFs in the 5’ UTR, that typically encode for molecular chaperones and 
transcription factors involved in cellular adaptation to stress, such as ATF4 (40).  Despite having 
no known chaperone function, BACE1 mRNA, which contains three uORFs and 4 uAUGs in the 
5’ leader sequence, is also translationally upregulated in response to ER stress and has been 
shown to increase via a translational mechanism  in neurons treated with ART drugs (7, 41, 42).   
Altogether, these results indicate that ART drugs activate the unfolded protein response 
in neurons, likely through a pro-oxidative mechanism, leading to translational upregulation of 
BACE1, aberrant production of Aβ, and cellular toxicity. Therefore, we hypothesized that 
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pharmacological inhibition of UPR signaling and/or BACE1 activity in ART-treated neurons would 
mitigate cellular damage and death.  Using an acute, in vitro model of ART exposure, we show 
that inhibition of two eIF2α kinases, PERK and PKR, suppresses ART-mediated BACE1 
upregulation in neurons while direct BACE1 inhibition is protective against ART-mediated 
neuronal damage, suggesting that BACE1 may be a potential therapeutic target in the treatment 
of HAND. 
 
4.3: EXPERIMENTAL METHODS 
Preparation of Primary Neuronal Cultures:  All primary rat cortical neuroglial cultures were 
isolated from frontal cortices of embryonic day 16.5-17.5 Sprague-Dawley rat pups, with 
modifications of previously described protocols (43).  Briefly, cortical cell suspensions were 
isolated from rat pups and plated in poly-L-lysine (Peptide International) coated tissue culture 
dishes and maintained in neurobasal media containing B27 supplement at 37
o
C with 5% CO2, as 
described previously (44, 45).  Unless otherwise indicated, all experiments were performed at 14-
21 days in vitro (DIV) on neuronal cultures containing approximately 90% neurons and 10% 
astrocytes/glia.  50% of neurobasal media volume was replaced with fresh media 10 days after 
plating cells. 
Drug Treatments: To model mild oxidative stress or ER stress in neurons, 10 DIV rat cortical 
cultures were treated for 12 hours with 10 and 20 µM hydrogen peroxide diluted in water from a 
30% w/w stock solution (Sigma, St. Louis, MO) or 10 µM ritonavir, respectively.  All antiretroviral 
drugs were obtained from the AIDS research and Reference and Reagent Program (Division of 
AIDS, NIAID, NIH) and prepared in DMSO at 25 mM stock concentrations.  To assess the 
neuroprotective properties of BACE1 inhibition, neuronal cultures were pre-treated with 1 µM 
Beta-Secretase Inhibitor IV (Calbiochem, Billerica, MA) for 30 minutes followed by treatment with 
hydrogen peroxide or ritonavir, as indicated.  eIF2α kinase inhibition assays were performed 
using the 7DG PKR inhibitor (Sigma; IC50 = 5 µM) and GSK2606414 PERK inhibitor (EMD 
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Millipore; IC50 = 0.4 nM) and were prepared in DMSO stocks and added to cultures by dilution at 
the indicated final concentrations.         
Immunofluorescence Staining of Neuronal Cultures:  To assess neuronal damage and death, 
15 µM propidium iodide was added to neuronal cultures grown on coverslips 15 minutes prior to 
the end of drug treatments.  Cultures were washed twice with PBS and fixed for 30 minutes in 4% 
paraformaldehyde/4% sucrose in PBS, followed by permeablization in 0.2% BSA + 0.1% Triton 
X-100/PBS for 1 hour at room temperature.  Coverslips were then washed twice with PBS and 
incubated with anti-MAP2 antibody (1:1000) in normal antibody diluent overnight at 4
o
C.  After 
washing in PBS-T, coverslips were incubated in a fluorescein isothiocyanate-conjuagated goat 
anti-mouse IgG secondary antibody (1:200 for 30 min at room temperature, Jackson 
ImmunoResearch Lab, West Grove, PA).  Coverslips were mounted on slides and the number of 
MAP2+ cells determined through blind counting of all fields (15 at 200x) in three adjacent vertical 
columns through the center of each coverslip.  Images were captured using a Nikon Eclipse E400 
fluorescent microscope (Nikon Corp, Tokyo, Japan) equipped with an Olympus DP70 digital 
camera (Olympus Corp, Tokyo, Japan).  Propidium iodide puncta were counted by hand using 
the NIH ImageJ software program (Image J v1.44, NIH) and plotted as fold change compared to 
untreated controls. Averages are expressed as mean ± SEM.    
To determine the effect of oxidative and ER stress on synaptic integrity, neuronal cultures were 
treated with H202 or ritonavir as described above, fixed, and incubated in anti-synapsin antibody 
(1:300) overnight at 4
o
C.  Coverslips were then incubated in a fluorescein isothiocyanate-
conjugated goat anti-rabbit IgG secondary antibody (1:200) for 30 minutes at room temperature. 
For each treatment group, 15 images were captured on three coverslips from three independent 
experiments using fluorescence microscopy.  Post-acquisition analysis was performed using 
Metamorph 6.0 (Universal Imaging, Downingtown, PA).  Briefly, intensity of synapsin staining was 
determined by the measurement of integrated pixel intensity (defined as total pixel intensity times 
the area of pixels with positive synapsin signal).  This value was divided by the total MAP2 area 
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(also quantified using Metamorph) to account for global changes in neuronal density.  For all 
imaging quantification, three coverslips were counted from three independent experiments.  
Averages are expressed as mean ± SEM.   
Immunoblotting:  Whole cell extracts of primary rat cortical cultures were prepared using ice-
cold whole-cell lysis buffer (50 mM Tris pH 7.5, 120 mM NaCl, 0.5% NP-40, 0.4 mM Na3VO4, 100 
mM DTT, and 1:100 protease inhibitor cocktail.  Lysates were centrifuged at 14,000 g at 4
o
C for 
10 minutes and protein concentrations determined using the Bradford method and equal amounts 
of protein (20 µg) loaded into each well of a 4-12% Bis-Tris Gradient gels followed by transfer to 
PVDF membranes at 25 volts at room temperature for 1 hour.  Membranes were then blocked in 
tris buffered saline (TBS) with 0.1% tween (TBS-T) plus 5% bovine serum albumin (BSA) for 30-
60 minutes at room temperature. Blocked membranes were incubated in BACE1 primary 
antibody (Cell Signaling) overnight at 4
o
C, washed with TBS-T, and incubated with HRP-
conjugated goat-anti rabbit secondary antibody for 30 minutes at room temperature.  Membranes 
were developed using SuperSignal West Dura extended duration substrate and pixel intensities 
of ROIs quantified via densitometric analysis using the NIH ImageJ software program.  BACE1 
band intensity was normalized to actin loading controls.  Immunoblots shown are representative 
of three independent biological replicates.    
Statistical Analysis: All data were analyzed by Prism 5.0 software (Graphpad Software, San 
Diego, CA).  All quantifications are expressed as mean ± SEM.  Data with multiple categories 
were analyzed by one-way analysis of variance (ANOVA) plus Newman-Keuls post hoc test, as 
indicated.  Values of p <0.05 were considered significant.          
 
4.4: RESULTS 
BACE1 inhibition mitigates MAP2 and synapsin loss in primary neurons treated with hydrogen 
peroxide.  Numerous studies have shown that neurons exposed to mild oxidative stress display 
increased expression of BACE1 at the transcriptional and translational levels leading to enhanced 
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production of Aβ species (8, 46, 47).  To investigate the role of BACE1 in neurons undergoing 
oxidative stress we first treated primary rat neuroglial cultures with 10 and 20 µM hydrogen 
peroxide (H202) for 24 hours in the presence or absence of a cell-permeable beta secretase 
inhibitor (BSI) and assessed cellular damage and death via MAP2 (blue), synapsin (green), and 
propidium iodide staining.  We observed that BACE1 inhibition alone had no apparent effect on 
cellular or synaptic density, nor did it have any effect on propidium iodide uptake compared to 
vehicle controls (Figure 1).  Neuronal cultures treated with 10 µM H202 showed decreased MAP2 
expression and increased uptake of propidium iodide, but no evident changes in synapsin, while 
cultures pre-treated with 1 µM BSI showed reduced uptake of propidium iodide but no apparent 
rescue of MAP2 expression (Figure 1).  At 20 µM H202, neuronal MAP2 and synapsin levels 
were reduced, while propidium iodide uptake was increased compared to vehicle controls but 
decreased compared to 10 µM H202-treated neurons.  Pre-treatment with 1 µM BSI partially 
rescued MAP2 loss and completely rescued loss of synapsin. The number of propidium iodide 
puncta was increased in BSI pre-treated 20 µM H202 neuronal cells, suggesting BACE1 inhibition 
may result in a delayed death response (Figure 1).   
BACE1 inhibition prevents MAP2 loss in ritonavir-treated neurons.  Our previous studies have 
shown that ritonavir, and other PI class drugs, induce toxic oxidative stress in primary neurons 
followed by translational upregulation of BACE1 (12, 20).  Therefore, we sought to determine 
whether BACE1 has a protective or deleterious effect on neuronal survival following chronic 
exposure to ritonavir.  Primary rat cortical cultures were pre-treated with DMSO vehicle or 1 µM 
BSI for 30 minutes then 10 µM ritonavir for 48 hours.  Cultures were stained with propidium iodide 
to assess cellular viability and immunostained for MAP2 and synapsin, as described above.  
Similar to our previous observations, BACE1 inhibition had no effect on MAP2+ cell count, 
synapsin intensity, or propidium iodide uptake compared to untreated and vehicle controls (Figure 
2A).  48 hour ritonavir treatment resulted in a three-fold decrease in MAP2+ cell count and nearly 
a three-fold increase in propidium iodide uptake, but no change in synaptic integrity relative to 
MAP2 area in 10 DIV neuronal cultures (Figure 2A-D).  Pre-treatment with BSI rescued MAP2+ 
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cell loss in ritonavir-treated neurons and decreased propidium iodide uptake (Figure 2F).  
Together, these results suggest BACE1 may contribute to neuronal damage and death in the 
context of oxidative stressors, such as hydrogen peroxide and PI-class antiretroviral drugs.   
Small molecule inhibitors of PKR and PERK block HIV protease inhibitor-mediated 
phosphorylation of eIF2α in neurons.  ART drugs have been shown to increase expression of 
neuronal BACE1 through an eIF2α-dependent translational mechanism in vitro (20).  Thus, we 
hypothesized that pharmacological inhibition of eIF2α phosphorylation would block ritonavir-
mediated BACE1 upregulation in neurons.  Among the four known eIF2α kinases, we first tested 
an inhibitor (7DG) of double-stranded RNA-dependent protein kinase (PKR), which has been 
shown to respond to various stressors including viral infection, calcium dysregulation, and 
oxidative/ER stress and has been implicated in translational BACE1 regulation (47-49).  We 
observed that neurons pre-treated with 7DG and exposed to 16 hour ritonavir or saquinavir 
treatment showed significantly reduced levels of phospho- eIF2α compared to ART-only treated 
cultures (Figure 3A and 3B).  Notably, 7DG also reduced levels of phospho- eIF2α to half the 
level of untreated and vehicle controls, indicating PKR may play a role in maintaining basal levels 
of phospho- eIF2α in neurons.  We also observed that PKR inhibition in the presence of ritonavir 
or saquinavir reduced BACE1 expression levels compared to ART-only controls, however, this 
change was not statistically significant (Figure 3C).   
 Based on our previous observations that PERK is involved in ART-mediated BACE1 
upregulation in neurons, we tested the effects of a PERK inhibitor (GSK2606414, abbreviated 
GSK) on phospho- eIF2α and BACE1 levels in ritonavir and saquinavir-treated neurons.  We 
found that 0.5 µM GSK significantly reduced phospho- eIF2α levels in ritonavir and saquinavir-
treated neurons compared to ART-only controls (Figures 3D-E and G-H).  Similar to 7DG, 
administration of GSK reduced BACE1 levels in the presence of ART, but the change was not 
statistically significant (Figures 3F and 3I).  These results suggest that PKR and PERK both 
contribute to BACE1 upregulation in ART-treated neurons through phosphorylation of eIF2α.  
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However, inhibition of only one eIF2α kinase may not be sufficient to fully suppress BACE1 
upregulation mediated by ART.   
PERK inhibitor compound, GSK2606414, does not alleviate ritonavir-mediated neurotoxicity in 
primary neuroglial cultures.  Genetic and pharmacologic knockdown of PERK activity has been 
shown to have protective effects in the CNS of animals infected with prions as well as in 
Alzheimer disease mouse models (7, 50-52).  Therefore, we tested whether PERK inhibition 
abrogates ritonavir-mediated neurotoxicity.  Unexpectedly, we found that use of the GSK PERK 
inhibitor augmented ritonavir-mediated losses in MAP2 and increased propidium iodide uptake 
(Figure 4).  Notably, administration of GSK alone appeared to have toxic effects on neuronal 
cultures, as indicated by reduced MAP2 expression and a robust increase in propidium iodide 
uptake compared to untreated and vehicle controls, suggesting that this compound may have 
toxic side-effects unrelated to PERK inhibition or that PERK itself may play an important role in 
cellular maintenance and homeostasis in neurons, thus limiting its therapeutic potential.       
 
4.5: DISCUSSION 
The persistence of less severe manifestations of HAND, including ANI and mild neurocognitive 
disorder (MND), despite the widespread implementation of combination ART in 1996 highlights 
the need for new therapeutic targets and adjunctive therapies in the management of HAND.  
Previous attempts to mitigate neurocognitive decline in HIV+ individuals focused on the use of 
ART regimens with high CNS penetrance, as estimated by the CNS-penetrance effectiveness 
(CPE) scoring system.  While many clinical studies found that higher CPE scores were initially 
successful at improving patients’ neuropsychological performance, others found an inverse 
relationship between CPE scores and neurocognitive/motor performance despite decreased CSF 
HIV RNA levels (53-57).  To date, promising adjunctive therapies with anti-oxidant and anti-
inflammatory properties such as selegiline, minocycline, and memantine, have been largely 
unsuccessful at reversing long-term cognitive decline in HAND patients.  Here, we build on our 
previous observations that ART drugs increase BACE1 expression in vitro and in vivo to show 
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that BACE1 inhibition is protective against ART-mediated neurotoxicity, thus identifying BACE1 
as a potential therapeutic target in HAND and other CNS inflammatory diseases in which 
oxidative and ER stress are prevalent.   
We first sought to understand the role of BACE1 in neuronal survival under conditions of 
oxidative stress.  Previous studies have demonstrated that oxidative stress can induce cellular 
redistribution of BACE1 to endosomal compartments co-localizing with APP and/or lead to 
transcriptional and translational upregulation of BACE1 expression in neurons (8, 47).  Given that 
BACE1 is translationally repressed under normal conditions, but selectively upregulated during 
ER and oxidative stress, we initially hypothesized that BACE1 may play a role in cellular stress 
adaptation and/or survival.  Consistent with this idea, Kamenetz et. al. reported that Aβ produced 
by BACE1 cleavage of APP was protective against neuronal hyperactivity and excitotoxicity in 
vitro (58).  However, our observations in H202-treated neurons suggest that BACE1 contributes 
to neuronal damage and death in the presence of mild to severe oxidative stress over 24 hours.  
These findings were corroborated with our 48-hour ART treatment studies in which BACE1 
inhibition partially rescued ritonavir-mediated losses in MAP2+ cell count and propidium iodide 
uptake.  While informative, these observations raise questions regarding the basic physiological 
functions of BACE1 in neurons, which remain largely elusive.  Among its few known roles, 
BACE1 appears to be involved in peripheral, and potentially CNS, myelination via cleavage of 
neuregulin-1, and is thought to be important for maintenance of synaptic functioning (2, 59).  
Additionally, BACE1 is upregulated in neurons in response to a host of inflammatory mediators, 
including interferon-γ, tumor necrosis factor α, interleukin-1β, and Aβ, and contains transcription 
factor binding sites for Sp1, CREB, NF-κB, STAT1, and PPARγ among others.   
Based on our studies and previous reports, neuronal upregulation of BACE1 appears to 
be deleterious to cell survival during stress conditions.  However, the cellular context of the 
specific stressor may be critical in determining whether the upregulated protein in question is pro-
survival or pro-death.  Recently, Baleriola et. al. demonstrated that Aβ42, when applied to distal 
axons of rat hippocampal neurons, induces phosphorylation of eIF2α and local translation of a 
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subset of mRNAs, including ATF4 (60).  ATF4, typically considered to be a neuroprotective gene 
involved in cellular adaption to ER stress, was then shown to propagate a neurodegenerative 
signaling cascade in Aβ42 –treated neurons, leading to cell death.  Therefore, it is likely that 
stress-induced genes, such as ATF4 and BACE1, that are translationally upregulated in response 
to phospho- eIF2α, which is elevated in brains of AD and HAND patients, play both protective as 
well as deleterious roles in neuronal survival depending on the chronicity and localization of the 
stressor.  Careful time course experiments will be necessary to determine if BACE1 has an initial 
protective role in neurons undergoing oxidative and ER stress that becomes toxic over time, 
similar to what has been reported with ATF4. 
The unfolded protein response has recently become an area of therapeutic interest in the 
treatment of neurodegenerative diseases and is of particular interest in HAND given our previous 
observations of elevated UPR markers in the CNS of HAND patients and ART drug-mediated 
BACE1 upregulation via phospho-eIF2α-dependent translational control in neurons (61, 62).  
Here, we used a pharmacological approach to assess the contribution of two eIF2α kinases, 
PERK and PKR, to ART-mediated BACE1 upregulation.  In agreement with our previous work, 
we found that inhibition of PERK blocked ART-mediated phosphorylation of eIF2α; however, 
BACE1 was not significantly reduced compared to ART-only controls, emphasizing the redundant 
nature of the four eIF2α kinases.  Furthermore, use of the GSK PERK inhibitor did not alleviate 
ritonavir-mediated loses in MAP2, indicating that this inhibitor, although protective in an AD 
mouse model, may be neurotoxic in vitro.  Alternatively, PERK may be critical for neuronal health 
and survival during normal and/or acute stress conditions, limiting its therapeutic potential.  
Indeed, disruption of PERK signaling in CNS neurons has been shown to induce cognitive and 
behavioral deficits in mice (63). Unexpectedly, we found that PKR played a major role in 
maintaining basal levels of neuronal phospho-eIF2α and PKR inhibition completely abrogated 
ritonavir and saquinavir-mediated phosphorylation of eIF2α, but only partially reduced BACE1 
levels.  Future studies with 7DG will be utilized to determine if PKR inhibition is protective against 
ART-mediated neurotoxicity in vitro and in vivo.   
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In the present study, we did not test the effect of GCN2 and HRI inhibitors, however, work 
by Vassar and colleagues suggests that GCN2 does not contribute significantly to ER-stress 
mediated upregulation of BACE1 in neurons (7).  Nonetheless, GCN2 remains an intriguing 
therapeutic target for HAND, as it has been shown to have inhibitory effects on HIV replication 
and is directly cleaved by the HIV protease to overcome this antiviral effect (64).  Ultimately, 
successful adjunctive therapies for HAND will likely have to include pharmacologics that alleviate 
ER and oxidative stress, thereby slowing or preventing the toxic accumulation of 
neurodegenerative proteins, such as Aβ, that have become increasingly prevalent in the 
pathology associated with HIV infection in the CNS.               
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Figure 1.  BACE1 inhibition mitigates MAP2 and synapsin loss in primary neurons treated with 
hydrogen peroxide.  Rat cortical neuroglial cultures grown on coverslips for 10 DIV were treated 
with DMSO vehicle or pretreated with 1 µM cell-permeable beta secretase inhibitor (BSI) for 30 
minutes then treated with 10 or 20 µM hydrogen peroxide (H202) for 24 hours.  Cultures were 
stained with propidium iodide (red) and immunostained for MAP2 (blue) and synapsin (green).  
Neurons pre-treated with 1 µM BSI displayed decreased propidium iodide staining, increased 
expression of synapsin and increased MAP2+ cells compared to untreated cultures in the 
presence of 10 and 20 µM H202.  Images were captured using epifluorescent microscopy at 40x 
magnification.  Representative images shown.   
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Figure 2.  BACE1 inhibition prevents MAP2 loss in ritonavir-treated neurons.  A) Rat cortical 
cultures were grown on coverslips for 10 DIV and treated with DMSO vehicle or 1 µM cell-
permeable beta-secretase inhibitor (BSI) for 30 minutes followed by 48 hour treatment with 10 µM 
ritonavir.  To assess cellular damage and death, cultures were stained with propidium iodide (red) 
and immunostained for MAP2 (blue) and synapsin (green).  B-D) In the presence of ritonavir, 
neurons pre-treated with 1 µM BSI showed a significant increase in the number of MAP2+ cells 
and a small decrease in propidium iodide staining.  No changes in synapsin were observed 
between treatment groups (n=4, *p<0.05, **p<0.01, ns: not significant, one-way ANOVA plus 
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Newman-Keuls post hoc testing).  Images were captured at 40x magnification using 
epifluorescent microscopy.  Representative images shown. 
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Figure 3.  Small molecule inhibitors of PKR and PERK block HIV protease inhibitor-mediated 
phosphorylation of eIF2α in neurons.  Primary rat neuroglial cultures aged 21 DIV were 
pretreated with DMSO vehicle or an inhibitor of PKR (7DG) or PERK (GSK2606414) for 1 hour 
followed by treatment with 10 µM ritonavir or 1 µM saquinavir for 16 hours.  Neuronal lysates 
were immunoblotted for phospho- and total eIF2α and BACE1.  Actin was used a loading control 
for BACE1 while phospho-eIF2α was normalized to total eIF2α.  A-C) PKR inhibition with 10 µM 
7DG in neurons significantly reduced basal levels of phospho-eIF2α and prevented ritonavir and 
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saquinavir-mediated phosphorylation of eIF2α.  7DG also reduced neuronal BACE1 expression in 
ART-treated neurons, however the change was not significant (n=3 **p<0.01, ***p<0.001, one-
way ANOVA plus Newman-Keuls post hoc testing).  D-I) Inhibition of PERK with 0.5 µM 
GSK2606414 did not affect basal levels of phospho-eIF2α, but resulted in a significant decrease 
in phospho-eIF2α expression in ritonavir and saquinavir-treated neurons compared to vehicle 
pre-treated controls (n=3, *p<0.05, one-way ANOVA plus Newman-Keuls post hoc testing).  
BACE1 levels were not significantly altered in neurons treated with GSK2606414, although we 
observed a trend towards decreased BACE1 expression in PERK-inhibited, ART-treated neurons.  
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Figure 4.  Pharmacological inhibition of PERK does not alleviate ritonavir-mediated neurotoxicity 
in primary neuroglial cultures.  Rat cortical neuroglial cultures were grown on coverslips for 10 
DIV and pre-treated with DMSO vehicle or 0.5 µM PERK inhibitor, GSK2606414 (GSK) for 30 
minutes followed by treatment with 10 µM ritonavir for 48 hours.  Cells were stained with 
propidium iodide (red) and immunostained for MAP2 (blue) and synapsin (green) to assess 
neuronal damage and death.  Neuronal cultures pre-treated with GSK did not appear significantly 
different compared to controls in the presence of ritonavir.  MAP2 and synapsin levels appeared 
similar while propidium iodide puncta were increased in GSK pre-treated neurons.   
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CHAPTER 5 
CONCLUSIONS AND FUTURE DIRECTIONS 
5.1: OVERVIEW 
The advent of combination antiretroviral therapy in 1996 represented a revolutionary 
breakthrough in the treatment of HIV and validation of rational drug design via structural biology 
as an essential methodology in the treatment of human disease.  When on ART, patients 
experience suppressed viral replication, reconstitution of the immune system, and improved long-
term survival.  However, with aging of the HIV-infected population, the prevalence of HAND has 
continued to escalate.  Furthermore, the life expectancy of ART-medicated, HIV-positive patients 
remains 10-30 years less than that of uninfected individuals, highlighting the need for 
advancements in the understanding of HIV comorbidities including HAND neuropathogenesis (1).  
Since the implementation of ART, HAND has evolved from a rapidly progressing, subcortical 
encephalitic condition to a prolonged, cortical, neurodegenerative disease.  While contributions of 
HIV replication, immune activation, and drugs of abuse are known to drive neuronal damage, it is 
less clear what effect antiretroviral drugs have in the onset and progression of HAND, however, a 
plethora of data suggests that ART toxicity is likely to play a key role in CNS toxicity, as it does in 
the peripheral nervous system.  The aim of our work has been to determine the contributions of 
ART, on a cellular and molecular level, to the evolution and persistence of HAND pathology with 
the long-term goal of uncovering novel therapeutic strategies to combat cognitive deficits in aging, 
HIV-infected populations.  To that end, we employed in vitro models of ART exposure to show 
that HIV protease inhibitors, and NRTIs to a lesser extent, induce UPR activation in primary rat 
and human fetal neurons (Chapter 3).  Consistent with previous studies, activation of the UPR 
resulted in translational de-repression of BACE1 and enhanced production of Aβ peptides.  
These effects were mitigated by knockdown of neuronal PERK or overexpression of a kinase-
dead PERK mutant.  Importantly, we found evidence of UPR activation and upregulation of 
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BACE1 protein levels in ART-treated humans and macaques infected with HIV and SIV, 
respectively.  In Chapter 4, we sought to elucidate the role of BACE1 in neuronal survival and 
stress response by challenging neurons with oxidative and ER stressors in the presence of a 
pharmacological inhibitor of BACE1.  We found that BACE1 inhibition partially protected cells 
against hydrogen peroxide and ART-mediated neuronal damage and death as indicated by 
decreased uptake of propidium iodide and rescue of MAP2 and synapsin protein expression. 
Additionally, we observed that inhibition of PKR, one of the four eIF2α kinases, blocked ART-
mediated phosphorylation of eIF2α and upregulation of BACE1.  Ultimately, a detailed 
understanding of the molecular mechanisms by which antiretrovirals induce toxicity in neurons is 
vital to the development of safer drug regimens and the discovery of novel therapeutics sorely 
needed in HAND. 
 
5.2: ANTIRETROVIRALS AND THE UNFOLDED PROTEIN RESPONSE  
In Chapter 3, we built upon previous observations of ART toxicity in neurons to determine 
which specific molecular pathways were affected in cells upon exposure to commonly prescribed 
antiretroviral drugs.  Consistent with findings in hepatocytes, adipocytes, and macrophages, PI 
and NRTI-class ART drugs were found to activate ER stress in rat and human fetal neurons in a 
dose-dependent manner, as indicated by elevated expression of BiP, p-eIF2α, and splicing of 
XBP1 mRNA by IRE1α.  We did not test the ability of other ART drug classes to induce ER stress 
in neurons; however, we are currently conducting an extensive analysis on a panel of NRTIs, 
nNRTIs, and PIs to determine if our findings with ritonavir, saquinavir, and AZT are representative 
of their drug class.  Current efforts are also underway to determine the precise mechanism by 
which PIs and NRTIs induce ER stress, although the answer is likely to be multifactorial (Figure 
1).  A 2005 study by Parker et. al. suggested that PIs activate ER stress in adipocytes via 
inhibition of 26S proteasome activity and blockade of glucose transporter 4 (GLUT4) (2).  
Intriguingly, Vassar and colleagues found that inhibition of glucose utilization resulted in PERK-
dependent phosphorylation of eIF2α in vivo and in vitro (3).  Furthermore, mutation of the Ser51 
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eIF2α phosphorylation site in mice results in fatal hypoglycemia and defective gluconeogenesis, 
indicating that the primary physiological function of p-eIF2α in mammals is nutrient-sensing and 
regulation of glucose homeostasis (4).  Given that PIs induce insulin resistance in patients, it 
stands to reason that inhibition of glucose transport and utilization may be a key mechanism of 
cellular stress in the periphery as well as in the CNS, where GLUT4 is known to be expressed in 
the hippocampus.  We will first assess glucose uptake in insulin-stimulated hippocampal neurons 
treated with increasing doses of ritonavir using a [
3
H]2-Deoxyglucose uptake assay.  Based on 
previous work with PIs in other cell types, we predict that ritonavir will dose-dependently block 
glucose uptake in neurons.  Using immunofluorescence analysis, we will then assess whether 
any of the major glucose transporters in neurons, including GLUT1, GLUT3, or GLUT4 fail to 
translocate to the plasma membrane after insulin-stimulation in the presence of ritonavir.  A 
previous study in 3T3-L1 adipocytes demonstrated that GLUT3 and GLUT1 properly translocate 
to the plasma membrane in the presence of indinavir, but that indinavir inhibits the intrinsic 
transport activity of GLUT4 after its translocation (5).  As glucose uptake by GLUT4 in muscle 
cells is dependent upon PI3-kinase activation (6), we will determine if ritonavir inhibits PI3-kinase 
in neurons as a mechanism of GLUT4-specific glucose transport inhibition.  Ultimately, a 
comprehensive analysis of the effects of PIs on neuronal insulin sensitivity and signaling will be 
critical for advancing our understanding of the potential metabolic side-effects of ART in the CNS 
of drug-treated, HIV-positive individuals.    
 Inhibition of 26S proteasome activity by PIs has been confirmed in various cell types and 
cell-free systems and is likely to be important as an ER-activating mechanism in neurons as 
indicated by a recent report showing that pharmacological inhibition of proteasome activity with 
MG115 or MG132 directly activates PERK in neural cells (7).  Future studies are necessary to 
determine if PIs can inhibit proteasome function in primary neuroglial cultures prior to 
phosphorylation of eIF2α.  This can be assessed with the use of a fluorometric assay wherein a 
peptide substrate of the proteasome (LLVY) is linked to a fluorophore (7-amino-4-
methylcoumarin) which fluoresces after cleavage of the LLVY-AMC bond.  In this manner it will be 
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possible to determine if proteasome inhibition is an early event in PI-mediated cell toxicity and if 
rescue of proteasome activity abrogates PI-mediated activation of ER stress. 
 We have previously shown that antiretrovirals induce production of reactive oxygen 
species (ROS) in primary neurons as early as 6 hours after treatment, hypothesized to be the 
result of disrupted mitochondrial DNA synthesis and depletion of enzymes necessary for the 
electron transport chain (8-11).  ROS, in turn, can activate ER stress via disruption of cellular 
calcium homeostasis or widespread oxidation of proteins leading to impaired protein degradation 
(12).  To assess whether ART-induced oxidative stress is sufficient and/or necessary for 
downstream activation of the UPR, we would inhibit ROS production with the use of a fumaric 
acid ester, monomethyl fumarate (MMF).  MMF, the hydrolyzed, active metabolite of dimethyl 
fumarate (DMF), is an anti-inflammatory that activates the Nrf2-dependent antioxidant response 
pathway leading to upregulation of detoxification enzymes, such as NQO-1 and heme oxygenase 
1 (HO-1), and has been shown to protect neurons from ART-induced damage and death (8, 13, 
14).  DMF is currently used for the treatment of psoriasis in Europe and ongoing clinical trials 
indicate DMF shows promise as a disease-modifying agent in multiple sclerosis, highlighting its 
favorable in vivo efficacy and safety profile (13, 15-18).  Thus, DMF represents an intriguing 
candidate for adjunctive therapy in the treatment of HAND, as reviewed by Gill and Kolson (19).   
   
5.3: MECHANISMS OF BACE1 REGULATION IN NEURONS   
Our work also confirms a 2008 report by O’ Connor et. al. that UPR activation in neurons 
results in translational upregulation of BACE1.  Importantly, we used a 5’UTR deletion construct 
to confirm that translational control of BACE1 during ER stress is dependent upon the presence 
of the 5’UTR.  Whereas 16 hour ritonavir treatment in neurons overexpressing wild-type BACE1 
resulted in increased BACE1 expression compared to vehicle controls, neurons overexpressing 
the -5’UTR construct did not show any changes in BACE1 protein when treated with ritonavir.  
Importantly, we observed a much larger increase in BACE1 protein due to deletion of the 5’ UTR 
as compared to induction of ER stress with ritonavir.  These results suggest that ritonavir partially 
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de-represses BACE1, likely through the use of p-eIF2α-mediated scan through of uORFs after re-
initiation.  However, secondary structures in the 5’UTR likely remain intact and therefore could 
contribute to partial repression of translation.  Elevated BACE1 in neurons containing the 5’UTR 
deletion-construct thus reflects a coincident loss of all uORFs and secondary structures leading to 
translational initiation of all associated ribosomes at the true start codon, compared to neurons 
transfected with the BACE1 cDNA containing the full length 5’ UTR where initiation at the bone 
fide start codon remains sub-maximal due to secondary structures or incomplete scan-through of 
all three uORFs.  Based on previous studies of BACE1 translational control, we predict that 
mutation or deletion of uAUG #2 and/or #4 would further enhance BACE1 expression during ER 
stress by limiting translation re-initiation at these start codons.  A thorough analysis of BACE1 
5’UTR uAUG mutants will be necessary to confirm if these uAUGs are critical to BACE1 
translational control during ER stress or if secondary structures play a more prominent role in 
repression.   
 Although not supported by our data, there is also evidence that BACE1 transcript and 
protein stability can be influenced by microRNAs and non-coding antisense mRNAs (20).  In 
particular, four microRNAs (miR-107, miR-9, miR-29a, miR-29b) are known to bind BACE1 
mRNA and regulate translational efficiency while increasing the stability of the transcript (21, 22).  
Interestingly, several of these microRNAs were shown to be downregulated in AD brains and 
were inversely correlated with BACE1 mRNA levels in the CNS (21).  Alternatively, BACE1 
stability can be affected by proteasome activity, as shown in a 2004 report where inhibition of 
proteasome activity with lactacystin, but not other protease inhibitors, led to accumulation of 
ubiquitinated BACE1 and increased amyloidogenic processing of APP (23).  We found that 
ritonavir had no effect on BACE1 protein stability in vitro, however, a parallel post-mortem 
analysis of BACE1 protein and mRNA levels in the CNS of HAND patients will be necessary to 
determine if BACE1 is increased only at the translational level as in AD.    
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 In addition to increasing the expression of BACE1, we also observed that ritonavir and 
combinations of antiretrovirals increased production of Aβ peptides by two-fold in CHO cells 
stably expressing human APP and in primary rat neuroglial cultures.  Unexpectedly, we found 
that CHO cells treated with ritonavir showed an increase in Aβ42 secretion but not Aβ40, 
conflicting with a report by Vassar et. al. which showed that overexpression of BACE1 in cells 
stably transfected with wild-type human APP increased production of Aβ40 and Aβ42 peptides 
equally (24).  Our results in CHO cells appear to be a cell-specific artifact, as we observed 
comparable increases in Aβ40 and Aβ42 in primary rat neuronal cultures treated with 
combinations of antiretrovirals.  Alternatively, our observations in rat neurons may be a result of 
combination ART treatment compared to the ritonavir-only treatments in CHO cells.  Rigorous in 
vivo validation of ART effects on Aβ production are needed to determine the long-term effects of 
these drugs on amyloidogenesis in the brain.  Although several groups have reported elevated 
Aβ accumulation and deposition in ART-treated, HIV-positive individuals compared to ART-naïve 
controls, there are several technical concerns with these studies regarding the antibody (4G8) 
used to detect amyloid.  Specifically, 4G8 can detect full-length APP in addition to sAPPβ, and Aβ 
peptides, therefore, it is unclear which Aβ domain-containing species these groups were 
observing in HAND patients.  Given the limitations associated with post-mortem human analyses, 
the use of transgenic mouse models of AD will be critical to ascertain a clear understanding of the 
interplay between antiretrovirals and amyloid pathology in the CNS.  Previously, Ikezu and 
colleagues found that 30-day oral administration of nelfinavir (PI) or lopinavir/ritonavir had no 
effect on Aβ accumulation in two-month-old APP SCID mice (generated by crossing CRND8 
transgenic mice with BALB/cBy-Prkdc
scid
 mice) despite achieving CSF/IC50 ratios of 4.3 and 3.3, 
respectively (25).  However, previous studies using CRND8 transgenics indicated that Thioflavin-
S-positive amyloid deposits were not prevalent until 3 months of age and dense-core neuritic 
plaques were not observed until 5 months of age (26).  Importantly, none of the animals included 
in the Ikezu study displayed evidence of amyloid pathology; therefore, inclusion of age-matched, 
CRND8 transgenic controls will be necessary to ensure pathology in the APP SCID mouse 
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develops in a similar, age-dependent manner.  We propose using the APP/PS1 double knock-in 
mouse model of AD, in which FAD-causing mutations were targeted into their endogenous genes, 
resulting in age and region-dependent amyloid deposition beginning at 6 months of age (27).  
Treatment of these animals with antiretrovirals at 6 and 12 months of age will provide critical 
insights into the effects of ART on the initiation of amyloidogenesis, while avoiding the caveats of 
a transgenic AD model that utilizes exogenous overexpression of APP.     
    
5.4: eIF2α KINASES AS THERAPEUTIC TARGETS IN HAND  
PERK is the primary kinase responsible for eIF2α phosphorylation during conditions of 
oxidative and ER stress.  Our results suggest that PERK is also involved in maintenance of basal 
p-eIF2α in neurons and ART-mediated increases in p-eIF2α and BACE1 (Chapters 3 and 4).  
Notably, while overexpression of kinase-dead PERK resulted in a significant decrease in p-eIF2α 
and BACE1 expression in neurons, overexpression of wild-type PERK increased p-eIF2α but did 
not change BACE1 levels, suggesting that in the absence of an oxidative or ER stressor, 
phosphorylation of eIF2α does not necessarily lead to translational upregulation of BACE1.  To 
confirm this hypothesis, future experiments will be conducted in which wild-type and kinase-dead 
PERK constructs are overexpressed in neurons in the presence and absence of ritonavir.  While 
overexpression of wild-type PERK is predicted to augment the effects of ritonavir through 
enhanced and/or sustained phosphorylation of eIF2α, overexpression of kinase-dead PERK 
should partially block ritonavir-mediated upregulation of BACE1, as observed in our PERK 
conditional knockout cells (Chapter 3) and PERK inhibitor studies with the novel compound 
GSK2606414 (Chapter 4).   
Accumulating evidence suggests that aberrant UPR signaling through PERK is a key 
mechanism underlying amyloidogenesis and cognitive decline in neurodegenerative diseases, 
such as AD (3, 28-32).  We and others have shown that ART contributes to enhanced 
amyloidogenic processing of APP in primary neurons via ER stress activation (33-35).  Therefore, 
to determine if PERK is directly involved in antiretroviral-mediated Aβ production in vivo, we will 
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cross APP/PS1 double knock-in mice (described previously) with conditional PERK knockouts 
and treat the resulting APP PERK-/- mice with ART for up to 30 days and assess changes in Aβ 
production and amyloid pathology beginning at 6 months of age.  As PERK haploinsufficiency is 
sufficient to prevent BACE1 elevation, reduce Aβ and plaque burden, and rescue memory deficits 
in a 5XFAD mouse model, we predict that conditional knockout of PERK in adult mice will 
abrogate ART-mediated phosphorylation of eIF2α and upregulation of BACE1, while preventing 
or slowing any accumulation of intraneuronal or extracellular Aβ that might occur.  These 
experiments will also reveal whether PERK inhibition represents a promising therapeutic avenue 
in the treatment of HAND.     
Phosphorylation of eIF2α is mediated by three kinases in addition to PERK, including 
HRI, GCN2, and PKR.  While HRI is not expressed in neurons, GCN2 is expressed at high levels 
in the brain compared to other organs and responds to a variety of stress conditions, similar to 
PERK.  Additionally GCN2 has been shown to play a role in learning and memory via regulation 
of early and late-phase long-term potentiation (LTP) (36).  Paradoxically, genetic deletion of 
GCN2 in APP/PS1 mice was shown to rescue impairments in synaptic plasticity and spatial 
memory, suggesting this kinase becomes dysregulated or maladaptive in neurodegenerative 
disease (31).  Additionally, GCN2 has been shown to inhibit HIV replication and is directly 
cleaved by the HIV-1 protease (37).  Therefore, future experiments involving in vivo and in vitro 
knockdown of GCN2 will be informative in understanding the contribution of this kinase to CNS 
health in the presence of HIV and/or antiretroviral drugs.   
PKR also appears to have a role in AD pathogenesis via stress-mediated upregulation of 
BACE1 (38-40).  Our results in Chapter 4 indicate that PKR is partially responsible for ART-
mediated increases in p-eIF2α and BACE1 and may play a role in maintaining basal levels of p-
eIF2α in neurons.  Although PKR knockout in APP/PS1 mice did not prevent amyloid pathology 
or rescue cognitive deficits (31), it is likely that PKR, GCN2, and PERK all contribute to eIF2α 
phosphorylation in chronic, neurodegenerative diseases given the widespread inflammation, 
energy deprivation, and accumulation of misfolded proteins that routinely accompany these 
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diseases.  Additionally, inhibition of any one of the eIF2α kinases via targeted therapeutics in vivo 
is likely to be compensated by the overlapping functions of the other kinases, suggesting that 
direct targeting of eIF2α itself may be more efficient at ameliorating aberrant UPR signaling in 
chronic CNS disease.  However, it remains unclear whether sustained eIF2α phosphorylation is 
an early, driving force behind the neurodegenerative process or a downstream cellular adaptation 
to the accumulation of misfolded proteins and gradual deterioration of protein folding and clearing 
mechanisms associated with normal aging.  Whether stress-induced eIF2α phosphorylation is 
ultimately protective or deleterious to neuronal survival in the brain is incompletely understood 
and likely depends on the chronicity and severity of the stressor.  Canonical activation and 
regulation of the UPR in general, and the PERK pathway in particular, is designed to be rapid and 
transient, exemplified by the fact that many of the translational targets of p-eIF2α are themselves 
transcription factors.  A 2007 report by DeGracia and Hu concluded that neuronal survival during 
transient cerebral ischemia was dependent upon recovery from translational inhibition by p-eIF2α 
(41).  However, long-term translational arrest via chronic UPR activation in neurons is associated 
with enhanced production of neurodegenerative proteins, impaired LTP, and in the case of 
ischemia/reperfusion, cell death.  These conflicting roles for the UPR suggest that its activation is 
biphasic: adaptive and protective during transient stress but  apoptotic during chronic/severe 
stress (42).  Extensive animal studies with modulators of eIF2α, such as growth arrest and DNA 
damage inducible protein 34 (GADD34), a specific eIF2α phosphatase, will be critical to 
determine the safety of this therapeutic approach in the context of HIV infection and long-term 
exposure to antiretroviral drugs. 
 
5.5: CONSIDERATIONS FOR IN VIVO ANALYSIS OF ART-ASSOCIATED CNS DAMAGE  
We confirmed the biological significance of our in vitro findings with a well-characterized, 
SIV/pigtail macaque model of HIV CNS disease in which 90% of infected animals treated with 
placebo develop neurologic disease within 12 weeks post-inoculation, while animals treated with 
ART do not develop SIV encephalitis nor do they develop neurological dysfunction (43). 
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Strikingly, SIV-infected macaques treated with combination ART showed significantly elevated 
expression of BACE1 and APP, a sensitive marker of neuronal damage, in the hippocampus 
compared to SIV-infected, placebo-treated controls (Chapter 3).  Together with our previous 
reports of ART-associated synaptic injury in this same macaque model (8), these results 
demonstrate that oral administration of successful ART to primates negatively impacts neuronal 
and synaptic viability in the CNS either through direct or peripheral toxicities.  Furthermore, these 
data strongly suggest that antiretroviral agents themselves, not viral infection, are responsible for 
increased CNS expression of BACE1.  Treatment of uninfected pigtails macaques with ART is 
currently ongoing and will be necessary to confirm this hypothesis.  Notably, we did not observe 
statistically significant changes in BiP or p-eIF2α in ART-treated macaques compared to 
uninfected or placebo-treated controls, however, changes in ER stress markers are likely to be 
region- and cell-specific, thus, immunofluorescent analysis will be necessary to properly assess 
the level of UPR activation in the macaque brain.  Furthermore, successful detection of phospho-
proteins in post-mortem tissue is highly dependent upon post-mortem interval (44), therefore, we 
will measure changes in alternative UPR markers, such as sXBP1, ATF6α/β, ATF4, and CCAAT-
enhancer-binding protein homologous protein (CHOP) via immunofluorescent and western 
blotting analysis. 
 Our initial post-mortem analysis of brain tissue from a small cohort of 13 patient samples 
from the NNTC revealed two important findings: BACE1 levels are significantly upregulated in the 
hippocampus of HAND patients compared to HIV-negative controls and intraneuronal Aβ 
oligomers are elevated in the hippocampus of HAND patients despite the absence of overt plaque 
pathology or changes in total APP (Chapter 3).  Interestingly, we did not find an association 
between the severity of HAND and Aβ oligomer burden in the hippocampus, indicating 
dysregulated APP processing may be an early event in pathogenesis.  Notably, the patients 
tested in this cohort ranged from 31 to 53 years of age, therefore, advanced amyloid pathology 
would not be expected even in the presence of FAD-causing mutations.  Similar to our findings in 
macaques, HAND patients did not display statistically significant changes in BiP or p-eIF2α 
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compared to uninfected or HIV-positive, neurocognitively normal controls by western blotting 
analysis.  These results conflict with our previous reports in which immunofluorescent analysis 
revealed elevated markers of UPR activation, including BiP and p-eIF2α, in HAND patients (45, 
46), emphasizing the importance of this approach to examine changes in protein levels that can 
vary across subcellular compartments, cell types, and brain regions.  Our analysis of HAND 
patients is also limited by low statistical power owing to small sample size and lack of data on 
antiretroviral regimens.  To address these concerns, we have begun extended analysis of a large 
cohort (n=60) of patients from the NNTC grouped into three categories: 20 HIV(-), 20 
HIV(+)/ART-naïve, 20 HIV(+)/ART-treated for at least 12 months (Table 5.1).  Importantly, the 
ART regimens of our drug-treated patient samples were carefully documented which will allow us 
determine for the first time if long-term use of specific ART regimens/antiretroviral drug classes 
correlate with changes in UPR activation, BACE1 expression, and aberrant APP processing in 
the CNS.  The importance of these studies are highlighted by the conflicting neuropsychological 
data obtained in cross-sectional and longitudinal clinical studies of HIV-positive patients 
beginning ART or switching to ART regimens with higher predicted CNS penetrance.  While these 
studies have largely assessed the initial effects of ART on neurocognitive function in drug-naïve 
patients, our studies will provide critical information on the cumulative, long-term effects of ART 
on neuropathology in HIV-positive individuals.  
 
5.6: BACE1 FUNCTIONS IN NEURONS: IMPLICATIONS FOR A NOVEL THERAPEUTIC 
TARGET IN HAND 
 A growing body of literature suggests that BACE1 is induced by a variety of stress 
conditions including oxidative stress, cerebral ischemia, traumatic brain injury, and impaired 
energy metabolism associated with neurodegeneration (3, 47-54).  In Chapter 4, we investigated 
the role of BACE1 in cell survival and adaptation to oxidative and ER stress.  Although the 
regulation and timing of BACE1 expression in neurons suggest it may be involved in an acute 
neuronal stress response, we found that inhibition of BACE1 activity protected cells from 
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hydrogen peroxide-induced damage and death.  At acute doses of hydrogen peroxide, BACE1 
inhibition mitigated loss of MAP2 and synapsin, but did not change the number of propidium 
iodide puncta, suggesting that loss of BACE1 activity either slowed the death response in 
neurons or restricted cell loss to glia.  Recent preliminary work in our lab has demonstrated that 
toxic doses of hydrogen peroxide induce acute loss of astrocytes prior to the loss of neurons, 
suggesting that astrocytes buffer and protect neurons from changes in redox potential and that 
BACE1 may be involved in a delayed death response in neurons.  In support of this conclusion, 
previous reports have shown that during apoptosis BACE1 protein degradation in lysosomes is 
inhibited by caspase-3-mediated cleavage of Golgi-localized γ-ear-containing ARF-binding 
protein 3 (GGA3), an adaptor protein required for BACE1 lysosomal trafficking and degradation, 
leading to enhanced Aβ production and cell death (55).  Thus, BACE1 may be involved in 
programmed cell death as a means to prevent spread of cytotoxic ROS in the brain.  However, 
what role BACE1 might play in sub-toxic oxidative stress conditions remains unclear.  An 
additional consideration is the possibility that the beta-secretase inhibitor utilized in our study is 
protecting neurons via off-target effects on other proteases, such as caspases, however, this is 
unlikely given the high-specificity of the compound, which has an IC50 of 15nM for BACE1, 230nM 
for BACE2, 7.6uM for cathepsin D, and greater than 50uM for the related aspartic protease renin.  
However, off-target effects of the BACE1 inhibitor on initiator and effector caspases will be 
verified by western blotting for active caspase-3 and caspase-9 in neurons following treatment 
with hydrogen peroxide, an important next step for our studies.      
Alternatively, BACE1 might exert a specific neuroprotective role against excitotoxic 
insults based on its ability to cleave voltage-gated sodium channels (VGSCs).  Excitotoxins, such 
as N-methyl-D-aspartate (NMDA), which bind to glutamate receptors, induce acute excitotoxicity 
in neurons via influx of calcium and sodium (56).  We propose to examine the role of BACE1 
during excitotoxicity by treating primary neurons with NMDA in the presence or absence of a 
BACE1 inhibitor.  Neuronal viability will be assessed by changes in MAP2, synapsin, and 
propidium iodide inclusion.  Additionally, we will correlate cell damage and death with levels of 
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calcium and sodium influx after NMDA treatment in BACE1 inhibited neurons with the use of 
fluorescent dye assays.  Although BACE1 inhibition is not predicted to mitigate NMDA-mediated 
influx of calcium, this assay will allow us to determine if BACE1 mediates neuroprotective effects 
by regulating sodium influx via VGSC activity and function, which would have larger implications 
in diseases such as epilepsy where neuronal hyperactivity is prevalent.  Hypothetically, BACE1 
cleavage of VGSCs could also counteract the enhanced, region-specific expression of cortical 
VGSCs found in a rodent model of absence epilepsy, which was thought to correlate with the 
determined regions of seizure onset (57).   
Finally, we found that BACE1 inhibition also partially protected neurons from ritonavir-
mediated toxicity over 48 hours.  Although we have data to suggest that ritonavir and other PI-
class drugs exert their neurotoxic effects through production of ROS, there is an abundance of 
data indicating ART drugs have a plethora of other toxic effects mediated through calcium 
dysregulation, inhibition of proteasome function, and mitochondrial toxicity, suggesting BACE1 
might play a role in balancing cell survival and death in response to a wide variety of insults.  As 
such, BACE1 is an appealing target for therapeutic intervention in HAND, wherein patients are 
chronically exposed to toxic effects of antiretroviral drugs, low levels of insidious HIV replication, 
neuroinflammation, and accelerated aging.  One major advantage of targeting BACE1 in HAND 
versus sporadic neurodegenerative diseases, such as AD, is the ability to identify HIV as a 
causative agent, and not merely a risk factor, for HAND, lending certainty to physicians for 
recognizing the at-risk patient population.  Presumably, BACE1 inhibition in HAND would exert 
neuroprotective effects primarily through inhibition of Aβ production, however, the failure of 
previous amyloid-directed therapeutic agents in AD, where amyloid pathology is abundant, 
warrants significant skepticism with this approach in HAND.  In particular, plaque disruptors, anti-
Aβ immunotherapy, and γ-secretase inhibitors and modulators all failed to demonstrate 
substantial reductions in CSF Aβ in clinical trials and many of these agents displayed significant, 
dose-limiting side-effects, which in turn restricted their Aβ-lowering capabilities (58).   
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Early BACE1 inhibitors also failed to exhibit sufficient in vivo potency due to their poor 
pharmacokinetic profiles.  Notably, first generation BACE1 inhibitors were structurally similar to 
the peptidomimetic HIV protease inhibitors, highlighting the structural homology between BACE1 
and the HIV protease.  Yet, despite their similarities to BACE1 inhibitors, HIV protease inhibitors 
have not displayed any apparent anti-BACE1 activity in vitro or in vivo.  Current efforts in BACE1 
inhibitor design have shifted towards the use of small molecule inhibitors, several of which have 
progressed into phase 3 clinical trials. The new generation inhibitors, including MK-8931 (Merck 
and Co.) and LY-2886721 display high affinity for BACE1, potently reduce CNS levels of Aβ in 
non-human primates and avoid the off-target effects on cathepsin D and renin that plagued earlier 
compounds.  Additionally, these compounds avoid the insurmountable mechanism-based side 
effects that accounted for the failure of γ-secretase modulators and inhibitors.  Although complete 
loss of BACE1 activity is known to cause a multitude of phenotypes, including peripheral 
hypomyelination, the use of potent pharmacological agents against BACE1 avoids these effects 
by only partially inhibiting BACE1 activity, which appears to be sufficient to achieve a desirable 
neuroprotective outcome.  Genetic studies in AD mouse models showed that 50% knockdown of 
CNS BACE1 in PDAPP/BACE1
+/-
 transgenic mice resulted in only a 12-20% reduction in Aβ 
levels, but which translated to 75% less amyloid plaque burden compared to PDAPP/BACE1
+/+
 
mice (58, 59).  Importantly, BACE1 heterozygous knockout mice display none of the phenotypes 
of homozygous BACE1 knockouts, suggesting that complete loss of BACE1 function is necessary 
for phenotypic abnormalities (58).  In patients with HAND, amyloid plaque burden has not been 
definitively established as a common pathological feature, however aberrant intraneuronal Aβ 
accumulation has been observed in addition to reduced CSF Aβ42 levels, which is a biomarker of 
AD and is thought to be the result of accumulation of insoluble Aβ within the brain parenchyma 
(60).  Taken together with our studies, these observations suggest that patients suffering from 
HAND would stand to benefit from BACE1-directed therapeutics as a means to normalize Aβ 
levels within the CNS and improve cognitive functioning.  
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 In summary, the body of work presented in this thesis advances our understanding of the 
cellular and molecular effects of antiretroviral drugs on CNS neurons in vitro and in vivo while 
further delineating the basic biological functions of BACE1 as a stress response protein.  
Additionally, we present novel features of HAND pathogenesis in the post-ART era, including 
intraneuronal accumulation of oligomeric Aβ, that have not previously been described pre-ART.  
Importantly, our work provides the first mechanistic link between the persistence and evolution of 
HAND as a chronic, neurodegenerative condition with the widespread use of antiretroviral drugs, 
taking into account the known toxicities of ART in the peripheral nervous system.  Our data 
demonstrate that PI-class antiretroviral drugs potently activate the UPR in neurons leading to p-
eIF2α-mediated translational upregulation of BACE1 and enhanced amyloidogenic processing of 
APP.  Furthermore, toxic effects of chronic ART treatment in neurons were reversible with the use 
of a cell-permeable beta-secretase inhibitor, thus providing preliminary evidence for BACE1 
inhibition as an adjunctive neuroprotective therapy in the treatment of HAND.  These results 
highlight the role of antiretroviral drugs as mediators of neuronal damage and death in HAND and 
underscore the importance of novel therapeutic strategies in the treatment of HIV CNS disease.  
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Table 1 
 
Summary of human samples from NNTC for post-mortem analysis 
        
Characteristic 
HIV - HIV + 
No ART 
HIV + 
w/ ART 
Number of Subjects 20 20 20 
Age at death, mean ± SD 42.8 ± 5.6 39.7 ± 7.3 45.3 ± 6.7 
Hours postmortem, mean ± SD 9.9 ± 5.7 10.0 ± 6.4 12.4 ± 7.9 
Sex    
       Male (%) 80% 90% 80% 
       Female (%) 20% 10% 20% 
Race    
       White (%)   11 (55%) 12 (60%) 15 (75%) 
       Black (%) 7 (35%) 8 (40%) 5 (25%) 
       Other/Unknown (%) 2 (10%) 0 (0%) 1 (5%) 
Ethnicity    
       Hispanic (%) 5 (25%) 3 (15%) 3 (15%) 
       Not-Hispanic (%) 15 (75%) 17 (85%) 17 (85%) 
Disease Parameters    
       HIVE (%) - 6 (30%) 1 (5%) 
       Log plasma HIV c/mL, mean ± SD - 4.1 ± 1.4 4.7 ± 1.1 
       Log Brain HIV c/g, mean ± SD - 3.4 ± 1.9 4.1 ± 0.9 
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       Log CSF HIV c/mL, mean ± SD - 3.4 ± 1.8 2.8 ± 1.1 
       CD4+ lymphocytes/mm3, mean ± SD - 108 ± 118 85 ± 118 
Neurocognitive Impairment Status    
       HAND (%) - 6 (30%) 14 (70%) 
              Subsyndromic (%)      - 1 (5%) 1 (5%) 
              MCMD (%) - 2 (10%) 9 (45%) 
              HAD (%) - 3 (15%) 4 (20%) 
       Neuropsych Impairment Other Origin       
(%) 
- 5 (25%) 4 (20%) 
       Neurocognitively Normal (%) - 1 (5%) 2 (10%) 
       No Neurocognitive Data - 8 (40%) 0 (0%) 
ART Treatment Status    
       PI-experienced (%) - - 17 (85%) 
       PI-naïve (%) - - 3 (15%) 
       NRTI-experienced (%) - - 20 (100%) 
       NRTI-naïve (%) - - 0 (0%) 
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Figure 1.  Proposed mechanisms of antiretroviral drug-induced ER stress in neurons.  ART drugs 
induce ER stress in a wide variety of cell types via multiple, distinct mechanisms including 
inhibition of GLUT4 transport activity, generation of reactive oxygen species, inhibition of 26S 
proteasome activity, and dysregulation of intracellular calcium stores.  These insults can induce 
chronic activation of ER stress in neurons leading to suppressed global protein synthesis and 
impaired LTP, accompanied by translational de-repression of BACE1 and ATF4, both of which 
have been implicated in apoptosis and neurodegeneration. 
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